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Inhibition of the enzyme, thymidine phosphorylase (TP) may lead to development of 
chemotherapeutic agents for overcoming the pathological effect of TP such as tumour 
progression via angiogenesis. The main purpose of this study was to investigate the 
hypothesis that derivatives of 1,3,5-triazin-2,4-diones and their fused analogues would 
exhibit TP inhibitory activity. To test this hypothesis, several objectives for this study 
were identified, namely to synthesize a series of 1,3,5-triazin-2,4-diones and their 
fused analogues  viz.  1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7-dione, pyrazolo[1,5-
a][1,3,5]triazin-2,4-dione and their thioxo analogues and to evaluate their TP 
inhibitory potential. Moreover, to generate pharmacophoric requirements of these new 
classes of TP inhibitors, 3D-QSAR studies were conducted. In addition, evaluation of 
the effects of the test compounds on the expression of downstream markers of 
angiogenesis and cell viability of breast cancer cell line were performed to investigate 
their potential antiangiogenic and antiproliferative property respectively.  
The synthetic schemes involved ring transformation reactions and annulation of 1,3,5-
triazine ring onto suitably substituted 1,2,4-triazoles and/or pyrazole ring through 
intramolecular heterocyclization reactions. A continuous UV spectrophotometric 
enzyme assay was performed on recombinant human TP (EC 2.4.2.4), using 
thymidine as substrate. Information on the enzyme inhibition kinetic was also derived 
from the enzyme assay. In addition, pharmacophore elucidation of the synthesized TP 
inhibitors was carried out via comparative molecular field analysis (CoMFA). 
Moreover, gelatinase zymography and enzyme-linked immunosorbent assay were 
performed to evaluate MMP-9 and VEGF expression level respectively in breast 
cancer cell line. A total of 82 compounds was successfully synthesized and 
ix 
 
characterized. Among all the synthesized compounds evaluated, compounds having 
keto group (C=O) and thioketo group (C=S) at particular orientation viz. 5-thioxo-5,6-
dihydro-4H-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-one and 2-thioxo-2,3-
dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one their thiomethyl derivatives showed 
varying degrees of TP inhibitory activity comparable to  positive control, 7-
Deazaxanthine  (IC50 value = 42.63 µM). In addition, compounds H5bxvii, H5bxix, 
H8i, H11g and H13a were found to exhibit significant TP inhibitory potential with 
low micro molar IC50 values (IC50 = 10.84, 13.09, 2.95, 13.07, and 3.82 µM 
respectively). The enzyme assay provided evidence that the these inhibitors might 
inhibit TP in mixed fashion in the presence of variable Thymidine (dThd) and 
phosphate (KPi) concentrations. The 3D-QSAR studies based on CoMFA method was 
satisfactory according to statistical validation results and contour map analysis. 
Moreover, it is evident from biological experiments that selected compounds can 
inhibit expression of angiogenic markers including MMP-9 and VEGF expression 
without exhibiting significant cytotoxicity. 
The use of ring transformation and intra-molecular annulation reactions to generate 
the target compounds were practical synthetic approaches. The compounds were 
found to exhibit TP enzyme inhibition as well as its associated antiangiogenic 
potential.  
(Words – 415) 
          
x 
 
LIST OF TABLES 
Table   Page 
1 Representative examples of different types of TP inhibitors  34 
2 Synthesis of 6 substituted 1,3,5-triazin-2,4-diones  57 
3 Synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7(4H,6H)-dione 
and its  derivatives 
63 
4 Synthesis of pyrazolo[1,5-a][1,3,5]triazin-2,4(1H,3H)-dione and 
its derivatives 
69 
5 Thymidine phosphorylase inhibitory activity of the synthesized 
compounds (H1-H13) 
74 
6  Synthesis of 5-thioxo-5,6-dihydro-4H-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-one analogues 
85 
7 Synthesis of 2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-
a][1,3,5]triazin-4-one analogues 
  89 
8 Thymidine phosphorylase inhibitory activity of H5bi-H5bxix 91 
9 Thymidine phosphorylase inhibitory activity of H8a-H8i and 
H11a-H11g 
94 
10 Thymidine phosphorylase inhibitory activity of H13a-H13k 96 
11 Synthesis of target compounds (derivatives of H5, H11, H13 and 
compound H14) 
99 
12 Thymidine phosphorylase inhibitory activity of the synthesized 
compounds (derivatives of H5, H11, H13 and compound H14). 
102 
13 Tautomerism in 3(5)-amino-1,2,4-triazoles in DMSO-d6 solution 112 
14 Optimization of reaction condition of N-(3(5)-3-pyridyl-1,2,4-
triazol-5(3)-yl)-N’-carbethoxythioureas 
116 
15 Tautomerism of  N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-
carbethoxythioureas in DMSO-d6 solution 
119 
16 Training set compounds with observed and predicted pIC50 values 131 
xi 
 
17 Statistical results from CoMFA analysis 132 
18 Test set compounds with observed and predicted pIC50 values 133 
19 A summary of the kinetic parameters 148 
20 A summary of biological activities of reference compounds (TPI 
and 7-DX) and synthesized TP inhibitors 
173 
21 Synthesis of N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-
carbethoxythioureas and their 
1
H NMR spectral data 
193 
22 Synthesis of N-(3(5)-substituted-benzyl-1,2,4-triazole-5(3)-yl)-N’-
carbethoxythioureas/carbethoxyurea and their  
1
H NMR spectral 
data 
218 
23 Synthesis of N-carbethoxy-N’-(3-aryl-pyrazolyl)thiourea/urea  
derivatives and their  
1
H NMR spectral data 
229 
24 Synthesis of corresponding thiourea derivatives of pyrazole-3,5-
diamine and their 
1






LIST OF FIGURES 
Figure   Page 
1 Structures of the three isomeric forms of  triazine 2 
2 Structures of purine, 1,2,4-triazolo[1,5-a][1,3,5]triazine and 
pyrazolo[1,5-a][1,3,5]triazine  
5 
3 Structures of representative biologically active compounds of 1,3,5-
triazine and its fused analogues 
20 
4 Structure of human thymidine phosphorylase 24 
5 The function of thymidine phosphorylase and 2-deoxy-D-ribose in 
tumour development – a schematic representation 
28 
6 Metabolic conversion and mode of action of 5FU, an anticancer 
drug, and its prodrugs 
37 
7  Schematic representation of the human TP active site and important 
interactions with TPI 
39 
8 Structures of known TP inhibitor (TPI and 7-DX) and target 
compounds (a, b and c) 
47 
9 Structures of target compounds to be synthesized in the preliminary 
study  
54 
10 Structures of lead compounds and their IC50 values 79 
11 Planned Craig plot guided structural modification of lead 
compounds H5b, H8, H11 and H13 
81 
12 A schematic diagram describing the structure-TP inhibitory activity 
relationship of the 1,2,4-triazolo and pyrazolo fused triazines 
105 
13 Structures of 1,2,4-triazole derivatives 108 
14 Correlation of ΔG for the tautomeric equilibrium of 3(5)-amino-
1,2,4-triazoles with the Hammett constant (σ) of the R group 
114 
15 Correlation of ΔG for the tautomeric equilibrium of N-(3(5)-aryl-
1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas with the Hammett 




16 X-ray structure of 4-carbethoxy-1-[4-(N,N-
dimethylamino)benzoyl]thiosemicarbazide 
124 
17 Structures of synthesized TP inhibitors used in CoMFA study 128 
18  CoMFA analysis 136 
19 Structures of synthesized TP inhibitors with low micromolar IC50 
value 
141 
20 Lineweaver-Burk plots of TP inhibition by H5bxix 144 
21 Lineweaver-Burk plots of TP inhibition by H5bxvii 145 
22 Lineweaver-Burk plots of TP inhibition by H8i 146 
23 Lineweaver-Burk plots of TP inhibition by H11g 147 
24 Lineweaver-Burk plots of TP inhibition by H13a 148 
25 Screening of compounds (IC50TP ˂ 30 µM) (series H5 and reference 
compounds) based on their inhibitory effect of MMP expression on 
breast cancer cell line, MDA-MB-231 
152 
26 Antiangiogenic effect (MMP-9 expression) of compounds (series 
H5 and reference compounds) on breast cancer cell line 
153 
27 Antiangiogenic potential (MMP expression) of selected synthesized 
compounds (series H11, H8 and H13) on breast cancer cell line 
154 
28 Densitometry analysis of MMP expression of selected synthesized 
compounds (series H11, H8 and H13) on breast cancer cell line  
155 
29 Antiangiogenic potential (VEGF expression) of selected synthesized 
compounds on breast cancer cell line 
157 
30 Antimetastasis potential of selected synthesized compounds on 
breast cancer cell line  
159 
31 Antiproliferative effect  of compounds on breast cancer cell line 160 





LIST OF SCHEMES 
Scheme  Page 
1 Synthesis of 1,3,5-triazin-2,4-dione from 2,4-dimethoxy-1,3,5-
triazine 
3 
2 Synthesis of 1,3,5-triazin-2,4-dione from condensation of urea 
with orthoester 
3 
3 Synthesis of 1,3,5-triazin-2,4-dione from thiourea derivatives 4 
4 Synthesis of 1,3,5-triazin-2,4-dione from aromatic and aliphatic 
isocyanates 
4 
5 Synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazine via two-bond 
formation through (3+3) atoms heterocyclization 
7 
6 Synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazine via two-bond 
formation and (5+1) atoms heterocyclization 
8 
7 Synthesis of 5,7-dioxo or dithioxo analogues of 1,2,4-triazolo[1,5-
a][1,3,5]triazine via two-bond formation and (5+1) atoms 
heterocyclization 
9 
8 Synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazine via one-bond 
formation and (6+0) atoms heterocyclization 
10 
9 Synthesis of 5,7-dioxo or dithioxo analogues of 1,2,4-triazolo[1,5-
a][1,3,5]triazine via one-bond formation and (6+0) atoms 
heterocyclization 
11 
10 Synthesis of 2,4-dioxo-pyrazolo[1,5-a][1,3,5]triazine via two bond 
formation through (3+3) atoms heterocyclization 
13 
11 Synthesis of 2,4-dithioxo-pyrazolo[1,5-a][1,3,5]triazine via two 
bond formation through (4+2) atoms hetrocyclization 
14 
12 Synthesis of 2,4-dioxo-pyrazolo[1,5-a][1,3,5]triazine via two-bond 
formation through (5+1) atoms heterocyclization 
15 
13 Synthesis of pyrazolo[1,5-a][1,3,5]triazine via one bond formation 
through intramolecular heterocyclization 
16 
14 Enzymatic reaction of thymidine phosphorylase 22 





16 Synthesis of 2-substituted-1,2,4-triazolo[1,5-a][1,3,5]triazin-
5,7(4H,6H)-dione and its derivatives (H2, H3, H4, H5 and H6) 
61 
17 Synthesis of 2-benzyl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
5,7(4H,6H)-dione and its derivatives (H7, H8 and H9) 
63 
18 Synthesis of 7-phenyl-pyrazolo[1,5-a][1,3,5]triazin-2,4(1H,3H)-
dione and its  derivatives (H10, H11 and H12) 
67 
19 Synthesis of (8-benzyl-4-oxo-2-thioxo-1,2,3,4-tetrahydro 
pyrazolo[1,5-a][1,3,5]triazin-7-yl)-thiourea (H13) 
68 
20 Synthesis of 5-thioxo-5,6-dihydro-4H-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-one (H5bi-H5bxix and H8a-H8i) 
85 
21 Tautomerism of 1,2,4-triazoles 86 
22 Synthesis of 2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-
a][1,3,5]triazin-4-one analogues (H11a-H11g) 
88 




24 Synthesis of 3(5)-amino-5(3)-(het)aryl-1,2,4-triazoles (87, 91) 110 
25 Tautomers of 3(5)-amino-1,2,4-triazoles 112 
26 Synthesis of N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-
carbethoxythioureas (88, 93) 
115 
27 Nucleophilicity of 3(5)-amino-5(3)-2-pyridyl-1,2,4-triazoles 118 
28 Synthesis of 4-carbethoxy-1-[4-(N,N-
dimethylamino)benzoyl]thiosemicarbazide (109) 
123 


















ADP adenosine diphosphate 
AEAC 6-(2-aminoethylamino)-5-chlorouracil 
BVDU 5-(E)-(2-bromovinyl)-2’-deoxyuridine 
CAM chorioallantoic membrane 
CB cannabinoid 
CDK2 cyclin-dependent kinase type 2 
CNS central nervous system 
CoMSIA molecular similarity indices analysis 
Cpd compound 







DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DPD dihydropyrimidine dehydrogenase 
dThd thymidine 
EC enzyme commission 
ECM extracellular matrix 
EI  enzyme-Inhibitor complex 
ELISA enzyme-linked immunosorbent assay 
EPC endothelial progenitor cells 
ESI enzyme-Substrate-Inhibitor complex 
ESI  electrospray ionization 
FAK focal adhesion kinase 
FDHU 5-fluorodihydrouracil 
FdUMP 5-fluorodeoxyuridine monophosphate 
FdUrd 5-fluorodeoxyuridine 
FUDP 5-fluorouridine diphosphate 
FUMP 5-fluorouridine monophosphate 
FUrd  5-fluorouridine 
FUTP 5-fluorouridine triphosphate 
HO-1 heme oxygenase-1 
HPLC high-performance liquid chromatography 
xviii 
 
HUVECs human umbilical vein endothelial cells 
IC50  concentration of inhibitor that causes 50% of Inhibition   
IFN interferons 
IL interleukin 




MMPs matrix metalloproteinase 
MNGIE mitochondrial neurogastrointestinal encephalomyopathy 
mRNA messenger RNA 
MS  mass spectrometry 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
MW   microwave 
NFkB nuclear factor-kappaB 
NMR nuclear magnetic resonance 
OPRT orotate phosphoribosyl transferase 
PDE phosphodiesterase 
PD-ECGF platelet-derived endothelial cell growth factor 
PMA phorbol myristate acetate 
QSAR quantitative structure–activity relationship 
RNA ribonucleic acid 
SD standard deviation 
SDS-PAGE sodium dodecyl sulphate –poly acrylamide gel electrophoresis 
siRNA small interfering RNA 
xix 
 
TAM tumour-associated macrophages 
TFT 5-trifluorothymidine 
TFT trifluorothymidine 
TIMP tissue inhibitor of metalloproteinases 
TK thymidine kinase 
TLC  thin layer chromatography 
TNF tumour necrosis factor 
TNF-α tumour necrotic factor-alpha 
TP thymidine phosphorylae 
TPI 5-chloro-6-[1-(2-iminopyrrolidinyl)methyl]uracil hydrochloride 
TS thymidylate synthase 
UK uridine kinase 
UP uridine phosphorylase 
UV  ultra violet 
VEGF vascular endothelial growth factor 
























Introduction - Review of 1,3,5-triazin-2,4-diones, Thymidine 












The triazine is among the oldest known heterocyclic organic compound. Three 
isomeric forms of triazine are distinguishable and they are referred to as 1,2,3-triazine 
(1), 1,2,4-triazine (2) and 1,3,5-triazine (3) (Figure 1). Among these three possible 
triazine isomers, the 1,3,5-triazine, also known as symmetric or s-triazine, is found in 







 and antihypertensive activities
4
. Therefore, there is an 
interest in developing new methods for incorporating the 1,3,5-triazine scaffold into 
new generation of bioactive compounds in drug discovery projects. In this first 
introductory section, a mini review on the reported synthetic procedures and 
biological activities of 1,3,5-triazin-2,4-dione and its fused derivatives will be 
described.  
 
Figure 1. Structures of the three isomeric forms of triazine 
1.1 Synthesis of 1,3,5-triazin-2,4-dione and its fused derivatives 
The synthesis of 1,3,5-triazin-2,4-dione and its fused analogues viz. 1,2,4-triazolo[1,5-
a][1,3,5]triazine and pyrazolo[1,5-a][1,3,5]triazine can be achieved via various 
different synthetic strategies using different starting materials. A complete listing of 
all possible synthetic routes is beyond the scope of this mini review. Therefore, a 
review of selected reported synthetic procedures related to 1,3,5-triazin-2,4-dione and 
its fused derivatives will be presented in the following sub-sections.  
3 
 
1.1.1 Synthesis of 1,3,5-triazin-2,4-dione 
Several synthetic strategies have been employed to prepare 1,3,5-triazin-2,4-diones. 
In 1959, Flament et al,
5
 developed a method to synthesize 1,3,5-triazin-2,4-dione (5) 
via the dealkylation of 2,4-dimethoxy-1,3,5-triazine (4) in refluxing aqueous medium 
in the presence of concentrated hydrochloric acid (Scheme 1). Compound 5 was 
exclusively isolated from the reaction mixture with 95 % yield.  
 
Scheme 1. Synthesis of 1,3,5-triazin-2,4-dione from 2,4-dimethoxy-1,3,5-triazine 
Alternatively, derivatives of 1,3,5-triazin-2,4-dione (7) could also be successfully 
synthesized by the condensation of urea (6) with orthoester (Scheme 2).  
 
Scheme 2. Synthesis of 1,3,5-triazin-2,4-dione from the condensation of urea with 
orthoester 
 
In 1963, Piskala et al 
6
 synthesized 1,3,5-triazin-2,4-dione derivatives by the treatment 
of urea with ethyl orthoformate in the presence of acetic anhydride with excellent 
yield (90 %). Using different substituted orthoesters, this reaction condition allowed 
the introduction of different functional groups at position C6 of 1,3,5-triazine. 
The reaction of thiourea derivatives with an isocyanate could be an alternative route 
to the synthesis of 1,3,5-triazin-2,4-dione too. In 1984, Sanemitsu et al 
7
 reported that 
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the reaction between N-ethoxycarbonyl-s-methylisothioureas (8) and isocyanates in 
DMF at room temperature could afford 1,3,5-triazin-2,4-dione
 
(9) with reasonable 
good yield (Scheme 3). Using this synthetic methodology, incorporation of various 
substituents at positions N3 and N5 of 1,3,5-triazin-2,4-dione could be possible by 
using different starting materials substituted with aromatic and aliphatic groups.  
 
Scheme 3. Synthesis of 1,3,5-triazin-2,4-dione from thiourea derivatives 
 In addition, Kantlehner et al 
8
 established a method using a range of substituted 
aromatic isocyanates with N,O-bis(trimethylsilyl)acetamidate to produce an 
intermediate, silylated azauracil (11) which after desilylation with alcohol would 
afford 1,3,5-triazin-2,4-dione (12) (Scheme 4). 
 





1.1.2  Synthesis of fused 1,3,5-triazin-2,4-dione and its thioxo analogues 
Section 1.1.1 described the methods for synthesizing monocyclic 1,3,5-triazin-2,4-
dione. Herein, the synthetic procedure of 1,2,4-triazolo and pyrazolo fused 1,3,5-
triazin-2,4-dione and their thioxo derivatives will be discussed. 1,2,4-triazolo[1,5-
a][1,3,5]triazine (14) and pyrazolo[1,5-a][1,3,5]triazine (15), also known as 5-
azapurine and 5-aza-9-deazapurine respectively, are the isosteres of purine (Figure 2). 
As a matter of fact, it is reported that derivatives of these scaffold would target the 
purinergic signalling receptors and enzymes involved in the metabolism of biogenic 
purines. Therefore, development of 1,2,4-triazolo[1,5-a][1,3,5]triazine and 
pyrazolo[1,5-a][1,3,5]triazine derivatives as biological active agents has drawn 
considerable interest in recent years. Several methods were developed and reported 





. These methods are broadly classified as A) annulation of the 
triazine ring onto a triazole or pyrazole scaffold; B) annulation of the triazole or 
pyrazole ring onto a triazine scaffold; C) concurrent formation of both rings; D) 
synthesis via ring transformation reactions. In the following sections, the methods that 
generate triazolo and pyrazolo fused 1,3,5-triazin-2,4-dione and their thioxo 
analogues will be elaborated and representative examples will be included.  
 






1.1.2.1 Synthesis of 1,2,4-triazole  fused 1,3,5-triazin-2,4-dione analogues 
The 1,2,4-triazolo[1,5-a][1,3,5]triazine scaffold was first described by Pellizzari and 
Roncaglilo in 1901
11
. However, the original structure was only established recently by 
X-ray crystallography
12
. Although many different ways have been reported on the 
construction of 1,2,4-triazolo[1,5-a][1,3,5]triazine, our target scaffolds viz. 1,2,4-
triazolo fused 1,3,5-triazin-2,4-dione and thioxo analogues were synthesized 
extensively via annulation of the 1,3,5-triazine ring onto a 1,2,4-triazole scaffold. In 
addition, special attention was given to the ways for introducing different substituents 
at various positions around the target scaffold. 
Two-bond formation through (3+3) atoms heterocyclization 
Several reports have described that a number of electrophilic reagents may be 
employed as triatomic synthons which will provide the C-N-C fraction for annulation 
of the 1,3,5-triazine ring onto a 3(5)-amino-1,2,4-triazoles. For example, the synthesis 
of  5,7-dioxo-1,2,4-triazolo[1,5-a][1,3,5]triazines (18) could be achieved via the 
condensation of 3(5)-amino-1,2,4-triazoles (16) with 17
13
. In addition, it is reported 
that reaction of 19 with N-aroyl isothiocyanates (20) in refluxing acetone led to the 
formation of 7-thioxo substituted-1,2,4-triazolo[1,5-a][1,3,5]triazines
14
 (22). In this 
reaction, it has been postulated that after initial attack of endocyclic nitrogen N1 by 
isothiocyanate, it formed an intermediate (21) affording target compound (22) after 
further rearrangement. However, isothiocyanate has been reported to react with the 
exocyclic nitrogen upon heating and thus gave rise to different intermediates (23) 
which underwent spontaneous rearrangement resulting in the formation of the 
isomeric product (24)
9
 (Scheme 5) .  
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Scheme 5. Synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazine via two-bond formation 
through (3+3) atoms heterocyclization 
Two-bond formation through (5+1) atoms heterocyclization 
The synthesis of 7-oxo or thioxo analogues of 1,2,4-triazolo[1,5-a][1,3,5]triazines has 
been achieved via two-bond formation through (5+1) atoms heterocyclization using 5-
amino-1,2,4-triazoles having carboxamidic or carbothioamidic moiety at N1. In this 
category of reaction, one carbon inserting reagents like triethyl orthoesters, diethoxy 
methyl acetate, formic acid, ethyl chloroformate have been employed depending on 
the reaction conditions used
9,15-17
. The reaction of 5-amino-1,2,4-triazolo-1-
carbothiamides (25) with triethyl orthoester or diethoxymethyl acetate under different 
conditions which produced 7-thio-oxo[1,2,4]triazolo[1,5-a][1,3,5]triazines (26) 
(Scheme 6)
15
 represents this category of synthesis. These kind of reactions help to 
incorporate a wide range of functional groups including aromatic and aliphatic 
moieties at positions C2, C5 and N7 of the triazolo fused triazine scaffold depending 




Scheme 6. Synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazine via two-bond formation 
and (5+1) atoms heterocyclization 
Alternatively, 5,7-dioxo or dithioxo analogues of triazolo fused triazine can also be 
synthesized via the use of 1,2,4-triazoles having -N-C-N appendage (ureas and 












 and diethyl carbonate
23
 have been reported to be successful in 
producing the fused triazine ring. Previously, it has been described that the 
heterocyclization of N-(1,2,4-triazol-3(5)-yl)-N’-(4-chlorophenyl)ureas (27) using 
ethyl chloroformate or carbon disulfide would result in the formation of 5,7-dioxo or 
5-oxo-7-thioxo substituted 1,2,4triazolo[1,5-a][1,3,5]triazines (28 and 29) 
respectively
22, 24
. Similarly, treatment of N-(1,2,4-triazol-3(5)-yl)thioureas (30) with 
carbon disulfide afforded 2-aryl-5,7-dithioxo[1,2,4]triazolo[1,5-a][1,3,5]triazines 
(31)
21




Scheme 7. Synthesis of 5,7-dioxo or dithioxo analogues of 1,2,4-triazolo[1,5-
a][1,3,5]triazine via two-bond formation and (5+1) atoms heterocyclization 
One-bond formation through (6+0) atoms intramolecular heterocyclization 
In alkaline medium, 5-amino-1,2,4-triazoles having -N-C-N appendage 
(carbethoxycarbamoyl (32) and carbethoxylthiocarbamoyl (34)) at N1 underwent 
intramolecular heterocyclization and afforded 5,7-dioxo[1,2,4]-triazolo[1,5-
a][1,3,5]triazines (33) and 5-oxo-7-thioxo1,2,4-triazolo[1,5-a][1,3,5]triazines (35) 
respectively
25,26, 27
 (Scheme 8). In this reaction condition, 3(5)-amino-1,2,4-triazole 
was commonly used as 1,2,4-triazole scaffold. However, 3(5) amino triazole 
substituted with aromatic (phenyl) or aliphatic (methyl) moiety could  also be 




Scheme 8. Synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazine via one-bond formation 
and (6+0) atoms heterocyclization 
Intramolecular cyclization of N-(1,2,4-triazol-3(5)-yl)-N’-carbethoxyurea (37) in 
aqueous solution of sodium carbonate produced 5,7-dioxo-[1,2,4]triazolo[1,5-
a][1,3,5]triazines (38)
27
 (Scheme 9). This reaction is an example of the formation of 
5,7-dioxo substituted 1,2,4-triazolo[1,5-a][1,3,5]triazines through intramolecular 
heterocyclization of 1,2,4-triazoles that have a –N-C-N-C appendage attached at 
position N5. Similarly, N-(1,2,4-triazol-3(5)-yl)-N’-carbethoxyurea (39) and 4 methyl 
substituted carbethoxyurea (42) could be cyclised to 7-oxo-5-thioxo-
[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives (40 and 43) respectively in alkaline 
medium
26-28
. The corresponding 5-methylthio substituted compounds (41) were 







Scheme 9. Synthesis of 5,7-dioxo or dithioxo analogues of 1,2,4-triazolo[1,5-
a][1,3,5]triazine via one-bond formation and (6+0) atoms heterocyclization 
1.1.2.2 Synthesis of pyrazolo fused 1,3,5-triazin-2,4-dione analogues 
The pyrazolo[1,5-a][1,3,5]triazine scaffold was first synthesized by Checchi and Ridi 
in 1957
29
. As described, although several methods are adopted to prepare 
pyrazolo[1,5-a][1,3,5]triazine scaffold, the synthesis of pyrazolo fused 1,3,5-triazin-
2,4-dione and its thio-oxo analogues was achieved via the annulation of the triazine 






Two bond formation through (3+3) atoms heterocyclization 
The reaction between  triatomic C-N-C synthons viz. the substituted imidates (N-
cyano-(a), and N-carbethoxyimidates (b) )
10
 with 3(5)-aminopyrazoles has been 
shown to afford 2,4-dioxo analogues of pyrazolo[1,5-a][1,3,5]triazine with a wide 
range of funtionalizations. It is reported that the reaction of substituted 3(5)-
aminopyrazoles (44) with chlorocarbonyl isocyanates or phenoxycarbonyl isocyanates 
(45) gave 2,4-dioxo- pyrazolo[1,5-a][1,3,5]triazine (46)
30
. This synthetic scheme has 
been employed to introduce substituents at C7 and C8 of the fused ring system. 
Furthermore, 3-alkyl-2,4-dioxopyrazolo[1,5-a][1,3,5]triazine (49) was reported to be 
synthesized via the condensation of 3(5)-aminopyrazoles (47) and N-alkyl 
bis(chloroformyl)amines (48)
31
 (Scheme 10). Depending on the substituents present in 
3(5)-aminopyrazoles, various substituents could be introduced at positions C7 and C8 
of pyrazolo[1,5-a][1,3,5]triazine scaffold. In addition, using different substituted 
bis(chloroformyl)amines, incorporation of different moieties including cycloalkyl, 
and branched alkyl chain at the position N3 of the fused ring could be achieved 




Scheme 10. Synthesis of 2,4-dioxo-pyrazolo[1,5-a][1,3,5]triazine via two bond 
formation through (3+3) atoms hetrocyclization 
Two bond formation through (4+2) atoms heterocyclization 
The thioxo analogues of the pyrazolo fused triazin-2,4-dione are prepared by two 
bond formation through (4+2) atoms heterocyclization. For example, the 2,4-dithioxo-
pyrazolo[1,5-a][1,3,5]triazine (51) could be produced by heterocyclization of methyl 
5-amino-3-arylpyrazole-1-carbodithioates (50) with cyanamide or isothiocyanates
32, 
33
(Scheme 11). Using different types of cyanamide or isothiocyanates, this reaction 
condition allows the introduction of aliphatic or aromatic functional group at position 




Scheme 11. Synthesis of 2,4-dithioxo-pyrazolo[1,5-a][1,3,5]triazine via two bond 
formation through (4+2) atoms heterocyclization 
Two bond formation through (5+1) atoms heterocyclization 
The reaction of 5-aminopyrazoles having C-N appendage at N1 with one carbon 
inserting reagent can generate 2,4-dioxo substituted pyrazolo[1,5-a][1,3,5]triazine  
derivatives with diverse functionalities. One carbon inserting reagents that can be 
used for this reaction include orthoesters
34-36







. It is reported that heating of 5-amino-1-
carbomyl-3-phenylpyrazole (52) with ethylformate in pyridine resulted in the 
formation of 2,4-dioxo-7-phenylpyrazolo[1,5-a][1,3,5]triazine (53)
32
. Analogously, 
the synthesis of 3-substituted 2,4-dioxo-7-methylpyrazolo[1,5-a][1,3,5]triazine (55) 









Scheme 12. Synthesis of 2,4-dioxo-pyrazolo[1,5-a][1,3,5]triazine via two-bond 
formation through (5+1) atoms heterocyclization 
One bond formation through intramolecular heterocyclization 
In alkaline medium, pyrazole having C-N-C appendage at N1 or a N-C-N-C 
appendage at C3(5) may undergo intramolecular heterocyclization to yield a wide 
range of 2,4-dioxo derivatives of pyrazolo[1,5-a][1,3,5]triazine. The heterocyclization 
of aminopyrazole (56) in the presence of DBU led to the formation of 8-cyano-4-
methylthio-2-oxo pyrazolo[1,5-a][1,3,5]triazine (57)
38
. On the other hand, 5-aza-9-
deazahypoxanthine (59) was successfully synthesized by heating of N-carbethoxy-N’-
(3(5)-pyrazolyl)formamidine (58) in the presence of a base or in xylene
39
. In a similar 
way, Capuano and Schrepfer developed methods to synthesize 5-aza-9-deazaxanthine 
(61) from N-carbethoxy-N’-(3(5)-pyrazolyl)urea (60)40. Several reaction conditions 
were established, such as reflux at 180 ºC
41
, heating in pyridine or triethylamine
28
 and 









 or potassium carbonate
10
 for heterocyclization of N-
carbethoxythioureas (62 and 63) that resulted in the formation of compound 64. A 
similar kind of reaction  of intramolecular heterocyclization of N-carbethoxy-N’-
16 
 
indazolylthiourea (65) was developed and reported
44
, and this reaction scheme gave 
rise to a fused tricyclic compound instead (Scheme 13). 
 
Scheme 13. Synthesis of pyrazolo[1,5-a][1,3,5]triazine via one bond formation 




In the above section, a variety of effective methods for the preparation of 1,3,5-
triazin-2,4-dione and its fused analogues have been reported. Several methods 
utilizing biurets, urea derivatives and substituted acetamidates as starting materials 
were found to be practical for the construction of the 1,3,5-triazin-2,4-dione 
derivatives. In addition, the annulation of  the 1,3,5-triazine ring onto a 1,2,4-triazole 
and/or pyrazole  scaffold has been observed as convenient synthetic approaches to 
afford 1,2,4-triazolo and/or pyrazolo fused 1,3,5-triazin-2,4-dione and its thioxo 
analogues. Several reports have demonstrated that the 1,3,5-triazin-2,4-dione and its 
fused scaffolds have been utilized for the design of biologically active compounds 
exhibiting wide spectrum of activity ranging from pesticides to chemotherapeutic 
agents. In the following section, the reported biological effects of the 1,3,5-triazin-
2,4-dione and its fused analogues will be described. 
1.1.3 Applications of 1,3,5-triazine and its fused analogues in medicine and 
agriculture 
 It was mentioned earlier that derivatives of 1,3,5-triazin-2,4-diones have potential 
herbicidal activity. It is claimed that hexazinone (67)
45
 is a potent herbicide, effective 
against annual and biennial weeds. In contrast, 1,2,4-triazolo[1,5-a][1,3,5]triazine, the 
fused structure of 1,3,5-triazine, is identified as an important scaffold in medicinal 
chemistry as its derivatives exhibited diverse biological activities (Figure 3). The 
derivatives of 5-amino-1,2,4-triazolo[1,5-a][1,3,5]triazine (68) has been found to be 
one of the most effective and selective class of adenosine receptor inhibitors
46-49
. As a 
result, these derivatives are claimed to be useful for the treatment of depression, 
anxiety, cerebrovascular disorder and parkinson’s disease 9. Due to structural 
similarity with purine, compounds having 1,2,4-triazolo[1,5-a][1,3,5]triazine scaffold 
18 
 
may interfere with the effect of biological purines (i,e. adenosine, guanine and 
xanthine). The metabolism of xanthine may be affected by some derivatives (69) 
through the inhibition of xanthine oxidase
50
. As a matter of fact, some of compounds 
(70) are reported to be potent bronchodilator
9
. In addition, few derivatives show 





Furthermore, the 5,7-diaryl substituted derivatives (71) of 1,2,4-triazolo[1,5-
a][1,3,5]triazine have promising antioxidant and antiproliferative potential
51
. Besides 
these activities, the derivatives of this scaffold are used as antibacterial, antifungal 
agents
21, 52, 53 
and herbicides in agriculture
9
.  
On the other hand, due to structural similarity with purines, pyrazolo[1,5-
a][1,3,5]triazine provides a rational design of medicinally useful compounds that may 
target the receptors and enzymes of biogenic purines producing diverse biological 
outcomes (Figure 3). Robins et al
54
 reported 8-phenyl-5-aza-9-deazahypoxanthine 
(72) as XO inhibitor which is used in the treatment of hyperuricemia, particularly for 
gout attack. Substituted aminopyrazolo[1,5-a][1,3,5]triazine (73) has been reported to 
inhibit type 2 cyclin-dependent kinase (CDK2) which regulates cell cycle and thus 
shows antiproliferative activity
10
. Some compounds (74) bearing pyrazolo[1,5-
a][1,3,5]triazine scaffold are identified as phosphodiesterase (PDE) inhibitors and are 
used for the treatment of autoimmune and inflammatory diseases
55
. It is also reported 
that some pyrazolo[1,5-a][1,3,5]triazine derivatives (75) are able to inhibit bacterial 
DNA gyrase and therefore used as antibacterial agents
42
. In addition to these enzymes 
based activities, a number of pyrazolo[1,5-a][1,3,5]triazine derivatives targets several 
G-protein coupled receptors including adenosine, P2Y1, corticotrophin-releasing 
factor, neuropeptide Y, 5-(HT), cannabinoid and angiotensin receptors. Compound 
(76) is reported to exert A2A adenosine receptor inhibitory activity
56
 and compound 
19 
 
(77) has shown P2Y1 associated ADP-induced platelet aggregation in  in vitro and in 
vivo models
57
. Some derivatives (78) of pyrazolo[1,5-a][1,3,5]triazine are believed to 




a][1,3,5]triazines are claimed to be the modulators of neuropeptide Y1 receptor
59
. In 
addition, some compounds are known to target cannabinoid (CB) receptor and they 
are used as therapeutic agent for CNS disorder
60








Figure 3. Structures of representative biologically active compounds of 1,3,5-triazine 
and its fused analogues             
In this section, a short summary on the therapeutic effects of the derivatives of 1,3,5-
triazine and its fused analogues is highlighted. It is revealed that although 1,3,5-
triazine is found in many bioactive compounds either as monocyclic or triazolo and 
pyrazolo fused forms, a limited examples of biological effects of the 1,3,5-triazin-2,4-
diones and its triazolo and/or pyrazolo fused analogues have been reported in the 
literature. As discussed, although significant efforts have been made to explore 
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exciting range of biological activities of 1,3,5-triazine and its fused analogues, the 
inhibitory activity of this scaffold against thymidine phosphorylase (TP) and its 
associated angiogenesis effects has not yet been established. Therefore, this field is 
open as a subject for further detail investigation. The following few sections will 
discuss the enzyme TP and its inhibitors known to date. 
1.2 Thymidine phosphorylase (TP) as a target of drug design 
During the last few decades, the target based drug design for anticancer therapy has 
met with increasing interest. In this approach, medicinal chemists identify and choose 
to interfere with a protein target molecule that plays a critical role in DNA replication 
or is involved in vital biochemical pathways. Initially, the natural ligand or substrate 
of this protein is modified structurally to generate lead compounds that can exhibit 
inhibition, antagonism or agonistic effect towards the identified target depending 
upon the intended therapeutic outcomes. This approach has produced rationally 
designed inhibitors of dihydrofolate reductase, thymidylate synthase, purine 
nucleoside phosphorylase, glycinamide ribonucleotide formyltransferase and matrix 
metalloproteases that can either inhibit DNA replication or block critical biochemical 
pathways resulting in the prevention of growth of the cancerous cells. Continuous 
efforts in this field, have discovered thymidine phosphorylase (TP, EC 2.4.2.4) as a 
potential therapeutic target in cancer therapy in 1954
61
. It catalyses the reversible 
phosphorolysis of thymidine-2’-deoxyuridine and their analogues to 2-deoxy-alpha-
D-ribose-1-phosphate (2DDR-1P) and respective bases 
62
(Scheme 14). It also acts in 
the salvage pathway of pyrimidine nucleotides by transferring the deoxyribosyl 







Scheme 14. Enzymatic reaction of thymidine phosphorylase. 
Although this reaction is reversible, the main enzymatic activity is catabolic in nature. 
The reason being the kinetic constants do not favour the synthetic reaction and the 
cells also lack sufficient concentration of 2DDR-1P
64,65
. It has low substrate 
specificity. Besides its natural substrate, this enzyme can also recognize several 
pyrimidines or pyrimidine nucleosides that have potential antiviral and/or antitumoral 





, and 5-fluoro-5’-deoxyuridine (5’DFUR), an 
intermediate metabolite of capecitabine
69
. It was reported that anticancer agent viz. 
TFT is metabolized to the inactive base, and therefore, it exhibits poor 
pharmacokinetic profile in cancer patients. 
Platelet-derived endothelial cell growth factor (PD-ECGF) was isolated from human 
blood platelets in 1987
70
. It has been demonstrated to induce endothelial cell 
chemotaxis in vitro and angiogenesis in vivo
71
. It also involves in thymidine 
incorporation into the cells. Interestingly, amino acid sequence analysis and gel 
chromatography revealed that PD-ECGF and TP are identical with each other
72
. PD-
ECGF/TP is also found to be identical to gliostatin, a glial growth inhibitory factor 






1.2.1 Structure of thymidine phosphorylase 
TP was purified from both Escherichia coli and Salmonella typhimurium in mid-
1970s
74,75
. Several years later, human TP was extracted from the 
amniochorion
76
(Figure 4). It was observed that the amino acid sequence of human TP 
was only 39% identical with E. coli TP
77
. The human TP gene is located on 
chromosome 22q13
78
 and is composed of 10 exons dispersed over a 4.3-kb region. Its 
promoter lacks a TATA box and a CCAAT box, which is prevalent in most 
eukaryotic promoters
79
. Instead, six copies of potential Sp1-binding sites (GGGCGG 
or CCGCCC) are clustered just upstream from the transcription start sites
80
. This SP1 
sites are also involved in the transcription of VEGF and therefore, many studies 
suggested the tendency of co-expression of both VEGF and TP
81,82
.  
This enzyme functions as a homodimer, having two identical subunits, with a 
molecular mass ranging from 90 kDa in E. coli to 110 kDa in mammals
83, 84
. The 
crystal structure of E. coli TP suggested that each subunit is composed of a large 
mixed α/β domain containing phosphate binding site and small α helical domain that 
contains the thymidine binding site. These two domains are separated by a cleft. The 
orientation of the active site seems to suggest that domain motion is critical to the 
generation of a closed catalytically active conformation of the enzyme. It was 
concluded that phosphate binding influences the formation of a hydrogen bond 
between His119 and Gly208 and helps to order the 115 to 120 loop. The formation of 
this hydrogen bond also induces the domain movement. The α domain moves as a 
rigid body, while the α/β domain shows some non-rigid body movement that is 
associated with the formation of the His119-Gly208 hydrogen bond
85,86
. The closed 
active conformation resulting from the movement of two domains is also supported by 
24 
 





Figure 4. Structure of human thymidine phosphorylase 
1.2.2 Biological functions of thymidine phosphorylase 
 Physiological role 
TP is distributed throughout various organs in the human body and is present in both 
cytoplasm and nucleus within the cell
88
. This enzyme is highly expressed in blood 
platelets and it contributes towards wound healing
89
. In addition, TP plays an 
important physiological role in the female reproductive cycle. A high level of TP is 
detected in endometrium, which undergoes extensive angiogenesis during each 
menstrual cycle. Its expression is inversely correlated to oestradiol concentration, 
whereas the combination of both progesterone and transforming growth factors-β 
1
90,91
 are known to induce the expression of TP. 
 
It helps in the vascularisation of the 







 Pathological  role 
 Various studies indicated that TP is involved in a wide variety of chronic 











 and chronic glomerulonephritis
97
. Loss-of-function 
mutations of the TP gene has good contribution for mitochondrial 
neurogastrointestinal encephalomyopathy (MNGIE), an autosomal recessive human 
disorder associated with multiple deletions of skeletal muscle mitochondrial DNA
98
. 
TP deficiency may lead to an increased level of plasma and tissue thymidine and 
deoxyuridine that may cause alteration of mitochondrial nucleoside and nucleotide 
pools leading to impaired mitochondrial DNA replication and repair. Therefore, 
therapies that can abrogate thymidine levels may provide beneficial effects for 
MNGIE patients. However, it was confirmed from different studies that loss-of-
function mutation is not sufficient to produce MNGIE. Examination of chromosome 
22q13.32 where the TP gene is located, revealed that the mutation of the SCO2 gene 
which overlaps with exon 10 of TP, contributes to MNGIE
99
.  
 The association of thymidine phosphorylase with cancer 
Western blot and histological analysis showed that TP is overexpressed in many solid 
tumours
100
 including oesophageal, gastric, pancreatic, ovarian, breast, renal, bladder 
and non-small cell lung cancers
101,102
. In addition, TP expression is also  up-regulated 
in lymph nodes of patients with classical Hodgkin lymphoma where the expression of 
TP is increased with disease progression
103
. Moreover, it was reported that the TP 
expression is correlated well with higher microvessel density, higher tumour staging, 
and more metastasis. Besides tumour cells, it is also expressed in endothelial cells, 
fibroblasts, lymphocytes and particularly in tumour-associated macrophages (TAM). 
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TAM is believed to play a crucial role in stimulating tumour growth and metastasis 
through the production of various growth factors, proteinases, chemokines, and 
cytokines. An elevated level of TP has been demonstrated in TAM of melanoma, 
gastric, glioblastoma, breast, colon, astrocytic, uterine endometrial and prostate 
cancer. Furthermore, the overexpression of TP in macrophages of gastric 
adenocarcinoma, astrocytic tumours, breast, and uterine endometrial cancer has been 
demonstrated that it is associated with microvessel density and thus it is believed that 
this enzyme plays a key role in tumour invasion
104-108
. 
Several studies suggested that TP expression is upregulated by various inflammatory 
cytokines. Tumour necrotic factor-alpha (TNF-α) upregulates the TP mRNA levels 
and TP activity in human colon carcinoma cells is increased via the activation of SP1 
transcription factors. In the monocytic cell line THP-1, TNF-α influences the 
overexpression of TP mediated via TNF-α receptor 2 and NFkB
80, 109
. In addition, 
interferon (IFN)-α/β has been demonstrated a crucial role in upregulation of TP by 
stimulating IFN-stimulated response element (ISRE) in the TP promoter
110
. The IFN-
γ stimulates the expression of TP in human monocyte U937 cells by increasing 
binding of signal transducer and activator of transcription (STAT)-1 to a gamma-
activated sequence-like element in the TP promoter
111
. Moreover, these interferons 
also increase the stability of TP-mRNA and upregulate its over expression
110
. Besides 
these factors, interleukins are also involved in stimulation of TP overexpression. 
Cancer treatments protocol, such as X-ray irradiation and various chemotherapeutic 
agents including paclitaxel, docetaxel, doxorubicin, oxaliplatin, cyclophosphamide, 
and mitomycin C have been reported to  increase the tumour TP levels via up 
regulation of cytokines such as TNF-a, IFN-g, IL-1
112, 113
. An increase level of TP and 
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its enzymatic activity have been detected in tumour microenvironment that are 
proximal to necrotic area and this fact suggested that the microenvironmental stress 
conditions such as low pH and hypoxia of tumour microenvironment may cause an 
elevated level of TP expression
114
. 
Recently, it has been revealed that epigenetic modifications, such as methylation and 
histone deacetylation influence TP expression. In the breast carcinoma SKBR-3 cells, 
the high expression of TP is probably due to its complete demethylation of the CpG 
dinucleotides located in the TP promoter. The low TP expression is correlated with 
hypermethylation of the CpG islands as in DLD-1 colon carcinoma cells. However, 
the expression of TP in DLD-1 cells, could be achieved by  demethylation with 5-aza-




1.2.3 Role of thymidine phosphorylase in tumour development and progression 
 Angiogenesis 
Angiogenesis, the formation of new blood vessels from pre-existing vascular network, 
serves many important roles in several physiological processes, such as embryonic 
development, wound healing, and reproduction. It involves a variety of coordinated 
events including degradation of the surrounding extracellular matrix (ECM), 
endothelial cell migration and proliferation, and differentiation into mature blood 
vessels. TP is considered as an important factor among others that are involved in this 
multistep processes. TP induces endothelial cell migration and tube formation in 
vitro
71,116,117
. This enzyme also stimulates angiogenesis in the CAM
71
 and in several 




, and mouse 
dorsal air sac assays
118





. Recently, it has been revealed that TP also regulates the angiogenic potential 
of endothelial progenitor cells (EPC), or bone marrow-derived cells, which can 




The requirement for TP activity for angiogenesis was further confirmed by the fact 
that the mutants of TP that lack enzymatic activity cannot induce the formation of 
new blood vessels in the gelatine sponge assay. The angiogenic activity of TP can be 
abolished by using TP-directed neutralizing antibodies, by adding a specific TP 
inhibitor such as 5-amino-6-chlorouracil or by down-regulating TP by siRNA
120
. It is 
further established that 2-deoxy-D-ribose (2DDR), which is a degradation product of 






Figure 5. The function of thymidine phosphorylase and 2-deoxy-D-ribose in tumour 
development – a schematic representation82 
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Unlike other angiogenic molecule, TP shows some exceptional characteristic features.  
Firstly, it exerts its angiogenic effect by staying inside of the cells whereas most 
angiogenic factors are released into the extracellular space to activate endothelial 
cells. This is probably due to its deficiency of amino-terminal hydrophobic leader 
sequence required for cell secretion
71
. However, some tumour cell lines such as the 
epidermoid carcinoma A431 and stomach cancer MKN74 cell lines secrete this 
protein into the cell culture medium. Although, TP is mostly confined inside the cell, 
its metabolite 2DDR diffuses out of the cell and exerts its biological effects on other 
cells. Secondly, in mammalian cells, TP and 2DDR are most likely able to induce 
angiogenesis through a nonreceptor-mediated mechanism whereas other angiogenic 
factors usually bind to a specific cell surface receptor followed by a transduction 
cascade that exerts biological response of the cell.  
The mechanism by which TP induces angiogenesis is not fully understood, and a 
receptor for TP has not yet been identified. Several reports suggested that the 
angiogenic activity of TP is depending on its enzymatic activity. Among the 
metabolites of thymidine generated by TP, 2DDR is expected to be responsible for the 
angiogenic activity of TP. TP produces monosaccharide 2DDR-1P as a metabolic by-
product, which is converted to 2DDR by the nonenzymatic dephosphorylation. This 
2DDR is then secreted from the cell to exhibit the angiogenic effect via direct and 
indirect pathway (Figure 5).  
Hotchkiss et al.
122
 revealed that 2DDR can directly affect endothelial cell migration 
through the activation of focal adhesion kinase (FAK) and focal adhesion formation 
by regulating the association with components of FAK (integrins α5β1 and vinculin) 
on the cellular surface in human umbilical vein endothelial cells (HUVECs). 
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Indirectly, it also stimulates the secretion or expression of other angiogenic factors 
like VEGF, interleukin-8, and MMPs in tumour microenvironments. Following 
thymidine treatment of TP-overexpressing human bladder carcinoma RT112 cells 
showed an elevated expression of heme oxygenase-1 (HO-1), producing an oxidative 
stress which induces the expression and/or secretion of other angiogenic factors
123, 124
. 
In addition, Brown et al.
124
 suggested that 2DDR is a strongly reducing sugar that may 
generate oxygen radical species during the early stages of protein glycation. Thus, 
through the formation of 2DDR, TP may induce oxidative stress in TP-overexpressing 
tumour cells causing these cells to secrete angiogenic factors, such as VEGF.  
 Metastasis 
Many clinical studies have reported that the elevated TP expression is correlated to 
invasion and metastasis of gastric, colorectal, renal, pancreatic, non-small cell lung, 
and ovarian cancers. The metastasis effects of TP are confirmed by the fact that the 
elevated metastasis in TP-overexpressing cells can be dramatically inhibited by the 
TP inhibitor TPI or by 2-deoxy-L-ribose (2DLR), a stereoisomer of 2DDR
125,126
. 
Moreover, it was observed that the lung colonization and spontaneous metastasis  in 
mice, xenografted with the human melanoma cancer cell line A-07 were inhibited by 
treatment with neutralizing antibodies against TP
127
. 
 Protection  of cancer cells against apoptosis 









, and oral squamous cell carcinomas
132
. Uchimiya et al 
reported that the apoptotic index in KB/TP tumours was significantly lower than that 
in KB/CV tumours demonstrating TP could protect cells against apoptosis
118
. It was 
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postulated that 2DDR would inhibit numerous hypoxia-induced pro apoptotic events, 
such as activation of caspase 3 and 9, mitochondrial cytochrome c release, loss of 
mitochondrial transmembrane potential, phosphorylation of p38 mitogen-activated 
protein kinase, and downregulation of the anti-apoptotic proteins Bcl-2 and Bcl-
xl
133,134
. Furthermore, 2DDR also inhibits the upregulation of the transcription factor 
HIF-1a
133
. Besides hypoxia-induced apoptosis, TP was reported to suppress the 




1.2.4 Thymidine phosphorylase inhibitors 
From the above literature review, it can be postulated that inhibition of thymidine 
phosphorylase in cancer cells may be viewed as a plausible strategy to control 
angiogenesis stimulation and apoptosis inhibition. In addition, TP inhibitors may also 
serve as adjuvant agent to enhance the bioavailability and therapeutic efficacy of co-
administered anticancer drugs that belong to the deoxynucleosides viz. 
trifluorothymidine (TFT) that is rapidly metabolized by TP.  Therefore, TP serves as 
an interesting target for the development of chemotherapeutic agents and thus many 
laboratories have synthesized various chemical classes of TP inhibitors which have 
been tested preclinically and clinically. However, up to now, no compound has been 
approved yet for clinical use. In the next few paragraphs, selected TP inhibitors will 
be discussed and representative example of different classes (according to their mode 
of enzyme inhibition) of TP inhibitors are tabulated in table 1. 
For more than 30 years, the prototypic TP inhibitors were 6-aminothymine (6AT) and 
the derivatives of 6-aminouracil such as 6-amino-5-chlorouracil (6A5CU) and 6-





When it was revealed that TP is directly or indirectly involved in angiogenesis, 
interest was raised to synthesize novel TP inhibitors which might prevent tumour 
progression. Such efforts resulted in the generation of compounds such as AEAC 
which demonstrated improved solubility and activity compared to parent 6A5BU
141
. 
In 1998, Balzarini et al developed the first purine derivative, 7-deazaxanthine (7-DX) 
as a potential inhibitor against a pyrimidine nucleoside phosphorylase (i.e. TP) based 
on three-dimensional structure of E. coli TP
142
. This inhibitor was designed by 
including an additional second ring on the pyrimidine base of 6-aminothymine, in 
order to create extra stabilising interactions. It was reported that 7-DX was able to 
efficiently inhibit the neovascularization in the CAM assay
142
. In addition, inhibitors 
having 6-methylenepyridinium and 6-(phenylalkylamino) uracil have been 
investigated and evaluated as well
143,144
. Efforts to develop novel TP inhibitors in 
order to improve the potency of antitumor 2´-deoxynucleosides, led to the 
investigation of 6-methylene linked pyrrolidinyl and imidazolyl uracil analogues that 
exhibited potent competitive inhibitory effect on TP. In 2000, Fukushima et al 
identified 5-chloro-6-[1-(2-iminopyrrolidinyl)methyl] uracil hydrochloride (TPI) as 
the most potent inhibitor of human TP so far, with an IC50 value of 35 nM
145
. TPI 
inhibited the migration and basement membrane invasion of TP-overexpressing KB 
cells in vitro and TP induced angiogenesis in the mouse dorsal air sac assay
146
. It also 
significantly reduced the tumour growth rate and increased apoptotic index of KB/TP 
xenografted tumours. In addition, it suppressed liver metastases of KB/TP cells 
xenografted into nude mice
147
. Therefore, TPI has been considered for combination 
therapy with trifluorothymidine (TFT), an anti-tumoral agent that is rapidly 
inactivated by TP. An oral combination therapy of TFT and TPI (at a molar ratio of 
1:0.5), called TAS-102, is currently developed and evaluated in phase I studies for 
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patients with solid tumours
148
. The concurrent application of thymidine phosphorylase 
inhibitor (TPI) increases the bioavailability and in vivo efficacy of TFT. In addition, 
TPI exerts antiangiogenic effects by inhibiting thymidine phosphorylase (TP). A 
phase I clinical trial demonstrated that TAS-102 was active against heavily pre-treated 
metastatic breast cancers
149
. However, TAS-102 showed no significant response in 
patients with solid (mostly colorectal) tumours
150
. In order to selectively deliver TP 
inhibitors, a series of prodrugs of known TP inhibitors were designed, synthesized and 
tested
151,152
. These compounds exhibited their inhibitory effects after bioreductive 
activation by xanthin oxidase (XO) in hypoxic tumour microenvironments. 
A series of N1-alkylphosphonouracil derivatives has been synthesized and tested as 
multisubstrate inhibitors of E. coli TP. These compounds are designed based on 
structural features of TP. These inhibitors contain a thymine base that would interact 
at the nucleoside binding site, a spacer of 6 to 9 atoms, and a phosphonate moiety that 
could interact at the phosphate binding site. Further modification of these compounds 
by replacing the thymine ring by 6-A5BU or 7-deazaxanthine afforded compounds 
TP64 and TP65 respectively, which exhibit IC50 values against E. coli or human TP in 
the micro molar range
153
. Detailed kinetic experiments revealed that these compounds 
inhibited TP in a purely competitive or mixed fashion
154
. It is reported that TP65 
completely inhibited TP-induced formation of microvascular sprouts from endothelial 




Recently, a series of novel, multisubstrate, bicyclic pyrimidine nucleoside inhibitors 
of human thymidine phosphorylase (TP) was synthesized and tested
156
. Another 
multisubstrate inhibitor, 5-aryl-1-[2-(phosphonomethoxy)ethyl]uracil derivative was 
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designed based on an assumption that the potential hydrophobic effect of the aryl 




In addition, a different purine derivative KIN59 (5′-O-tritylinosine) was synthesized 
and tested against human and bacterial recombinant TP and TP-induced angiogenesis. 
The kinetic study suggested that this inhibitor exerted its inhibition in a non-
competitive manner in the presence of both thymidine and phosphate as the variable 
substrate. In addition, KIN59 has been found to inhibit angiogenesis in the 
chorioallantoic membrane assay. The data suggested that TP triggered angiogenesis 
may not solely be directed through its functional substrate binding sites, but other 
regulatory (allosteric) site(s) may be playing a crucial role to exert this biological 
property, which is still to be explored
158,159
. Recently, the purine ring and ribose 
moiety of the lead compound KIN59 was modified and it is demonstrated that this 
kind of modification resulted in improvement of inhibitory activity
160
. 
Within the last few years, extensive research work in this field generated many 
inhibitors having diverse molecular structure including 5,6-disubstituted uracil 
derivatives
161





substituted thymine acyclic nucleoside phosphonate derivatives
163
 and schiff bases of 
3-formylchromone
164
 that show promising inhibitory activity against TP.  It was also 
demonstrated that a few glycosides isolated from plant origin viz. symplocomoside 
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6A5BU (6-amino-5-bromouracil), AEAC (6-(2-aminoethylamino)-5-chlorouracil), 5C6-2’AIMU (5-chloro-6-(2’-
aminoimidazol-1’-yl)methyluracil), 5C6-2’-NIMU (2-chloro-6-(2’-nitroimidazol-1’-yl)methyluracil)- prodrug of 5C6-
2’AIMU, 7DX (7-deazaxanthine), KIN59 (5’-O-trityl-inosine), PBAU (6-(4-phenylbuthylamino)uracil), POABrU (1-(8-




A number of studies has demonstrated that 2-deoxy-L-ribose (2DLR), a stereoisomer 
of 2-deoxy-D-ribose, does not inhibit the enzymatic activity of TP but it suppresses 
the angiogenesis activity of TP. Indeed, it inhibits 2-deoxy-D-ribose-induced 
endothelial cell migration in a Boyden chamber, tube formation in collagen gel, and 
invasion of KB cells overexpressing TP (KB/TP) into matrigel. 2DLR has been 
shown to able to abrogate TP-induced angiogenesis in a rat corneal assay and in the 
mouse dorsal air sac assay
118
. Moreover, it significantly reduces the 2-deoxy-D-ribose 
stimulated VEGF, IL-8 and MMP-9 expression
126,166
. In contrast to TP inhibitors, 2- 
deoxy-L-ribose abrogates the biological activities of TP without affecting its 
enzymatic activity and therefore this may offer advantages for its use in combination 
therapy with 5FU prodrug that requires activation by TP. 
1.2.5 Thymidine phosphorylase mediated activation of anticancer prodrug 
It is mentioned earlier that due to low substrate specificity of TP, it can recognize 
various pyrimidine deoxynucleoside analogues possessing anti-tumour or anti-viral 
properties. Therefore, it plays a crucial role in the activation of chemotherapeutic 
drugs such as  5-fluorouracil (5-FU) and its  prodrugs such as 1-(tetrahydro-2-
furanyl)-5-fluorouracil (Tegafur), 4-N-pentyloxy-carbonyl-5’-deoxy-5-fluorocytidine 
(capacetabine),
 
 5-fluoro-2’-deoxyuridine (FdUrd, floxuridine) and doxifluridine (5’-
deoxy-5’-fluorouridine, DFUR). 5FU, an antimetabolite, has been used for the 
treatment of colorectal carcinoma for more than a decade. In systemic circulation, it is 
converted to FUTP and incorporated into replicating RNA and thus exerts 
cytotoxicity effects. Alternatively, in the presence of sufficient co-substrate, 2-
deoxyribose-1-phosphate TP may convert 5FU to FdUrd, which is then 
phosphorylated to FdUMP by TK.  The FdUMP can inhibit thymidylate synthase 
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resulting in thymidine depletion for DNA synthesis
168
. However, it is reported that the 
clinical efficiency of 5FU is unsatisfactory due to its rapid degradation by DPD and 
poor oral absorption. Therefore, significant research has been carried out to develop 
prodrug of 5FU. Doxifluridine (DFUR) and capecitabine are thus designed as 
prodrugs of 5FU to improve poor pharmacokinetic profile of the parent drug
169
. It 
should also be mentioned that capecitabine after converting to DFUR by enzymatic 
process in intestine and liver, is metabolized to 5FU by TP, which is up-regulated in 
tumour microenvironment compared to normal cells resulting in lower toxicity to 
normal tissues (Figure 6)
170
. Therefore, the metabolism of capecitabine by TP is 
considered as the rate limiting step for cytotoxicity effects of this prodrug and this has 
led to the hypothesis that a combination of TP-inducible chemotherapy (i.e.,  
cyclophosphamide and taxanes) and TP-targeted treatment (i.e., DFUR and 
capecitabine) may improve the effectiveness of anti-cancer therapy
171
. Based on this, 
several combination chemotherapy of capecitabine with standard TP inducible 
chemotherapy  is in phase-III trials and the outcomes suggested that this type of 










1.2.6 Structural aspect and crystal structure of human thymidine phosphorylase  
Due to the failure of many crystallization trials in producing well-diffracting crystals, 
it took several years to solve the structure of human TP
173
. Spraggon et al
174
 reported 
the crystals of human TP using a synchroton X-ray source in which diffraction was 
limited to 3.5 Å resolution.  In 2004, the crystal structure of human thymidine 
phosphorylase complexed with TPI
173
 was elucidated.  In this crystal, TP was found 
as a dimer with similar orientation as observed in E. coli TP. It was also deduced that 
TPI appeared to mimic the substrate transition state and bind to the enzyme as a 
zwitterions. The 5-chlorouracil moiety of TPI was found to form strong hydrogen 
bonds with R202, S217 and H116 and contribute to the tight binding of TPI to the 
active site. In addition, the chlorine atom in the 5-chlorouracil moiety was 
accommodated in a hydrophobic pocket formed by V208 and I214 of the α domain 
and L148 and V241 of the α/β domain in the enzyme. The 2-iminopyrrolidinyl moiety 
of TPI was found to make two hydrogen bonds with the active site; one of which 
interacted with the carbonyl oxygen of S117 and another to a water molecule (W) 
(Figure 7). However, in this structure several amino acid residues (amino acids 409 
and 410) were missing as it was subjected to limited proteolysis with trypsin to grow 
crystal as a result the loop formed by amino acid residues 405–416 was disordered.  
In 2006, El Omari et al
175
 solved a complete, good quality diffracting crystal structure 
of unproteolyzed human TP at 2.3 Å resolution in presence of thymidine. 
Surprisingly, the product thymine was found to be present in three of the four 
monomers of the asymmetric unit instead of thymidine, which was added during 
crystallization. Results from the kinetic studies of E. coli TP have suggested an 
ordered binding mechanism in which phosphate is the first substrate that binds to TP 
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whereas 2DDR-1P dissociates last from the enzyme. Therefore, this finding suggests 
that thymine, a non-competitive inhibitor of TP, may associate with the unoccupied 
enzyme, and induce domain closure and stabilize the closed conformation after 
product release, and thus explaining the mechanism of noncompetitive inhibition. 
This work also suggested the presence of higher electron density closer to residues 
Ser117, Gly152 and Tyr199 that could be further explored in drug design by 
incorporating some suitable substituent to an inhibitor, which might form strong 
hydrogen bonds with these residues. In 2009, Mitsiki et al
176
 reported the crystal 
structure of recombinant human TP complexed with 5-iodouracil (5IUR) at 3.0 and 
2.5 Å resolutions, respectively. This study provides some information about the role 













1.3 CoMFA, a 3D-QSAR method, as a means of lead optimization 
Drug discovery is considered as a long term and expensive process. It is mostly the 
result of accidental discovery and intensive screening of large libraries of synthesized 
or naturally occurring compounds. The most important step in drug design is to 
identify a lead, which can be discovered by in vitro screening of large libraries of 
compounds. It is noteworthy that after lead identification, it takes quite long time in 
lead optimization process to finally derive a commercial drug. A lead may 
demonstrate a low affinity for the target receptor, can be unstable in nature, possess 
high toxicity, exhibit poor pharmacokinetic properties or can be expensive to 
synthesize in large quantities. To make the lead compound suitable for 
commercialization, computer-aided drug design has been employed. The availability 
of three-dimensional (3D) structural information of biological receptors and their 
complexes with various ligands can be extremely useful in improving the affinity of 
the lead towards the target. Whenever, detailed structural information of target 
molecule is not available, the drug design process will follow a more indirect 
quantitative structure-activity relationship (QSAR) approach
177
. This approach 
basically creates a reliable statistical model using physicochemical properties of 
chemical substances and their biological activities for prediction of the activities of 
new chemical compounds. In classical QSAR studies, the biological end points are 
correlated with a range of  atomic, group or molecular properties such as lipophilicity, 
polarizability, electronic and steric properties
178,179
. However, such studies have 
exhibited their limitations for designing a new molecule due to the lack of 
consideration of the 3D structure of the molecules.  
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Nowadays, 3D-QSAR has emerged as a natural extension to the classical QSAR 
approaches pioneered by Hansch and Free-Wilson. In these approaches, the three-
dimensional properties of the ligands are exploited to predict their biological activities 
using robust chemometric techniques such as PLS, gPLS, ANN etc. In the absence of 
adequate structural information of the biological target, the drug design process has 
been adopted indirect 3D QSAR approach that uses molecular alignment of atoms, 
pharmacophores, volume, or fields to generate a virtual receptor. However, when the 
receptor structure is known, it is possible to investigate the ligand-receptor 
interactions and derive 3D-QSAR models from the corresponding parameters. In 
1987, Cramer developed the 3D-approaches named as DYnamic Lattice-Oriented 
Molecular Modeling System (DYLOMMS) that use PCA to calculate vectors from 
the molecular interaction fields, which are then correlated with biological activities. 
Subsequently, it was modified by including the two existing techniques, GRID and 
PLS, to develop a powerful 3D-QSAR methodology, known as Comparative 
Molecular Field Analysis (CoMFA)
180
 . Today CoMFA is considered as leading 3D-
QSAR methods. 
The primary objective of CoMFA study is to derive a correlation between the 3D 
shape and biological activity of a series of molecules in a superimposed conformation.  
These conformations are presumed to be the biologically active structures, overlaid in 
their common binding mode. From these conformations, the molecular fields viz. 
electrostatic and steric (van der Waals interactions) are calculated. The fields, usually, 
are measured at the lattice points of a regular Cartesian 3D grid; the lattice spacing is 
typically set to 2 Å. The interaction between the molecule and a probe atom (a sp
3
-
hybridized carbon with +1 charge) is measured. In addition, CoMFA uses a partial 




In summary, this introductory chapter has described various practical approaches for 
the construction of the 1,3,5-triazin-2,4-dione derivatives. In addition, several ways to 
convert triazolo fused 1,3,5-triazin-2,4-dione and its thioxo analogues are discussed. 
Depending on the starting reagents and reaction condition, different derivatives of 
1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7-dione and its thioxo analogues can be 
synthesized. In particular, substitutions at position C2, N3, C5 and N6 can be 
introduced with the use of differently substituted starting reagents. Similar 
observations are seen in the pyrazolo[1,5-a][1,3,5]triazin-2,4-dione analogues. In 
addition, a brief overview of TP and its reported inhibitors was described. 
Furthermore, attention was given to computer aided drug design based on CoMFA 
analysis.  
The brief literature review suggested that although 1,3,5-triazin-2,4-dione and its 
fused analogues exhibited wide range of biological properties, the activity of these 
scaffolds against thymidine phosphorylase (TP) has not yet been investigated. 
Therefore, the major part of this thesis is concerned with the synthesis and exploration 
of TP associated bioactivities of the said scaffolds. Moreover, a pharmacophore based 
3D-QSAR model will be generated using CoMFA analysis to predict the activity of 
novel TP inhibitor. Therefore, it is assumed that these research activities may be able 
to fill the gaps of previous research and it may have significant impact on the 











































2.1 Importance of the development of thymidine phosphorylase inhibitors as a 
novel antiangiogenic agents 
The diagnosis of cancer is often accompanied by the staging of the cancer 
development. The type and staging of cancer determine the treatment to be prescribed. 
In order to provide good clinical outcomes in chemotherapy of cancer patients, there 
is still room to develop new treatment strategies that target at various stages of cancer 
growth and development. Considerable evidence has identified angiogenesis as one of 
the processes in cancer development that can be interrupted as it promotes tumour 
growth and metastasis
181-183
. Therefore, in 1971, Folkman postulated that anti-
angiogenesis could be an effective strategy to be adopted in chemotherapy
184
. Since 
then, interests for developing anti-angiogenic factors have increased. Among 30 pro-
angiogenic factors identified, the family of vascular endothelial cell growth factor 
(VEGF) receptors is considered as potential targets for drug development as it is often 
expressed in various malignant tumours
185-187
. A humanized anti-VEGF monoclonal 
antibody, bevacizmab was developed and it was approved by the US Food and Drug 
Administration (FDA) for use in combination with standard chemotherapy for the 
treatment of metastatic colorectal, non-small cell lung and breast cancers. Thereafter, 
many other potential anti-VEGF monoclonal antibodies were developed. However, 
this anti-angiogenic adjunct therapy suffers from several serious problems. Firstly, 
selection of the most effective combination of anti-angiogenic agents with 
chemotherapeutic agents is always challenging. Secondly, anti-angiogenic therapy has 
been demonstrated in some cases to show resistance to response
188-190
. Although an 
increased dose can overcome such problem, but higher doses are likely to adversely 
affect the vascula of normal tissue. Some clinical studies have reported that 





. Lastly, anti-angiogenic therapy may also create hypoxic conditions 
and obstruct drug delivery to the tumour. This hypoxic tumour microenvironment 
may promote upregulation of chemokines and other angiogenic factors from stromal 
cells, including tumour associated macrophages and carcinoma-associated 
fibroblasts
192
. Therefore, there is a need to explore alternative targets for further 
development of angiogenic inhibitors to overcome the said limitations of traditional 
anti-angiogenic therapy. From the literature review, it is evident that the enzyme 
thymidine phosphorylase (TP) induces tumour vascularisation, promotes tumour 
growth and metastasis by inducing the secretion and/or expression of the angiogenic 
agents
82
. Therefore, TP may serve as an alternative target for the development of new 
anti-angiogenic therapy. 
Thymidine phosphorylase (TP, EC 2.4.2.4), also known as platelet derived endothelial 




, is involved in the catalysis of  the 
reversible phosphorolysis of thymidin-2’-deoxyuridine, and its analogues into 2-
deoxy-alpha-D-ribose-1-phosphate (2DDR-1P) and the respective bases
62
. It also acts 
in the salvage pathway of pyrimidine nucleotides by transferring the deoxyribosyl 
moiety to form new nucleoside
63
. TP is overexpressed in many solid tumours
100
 
including oesophageal, gastric, pancreatic, ovarian, breast, renal, bladder and non-
small cell lung cancers
101, 102
. It is reported that this enzyme and its metabolite 2DDR-
1P stimulate the secretion and/or expression of the angiogenic agents and involve in 




In addition, increased level of TP 
is associated with protection of the tumour against apoptosis
135, 196
 and enhancement 
of metastatic potential
127
 that may influence tumour progression. Therefore, inhibition 
of thymidine phosphorylase may be viewed as a plausible strategy to overcome its 
pathological effects. In addition, TP inhibitors may also serve as adjuvant to enhance 
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the bioavailability and therapeutic efficacy of co-administered anticancer drugs that 
belong to the deoxynucleosides
197
.  
Pioneering work in this field have generated  several potent thymidine phosphorylase 
inhibitors, most of which are derivatives of pyrimidin-2,4-dione, with only a few that 
are fused bicyclic heterocycles possessing the homophthalimide moiety which is 
believed to be essential for binding to the active site of TP
198
. In 2000, Fukushima et 
al synthesized 5-chloro-6-[1-(2-iminopyrrolidinyl) methyl]uracil hydrochloride (TPI), 
the most potent human TP inhibitor known so far, which has an IC50 value of 35 nM 
and Ki of 20 nM
145
. In addition, Balzarini et al (1998)
142
 designed a fused bicyclic TP 
inhibitor, 7-deazaxanthine (7-DX) based on three-dimensional structure of E. coli TP 
(Figure 8). 
Among the bioactive 1,3,5-triazines, derivatives of 1,3,5-triazin-2,4-dione have been 
known for their wide application in agricultural field. In contrast, fused 1,2,4-triazolo-
[1,5-a][1,3,5]triazines have shown bioactivities such as selective adenosine receptor 
antagonism
47,49
 and xanthine oxidase inhibition
50
. Beside these activities, this fused 
scaffold also exhibits anti-inflammatory, antioxidant, antiproliferative, antibacterial, 
and antifungal properties
9
. In addition, its closely related fused pyrazolo[1,5-
a][1,3,5]triazine derivatives are also known for their diverse medicinal applications as 
reported over the past few decades. Due to the close resemblance with purine, 
derivatives of pyrazolo[1,5-a][1,3,5]triazine are known to modulate various enzymes 
and G-protein coupled receptors that are involved in purine metabolism and are 
therefore used in treatment of several pathological conditions
10
. However, inhibitory 
activity of 1,3,5-triazin-2,4-dione and its fused bicyclic analogues against TP has not 
yet been explored. Therefore, its potential interaction with TP is worth investigating.  
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2.2 Hypotheses and objectives  
The most potent TP inhibitor TPI contains a pyrimidin-2,4-dione nucleus, hence it is 
hypothesized that the 1,3,5-triazin-2,4-dione having the essential homophthalimide 
moiety (O=C-NH-C=O), should be able to interact with the enzyme. In addition, it is 
postulated that structural modification of 7-deazaxanthine (7-DX) (Figure 8), a 
bicyclic TP inhibitor, by replacing the two carbon atoms at positions C9 and C5 with 
nitrogen would generate new compounds viz. 1,2,4-triazolo[1,5-a][1,3,5]triazine 
(Figure 8b) and pyrazolo[1,5-a][1,3,5]triazine (Figure 8c) would also demonstrate TP 
inhibitory activity. Furthermore, it is assumed that these compounds would 
demonstrate the TP associated anti-angiogenic property by attenuating the expression 
of various downstream angiogenic mediators and exhibited antiproliferative activity.   
 
Figure 8. Structures of known TP inhibitor (TPI and 7-DX) and target compounds (a, 
b and c) 
To test these hypotheses, the following objectives have been considered in this study. 
(i) To develop a practical synthetic methodology for preparing a library of 
various substituted 1,3,5-triazin-2,4-dione derivatives. The strategy for the 
synthesis of these monocyclic target compounds will include ring 
transformation reactions. In addition, molecular diversity of 1,3,5-triazin-
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2,4-dione scaffolds will be achieved by introducing different groups at the 
position C6 of  the core ring structures.  
(ii) To synthesize bicyclic analogues that carry the 1,2,4-triazolo[1,5-
a][1,3,5]triazine and pyrazolo[1,5-a][1,3,5]triazine scaffolds via 
intramolecular heterocyclization. In addition, work will be carried out to 
investigate the optimal interactions and explore the chemical space of the 
binding site of the enzyme. The positions of C5 and C7, and the positions 
of C2 and C4 of the respective triazolo and pyrazolo fused triazine 
scaffold would be modified to include a carbonyl, a thiocarbonyl and a 
thiomethyl group. While the position C2 of 1,2,4-triazolo[1,5-
a][1,3,5]triazine and C7, C8 of pyrazolo[1,5-a][1,3,5]triazine scaffolds 
would be modified by inserting different aromatic group and longer 
flexible side chain. Moreover, the structures of the target compounds and 
intermediates would be characterized, with an aim to understand the 
mechanism and regiochemistry of the reaction process.  
(iii) To evaluate the TP inhibition potential of the synthesized compounds by 
using an in vitro enzyme assay. This assay would be used to estimate the 
inhibition kinetic behaviour of the active target compounds. To quantify 
the TP inhibitory activity, a spectrophotometric assay method would be 
adopted. In this assay, recombinant human thymidine phosphorylase 
would be used together with thymidine as the substrate. 
(iv) To evaluate the structure activity relationship of the synthesized 
compounds by 3D-QSAR model based on the enzyme inhibition study. 
The 3D-QSAR study would be conducted based on comparative 
molecular field analysis (CoMFA).  
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(v)  To evaluate cellular responses viz. antiproliferative and antimetastasis 
potential of these compounds using cell viability assay and cell migration 
assay respectively. The MTT colorimetric assay would be employed to 
determine the cell viability while the cell invasion property would be 
estimated by using a ThinCert cell culture inserts with 8 µM 
polycarbonate filters coated with BD Matrigel matrix of the synthesized 
compounds on breast cancer cell line, MDA-MB-231.  
(vi) To evaluate anti-angiogenesis effect via estimation of the expression of 
MMP-9, VEGF, IL-8 in breast cancer cell line. The gelatine zymography 
would be used to determine MMP expression on the same cell line 
whereas to quantify VEGF and IL-8 expression, a colorimetric enzyme-
linked immunosorbent assay (ELISA) method would be adopted. 
2.3 Significance of the study 
The outcome of this study will demonstrate the utility of some of the reported 
methodologies for the synthesis of 1,3,5-triazin-2,4-dione, 1,2,4-triazolo[1,5-
a][1,3,5]triazine and pyrazolo[1,5-a][1,3,5]triazine scaffold. Although, the synthetic 
methodologies for the  construction of the  monocyclic and fused  bicyclic 1,3,5-
triazine derivatives are based on previously described schemes, extensive structural 
modifications by incorporating a wide range of substituents around different positions 
of the core scaffolds have never been synthesized nor have their regiochemistry been 
investigated. Therefore, most of the compounds reported in this thesis will be new. 
Moreover, the investigation of the influencing factors in regioselectivity of the 
reaction processes will help to generate new derivatives of these scaffolds. 
Furthermore, the inhibition potential of these compounds against TP and their 
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inhibition kinetic behaviour have not been elucidated and reported. Therefore, it will 
be a first attempt.  The set up of a 3D-QSAR study based on CoMFA analysis will 
provide the important structural pre-requisites for the interaction with TP. To 
demonstrate the potential significane of these new compounds in anticancer therapy, 
this study will also explore the inhibitory effect of these new TP inhibitors against 
tumour vascularisation, tumour growth, and metastasis. Overall, this study will be 
helpful in laying the foundation for further design and optimization of the new 
bicyclic TP inhibitors. Even though it is evident from literature review that these 
scaffolds exhibit diverse biological activities, this project mainly focuses on specific 
biological aspects of these compounds. A complete evaluation of all the possible 
biological activities is beyond the scope of this study.  
In the subsequent chapters, detail descriptions on the experimental design, results and 
discussion of the synthesis, biological evaluations and QSAR study of 1,3,5-triazin-
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3.1 Synthesis of 1,3,5-triazin-2,4-dione and their fused analogues to explore lead 
inhibitor compounds of thymidine phosphorylase  
Functionalization of the 1,3,5-triazine scaffold with suitable substituents can generate 
a large number of biologically active compounds having exciting range of medicinal 
values. However, few derivatives of 1,3,5-triazin-2,4-dione have exhibited in their 
pharmaceutical uses. The compounds bearing this scaffold have a long history in their 
agricultural applications such as fungicides, insecticides and herbicides
45
. In contrast, 
fused 1,2,4-triazolo[1,5-a][1,3,5]triazines and pyrazolo[1,5-a][1,3,5]triazines are well 
known for their diverse medicinal applications
9,10
. As a result, the synthesis of 1,2,4-
triazolo and/or pyrazolo fused 1,3,5-triazine continues to draw considerable attention 
of the organic and medicinal chemists. Derivatives of 1,2,4-triazolo[1,5-
a][1,3,5]triazine have been of special interest due to their biological activities such as 
adenosine receptor inhibition
47,49
 and xanthine oxidase antagonism
50
. This scaffold 
with appropriate substituents is known for its antiinflammatory, antioxidant, 
antiproliferative, antibacterial, and antifungal properties
9
. On the other hand, the 
derivatives of the pyrazolo[1,5-a][1,3,5]triazine scaffold are known to target enzymes 
involved in the metabolism of biogenic purines including xanthine oxidase (XO), type 
2 cyclin-dependent kinase (CDK2), phosphodiesterase (PDE), DNA gyrase etc. 
Furthermore, some derivatives of this scaffold also modulate the activities of G-
protein coupled purinergic signalling receptors viz. adenosine, P2Y1, corticotrophin-
releasing factor, neuropeptide Y, 5-(HT), cannabinoid and angiotensin receptors, thus 
resulting in diverse biological outcomes. To date, on-going efforts are being made in 
exploiting the therapeutic potential of developing the 1,3,5-triazine and its fused 
analogues. With regards to our interest in the synthesis of 1,3,5-triazine derivatives 
with potential biological activity, our laboratory has reported some synthetic aspects 
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as well as medicinal properties of the 4,6-diamino-1,3,5-triazines
199-201
. The success 
of this project has encouraged us to extend 1,3,5-triazin-2,4-dione and its fused 
analogues expected to have interesting medicinal and biological properties. As stated, 
although significant efforts have been made to explore wide range of biological 
activities of 1,3,5-triazine and its fused analogues, no unequivocal study on inhibitory 
activity of this scaffold  against thymidine phosphorylae (TP) is currently available 
despite large number of TP inhibitors with wide range of structural diversity has been 
investigated. Obviously, an investigation of 1,3,5-triazin-2,4-dione and its fused 
analogues for TP inhibition is worthy of an attempt. 
Significant research works in exploring novel TP inhibitors have identified 5-chloro-
6-[1-(2-iminopyrrolidinyl) methyl] uracil hydrochloride (TPI) and 7-deazaxanthine 
(7-DX) as leading TP inhibitor candidate
145
. Herein, it was assumed that monocyclic 
1,3,5-triazin-2,4-dione and bicyclic 1,2,4-triazolo[1,5-a][1,3,5]triazine and 
pyrazolo[1,5-a][1,3,5]triazine would exhibit anti-thymidine phosphorylase activity 
due to their close resemblance to TPI and 7-DX structural motifs (Figure 8).  
To address these hypotheses, a library of compounds bearing 1,3,5-triazin-2,4-dione 
and its fused analogues was synthesized and the compounds were screened for their 
TP inhibitory activity to explore potential lead inhibitors against thymidine 
phosphorylase.  In an attempt to determine the pharmacophoric requirements and to 
explore the chemical space of the active site of the enzyme, the fused scaffolds were 
modified by introducing a carbonyl, a thiocarbonyl and a thiomethyl group. In 
addition, the respective position C2 and C7 of these two fused analogues was 
modified by inserting aromatic or aliphatic groups. Moreover, further  modification at 
the position C2 of the 1,2,4-triazolo[1,5-a][1,3,5]triazine scaffold was made by 
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incorporating one methylene bridge in between the fused skeleton and lipophilic 
aromatic moiety. Similar approach was adapted to modify the position C8 of the 
pyrazolo[1,5-a][1,3,5]triazine scaffold. Analogous synthetic methodology allowed the 
introduction of additional thiourea moiety at position C7 of the same scaffold. In this 
preliminary study, the target compounds to be synthesized are provided in Figure 9. 
 








3.2.1 Synthesis of 1,3,5-triazin-2,4-diones derivatives  
Several methods for the synthesis of 1,3,5-triazin-2,4-diones have been reported in the 
literature. These include, for example, the condensation of biurets with orthoester 
202
, 
the reaction of urea derivatives with an isocyanate etc
7
. Alternatively, Kantlehner et al 
8
 developed a method to synthesize this scaffold via the reaction of aromatic or 
aliphatic isocyanates with N,O-bis(trimethylsilyl)acetamidate followed by desilylation 
using alcohol.  
In an attempt to synthesize monocyclic 1,3,5-triazin-2,4-dione derivatives (H1a – 
H1f) with potential anti-TP activity, a multi-step synthetic approach has been 
developed (Scheme 15).  
 
Reagents and conditions: (a) CS2, acetone, r.t., acetic acid  (b) CH3NH2, DMF, r.t. 2 
M NaOH (c) Reflux in 6M HCl (d) MeI, 2.5M NaOH, r.t. (e) RNH2, reflux in MeOH  
Scheme 15. Synthesis of monocyclic 1,3,5-triazin-2,4-dione derivatives (H1a–H1f) 
Although, previously disclosed methods were modified to construct the desired 
compounds, the compounds reported here are new. The adopted synthetic scheme 15 
allowed the reactive methyl mercaptan group of compound 83 to be substituted by 
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primary and secondary amines via single step that led to the formation of various 
target compounds (H1a-H1f). The compounds were characterized by NMR and mass 
spectroscopic analysis. The reaction yields and melting points of the compounds were 
also determined and presented in Table 2. 
The synthesis of 1-methyl-6-methylthioxo-1,3,5-triazin-2,4-dione (83) reported here 
has been successfully accomplished via four steps. The first step of the process began 
with the preparation of the 4,6-diamino-2-mercapto-1,3,5-thiadiazine (80), which was 
promptly obtained as previously described by Birtwell (1948)
203
. In this step, the 
cyclocondensation of cyanoguanidine (79) with carbon disulphide in presence of 
potassium hydroxide afforded an intermediate, dipotassium ω-
cyanoguanidinodithiocarbonate, which upon ring closure in the presence of acetic 
acid has led to the formation of 80. The reaction was very straight forward and 
proceeded with satisfactory yield (55%). The main features in the 
1
H NMR spectrum 
of 80 consisted of four singlets located at around 8.03, 8.30, 8.67 and 8.81 ppm and 
each singlet corresponded to one proton of the four H of the two NH2 groups. This 
splitting of the two -NH2 group was probably due to restricted rotation of N-C bond 
resulted from charge delocalization from the ring onto exocyclic amino group. In the 
second step, the successful synthesis of 1-methyl-4,6-diamino-1,3,5-triazin-2(1H)-
thione (81) was achieved by a previously reported method, with some 
modifications
204
. In brief, in a suspension of 80 in DMF, methylamine was added to 
react for 30 min and followed by addition of 2M NaOH solution allowed to ring close 
in one-pot reaction. The appearance of the N-Me peak at about 3.68 and  35.5 ppm in 
1
H NMR and 
13
C NMR respectively indicated the formation of 81. To synthesize 6-
thioxo-1,3,5-triazin-2,4-dione (82), initially, the previous described  method was 
adopted
205
. However, due to the prolonged reaction time in acidic medium, the 
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hydrolytic step afforded 1-methyl-[1,3,5]triazin-2,4,6-trione instead. The structure of 
this compound was confirmed by the use of 
13
C NMR spectroscopy. The three 
carbonyl carbons appeared in 149.2 and 150.6 ppm respectively in 
13
C NMR spectra. 
Thereafter, to optimize the reaction condition in order to achieve the desired 
compound 82, the reaction time was shortened to 2 hours using the same 
concentration of hydrochloric acid (6M) and this condition indeed afforded the 
desirable product. The appearance of the peak of thiocarbonyl carbon atom in 
13
C 
NMR at about 179.4 ppm indicated the formation of compound 82. In the subsequent 
step, the corresponding 6-methylthio derivative (83) was prepared by the reaction of 
82 with iodomethane in alkali. Due to presence of several nucleophilic centers in 82, 
the methyl group of iodomethane could attack at different positions under different 
reaction conditions and afforded a mixture of products. However, the condition
26
 
adopted here, produced thermodynamically most stable compound 83 exclusively 
with reasonably good yield (60%). The appearance of a sharp singlet at 2.50 ppm 
corresponding to the three protons of SMe in the 
1
H NMR spectrum confirmed the 
structure of the product. In the final step, compound 83 was employed to synthesize 
substituted 1,3,5-triazin-2,4-diones (H1a-H1g) via nucleophilic substitution with 
different primary and secondary amines. Simple reflux in methanol for duration 
between 3-5 hr was employed as the reaction condition. The products were obtained 







Table 2. Synthesis of 6 substituted 1,3,5-triazin-2, 4-diones  
 
Entry Cpd R Yield (%) mp (ºC) 
1 H1a CH3 66 305-307 
2 H1b C2H5 76 263-265 
3 H1c CH2Ph 53 297-298 
4 H1d cyclopropyl 61 259 
5 H1e morpholinyl 85 240-242 
6 H1f pyrrolidinyl 23 220 
 
3.2.2 Synthesis of fused 1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7(4H,6H)-dione and 
its thioxo-bioisosteres 
As mentioned in the literature review, the synthesis of 1,2,4-triazolo[1,5-
a][1,3,5]triazine could be successfully achieved by several reported methods and 
these methods can be broadly categorized as: A) annulation of the 1,3,5-triazine ring 
onto a 1,2,4-triazole scaffold; B) annulation of the 1,2,4-triazole ring onto a 1,3,5-
triazine scaffold; C) concurrent formation of both the 1,3,5-triazine and 1,2,4-triazole 
ring; (D) synthesis via ring transformation reactions. Herein, the synthesis of 1,2,4-
triazolo[1,5-a][1,3,5]triazin-5,7(4H,6H)-dione and their thioxo-bioisosteres was 
performed via annulation of 1,3,5-triazine ring onto a 1,2,4-triazole scaffold. The 
adopted synthetic methodology allowed the synthesis of different derivatives of this 
fused scaffold with modification at the position C2 conveniently. Strategically, the 
position C2 of the 1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7(4H,6H)-dione and their 
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thioxo-bioisosteres was modified by introducing substituents which are either directly 
attached with the fused ring or via methylene bridge respectively (Scheme 16 and 17). 
 Synthesis of derivatives modified at the position C2 (substituents directly 
attached with fused ring) 
  In these reaction methods, 5-amino-1,2,4-triazoles bearing -C-N-C appendage 
(carbethoxylthiocarbamoyl) at N1 or 1,2,4-triazoles having N-C-N-C at N(5)3 
underwent intramolecular heterocyclization resulting in formation of target 
compounds (H2-H6). Before synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazine, two 
general methods which were previously developed by our group and other lab 
206-208
, 
were adopted to synthesize the key intermediate, 3(5)-amino-1,2,4-triazoles (87) 
(Scheme 16). In the first method, the reaction of benzhydrazide (84) with S-methyl 
isothiourea in basic condition afforded arylamidoguanidines (85) which underwent 
cyclocondensation in microwave irradiation, and subsequently afforded 3(5)-amino-
1,2,4-triazoles (87) in water. It gave quantitative yield and excellent purity of the 
products. In the second method, the reaction of dimethyl-N-cyanodithiocarbonimidate 
(86) with hydrazine produced 3-(methylthio)-amino-1,2,4-triazoles (87). Therefore, 
these two methods provided scope to introduce aromatic and aliphatic substituents at 
C2 of the fused ring respectively.  
Due to the presence of several nucleophilic centres, different regioisomeric products 
could be produced from the reactions of 3(5)-amino-5(3)-aryl-1,2,4-triazoles (87) 
with ethoxycarbonyl isothiocyanate and the regiosectivity of the reaction  depended 
on the conditions used for the reactions. For example, in DMF, ethoxycarbonyl 
isothiocyanate attacked the exocyclic nitrogen of 3(5)-amino-1,2,4-triazoles (87) 
resulting in the formation of the thermodynamically more stable products N-(3(5)-
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aryl-1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas (88) exclusively with good yields. 
Due to mesomeric effect, probably the lone pair electron of N(1)H was withdrawn by 
substitutions attached at the position C3(5) resulting in decrease of the nucleophilicity 
of N(1)H and consequently addition product 88 was exclusively isolated in DMF. 
However, the reaction of 3(5)-amino-5(3)-aryl-1,2,4-triazoles (87) with 
ethoxycarbonyl isothiocyanate in anhydrous acetone afforded a separable mixture of 
two regioisomeric products (88 and 89). The 5-amino-1-carbethoxylthiocarbamoyl-
1,2,4-triazole (89) was thermodynamically unstable isomer and it was readily 
converted to the more stable N-(1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas (88) in 
DMSO or at higher temperature. 
The synthesis of target compounds H5a-H5b and H3a-H3b was achieved by 
intramolecular heterocyclization of N-(1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas 
(88) and 5-amino-1-carbethoxylthiocarbamoyl-1,2,4-triazole (89) respectively in an 
alkaline medium 
26
 as illustrated in scheme 16. This approach afforded products of 
high yields and purity. The compounds H4 and H6, corresponding methylthio 
derivatives of H3 and H5 respectively, were prepared via the treatment of  parent 
compounds with iodomethane in aqueous alkaline medium and this method afforded 
generally good yields (61-67%) of products. These methylthio derivatives H4a-H4b 
were converted subsequently to compounds H2a-H2b by the treatment of a mild 
oxidizing agent, hydrogen peroxide, in an alkaline medium and this reaction afforded 




Reagents and conditions: (a) NaOH, r.t, 72 h, (b) Water, MW irradiation, 180 ºC, 10 min (c) MeOH, 40 ºC, 5 h (d) Ethoxycarbonyl 
isothiocyanate, acetone, r.t. (e) Ethoxycarbonyl isothiocyanate, DMF, r.t. (f) NaOH, 80% ethanol (aq.), 100 ºC. (g) MeI, NaOH, water, r.t. (h) 
H2O2, NaOH, water, 60-70 ºC. 
Scheme 16. Synthesis of 2-substituted-1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7(4H,6H)-dione and its derivatives (H2, H3, H4, H5 and H6) 
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NMR spectroscopy and mass spectrometry. The purity of compounds was determined 
by reverse phase HPLC. Interestingly, the structures of compounds H2-H6 were 
readily distinguished and confirmed by the use of 
13
C NMR spectroscopy. The 
13
C 
peak of the thiocarbonyl (C=S)  carbon of H5b appeared at around 175.8 ppm; while 
this group showed peaks at about 170.8 ppm for H3b. The two signals of the carbonyl 
(C=O) groups of compound H2a appeared at about 152.5 and 162.2 ppm in 
13
C NMR 
spectra. The appearance of the peak at about 11.8 and 13.9 ppm assigned to SMe in 
the 
13
C NMR spectrum indicated the formation of product H4b and H6b respectively. 
The purity of all compounds was satisfactory (above 95%).  
 Synthesis of derivatives with benzyl group at the position C2 (substituents 
attached with fused ring via methylene bridge) 
Analogously, the synthesis of 2-benzyl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
5,7(4H,6H)-dione and its derivatives (H7, H8, and H9) was successfully achieved by 
a ring annulation reaction (Scheme 17). Although the general synthetic route for the 
base catalyzed annulations of triazine ring is based on chemistry developed by 
Bokaldere and co-workers 
26
, this study described for the first time, a simple and 
efficient method for the preparation of related compounds having 1,2,4-triazolo fused 
triazine structure with one methylene bridge at position 2. The synthesis started from 
the preparation of building block, benzyl substituted 1,2,4-triazole (91) via the 
reaction of 2-phenylacetohydrazide (90) with S-methyl isothiourea in an aqueous 
alkaline medium which was previously established in our lab
206
. The reagent 2-
phenylacetohydrazide would provide the methylene bridge at the position C2 of target 
compounds. The treatment of 91 with ethoxy carbonyl isothiocyanate and ethyl 
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isocyano formate in DMF afforded the corresponding thiourea and urea derivatives 
(92 and 93) which underwent intramolecular heterocyclization in presence of base 
resulting in formation of target compounds (H7 and H8) respectively in 47-55% yield 
(Table 3). In alkali medium, compound H8 was subjected to treatment with 
iodomethane to produce H9.  
 
 Reagents and conditions: (a) NaOH, r.t, 72 h (b) Ethoxycarbonyl isothiocyanate, or 
ethyl isocyano formate, DMF, r.t. 5 h (c) NaOH, 80% ethanol (aq.), 100 ºC. (d) MeI, 
NaOH, water, r.t.  
Scheme 17. Synthesis of 2-benzyl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5,7(4H,6H)-
dione and its derivatives (H7, H8 and H9) 




C NMR and mass spectroscopy. 
The ring closure of H8 was evident by the disappearance of triplet around 1.24 ppm 
and quartet at around 4.19 ppm corresponding to the CO2Et signal and singlet at 
around 13.52 and 13.78 ppm corresponding to tautomeric NH signal of intermediate 
93 in the 
1
H NMR spectra when the spectra was recorded in DMSO-d6. In addition, a 
low field movement of the signal corresponding to the aromatic proton was observed 
when the spectrum of open (93) to the close analogues (H8) was compared. In 
13
C 
NMR, the sharp signal of carbonyl (C=O) and thiocarbonyl (C=S) appearing at 
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around 165.0 and 175.8 ppm respectively indicated the formation of desired 
compounds (H8). In contrast, two sharp peaks at around 152.1 and 164.8 ppm 
corresponding to two carbonyl (C=O) carbon were observed in 
13
C NMR spectra for 
compound H7. 
 The characteristic signal of methyl group appeared at around 2.50 and 34.4 ppm in 
1
H NMR and 
13
C NMR respectively suggested formation of compound H9.  The 
purity of all compounds determined by HPLC was above 95 %. 
Table 3. Synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7(4H,6H)-dione and its 
derivatives  
 
Entry Cpd R %Yield mp (ºC) Entry Cpd R %Yield mp (ºC) 
1 H2a SCH3 68 284-286 8 H5b Ph 78 258-259 
2 H2b Ph 54 318-319 9 H6a SCH3 54 241-243 
3 H3a SCH3 72 254-256 10 H6b Ph 58 292-294 
4 H3b Ph 59 285-287 11 H7 Ph 47 ˃75- 
5 H4a SCH3 67 274-276 12 H8 Ph 55 246 
6 H4b Ph 61 300-301 13 H9 Ph 54 96-98 
7 H5a SCH3 64 263 
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3.2. 3 Synthesis of pyrazolo[1,5-a][1,3,5]triazin-2,4(1H,3H)-dione and its  thioxo 
bioisostere 
Similarly, we adopted reported method and modified it to construct pyrazolo[1,5-
a][1,3,5]triazin-2,4(1H,3H)-dione and their thioxo-bioisosteres H10-H13
41,44
. The 
synthesis of these target compounds was achieved via annulation of the triazine ring 
onto a pyrazole motif. In this synthetic pathway, pyrazole ring having a N-C-N-C 
appendage at C3(5) underwent intramolecular heterocyclization in alkaline medium  
to afford the desired compounds  H10-H13. By adopting this synthetic methodology, 
various substitutions could be introduced at the position C7 and C8 of the fused ring 
system depending on the starting materials used which are available commercially. 
Initially, the C7 of fused ring was modified by inserting substituent which was 
directly attached with the core structure. Moreover, an attempt was made to include 
substituents at the positions C7 and C8 of the fused ring using similar reaction 
condition. 
 Synthesis of derivatives modified at the position C7 (substituent directly 
attached with fused ring) 
To generate the target compounds H10-H12, initially, the key intermediate, 
aminopyrazole (96) was synthesized via two convenient practical steps (Scheme 18). 
In the first step, the bromoacetophenone (94) was converted to cyanoacetophenone 
(95) by sodium cyanide in aqueous ethanol in the presence of dilute hydrochloric 
acid
209,210
. Consequently, the cyanoacetophenone (95) was subjected to microwave 
irradiation in the presence of hydrazine hydrate to afford the aminopyrazole
211
. 
Following these steps, the nucleophilic reaction between the synthesized 
aminopyrazole and ethoxycarbonyl isocyanate or ethoxycarbonyl isothiocyanate in 
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DMF resulted in the formation of the addition product viz. compound 97 and 98 
respectively with good yields. The compounds 97 and 98 having 
carbethoxycarbamoyl and carbethoxylthiocarbamoyl moiety underwent 
intramolecular cyclization to afford desired compounds H10 and H11 respectively 
when heated in presence of the sodium hydroxide with acceptable yield and purity. 
The corresponding thiomethyl derivative H11 was synthesized by treating H12 with 
methyl iodide in alkaline medium. It is reported that the compounds H11 and H12 
were successfully synthesized via similar reaction condition in different solvent 
system
44a
. However, this reaction took prolong time to complete.  
The structures of the synthesized compounds were determined using different 




C NMR, and mass spectroscopy whereas the 
purity of the compounds was evaluated using reverse phase HPLC. Analysis of the 
13
C NMR spectral data of these compounds revealed that two sharp signals of 
carbonyl (C=O) and thiocarbonyl (C=S) carbon of compound H11 were appeared at 
around 155.9 and 173.6 ppm respectively while two peaks corresponding to carbonyl 
(C=O) moiety of compound H10 were found at around 148.3 and 155.0 ppm in 
13
C 
NMR spectral data. Moreover, the appearance of sharp peaks at around 13.6 ppm 





Reagents and conditions: (a) NaCN, HCl, aq-ethanol, r.t. (b) NH2NH2.H2O, Methanol, MW, 140 ºC, (c) EtO2CN=O, DMF, r.t., 5 h (d) 
EtO2CN=S, DMF, r.t., 5 h  (e) NaOH, 80% ethanol (aq.), 100 ºC. (f) MeI, NaOH, water, r.t., 30 min, 2.5 M HCl. 





 Synthesis of derivatives modified at the positions C7 (introduction of 
thiourea moiety) and C8 (introduction of benzyl moiety) 
Introduction of substituents at both C7 and C8 of the pyrazolo fused triazine scaffold 
was achieved by using 4-substituted-1H-pyrazol-3,5-diamine as a building block, 
which upon treatment with ethoxycarbonyl isothiocyanate afforded corresponding 
thiourea derivatives. The intramolecular heterocyclization of thiourea derivative in the 
presence of base led to the formation of target compounds (H13) (Scheme 19).  
 
Reagents and conditions: (a) Malononitrile, aq-ethanol, NaBH4, HCl, r.t. (b) 
NH2NH2.H2O, ethanol, reflux, 5-8 h  (c) Ethoxycarbonyl isothiocyanate, DMF, r.t., 5 
h (d) NaOH, 80% ethanol (aq.), 100 ºC 
Scheme 19. Synthesis of (8-benzyl-4-oxo-2-thioxo-1,2,3,4-tetrahydro pyrazolo[1,5-
a][1,3,5]triazin-7-yl)-thiourea (H13) 
The diamino pyrazole (101) was synthesized via a practical two-step procedure 
starting from benzaldehyde (99). The first step of the process comprised of the 
synthesis of monosubstituted malononitriles (100) via the reductive alkylation of 
malononitrile with benzaldehyde (99) which readily converted to di-amino pyrazole 
(101) through simple reflux in ethanol with hydrazine hydrate. To synthesize the 
monosubstituted malononitrile (100), reported method was adopted that afforded 
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clean and high yield of products. This reaction process consisted of two steps 
including condensation of malononitrile and benzaldehyde in aqueous-ethanol 
medium followed by reduction of intermediate dicyanoalkene in the presence of  
sodium borohydride in the same pot
212
. The monosubstituted malononitriles formed in 
the reaction mixture were isolated via filtration or extraction process. Following this 
step, the reaction of 100 with hydrazine hydrate was carried out by conventional 
reflux in ethanol for 5-8 h which proceeded to 4-substituted-1H-pyrazol-3,5-diamine 
(101) with satisfactory yield
213
. In the subsequent step, the nucleophilic addition 
reaction of 4-substituted-1H-pyrazol-3,5-diamine (101) with ethoxycarbonyl 
isothiocyanate in DMF, afforded product 102 in good yield.  
Heating of thiourea derivative (102) in aqueous-ethanol in the presence of a base 
resulted in the hydrolysis of ethoxycarbonyl group from one of the 
carbethoxythiourea chains while the other underwent subsequent (6 + 0) 
heterocyclization to give target compound H13 (Scheme5). The heterocyclization was 
found to proceed regioselectively (1,5-a ring junction) resulting in the formation of 
target compound H13 exclusively. The structures of the target compound were 




C NMR and mass spectral data. The characteristic signal 
of carbonyl carbon (C=O) was observed at 151.9 ppm, whereas the two sharp peaks 
of thiocarbonyl moiety (C=S) appeared around 173.5 and 179.8 ppm respectively  in 
13
C NMR spectra. The results are in agreement with those obtained in our previously 
synthesized structurally related compounds.  
The appearance of two sharp singlets at 8.94 and 9.07 ppm that corresponded to one 
proton each of the NH2 group of the thiourea chain in 
1
H NMR spectrum of H13 
indicated restricted rotation of NH proton around N-C bond. The satisfactory purity of 
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the compound (above 95%) was assessed by HPLC method. In addition, the 
physicochemical properties including yield and melting point of compound H13 were 
determined and tabulated in table 4.  
Table 4. Synthesis of pyrazolo[1,5-a][1,3,5]triazin-2,4(1H,3H)-dione and its thioxo-
derivatives 
 
Entry Cpd R %Yield mp (ºC) Entry Cpd R %Yield mp (ºC) 
1 H10 Ph 55 312-314 3 H12 Ph 46 240-242 
2 H11 Ph 72 286-288 4 H13 Ph 73 239-241 
 
3.3 Evaluation of anti-thymididine phosphorylase (Anti-TP) activity  
The thirteen groups of compounds (H1-H13) were evaluated for in vitro TP inhibitory 
activity by a spectrophotometric assay that used recombinant human thymidine 
phosphorylase, expressed in E. coli (T2807- Sigma Aldrich). The original method 
developed by Krenitsky (Krenitsky et al, 1979)
214
 was modified and adopted. Briefly, 
in this assay, the change of absorbance of thymidine (dThd) at 290 nm due to 
enzymatic reaction was monitored after 4, 8, 12, 16, and 20 min and the initial 
reaction rate was determined from the slope of change in absorbance. For calculation 
of enzyme inhibition, the initial rate of change in absorbance at different 
concentrations of the test compound were converted to percentage inhibition of 
enzyme, and plotted against inhibitor concentration using Graphpad Prism vs 4.0 to 
obtain the IC50 values. Preliminary screening of enzyme inhibition was carried out at 
100 μM of each compound. The results of inhibitory potency of each compound 
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evaluated were expressed in terms of IC50 values, and was compared with that of 7-
DX (Table 5). 
Unexpectedly, compounds H1a-H1f, having the homophthalimide moiety did not 
show any inhibitory potential at 100 µM. From the x-ray crystal structure of TP 
complexed with TPI, it was revealed that TPI appeared to mimic the substrate 
transition state and bound to the enzyme as zwitterions (Figure 7). The nucleotide 
base interacted with residues Ser217, Arg202, Lys221 and His116 via hydrogen 
bonds while electron withdrawing chlorine atom at C5 projected into a lipophilic 
pocket formed by residues Leu148, Val208, Ile214 and Vall24. In addition, the NH2 
group of the iminopyrrolidine ring formed two hydrogen bonds with an oxygen atom 
of S117 and with a water molecule of the bound phosphate group.  
Compounds H1a-H1f, bearing the homophthalimide moiety, were predicted to bind in 
a similar orientation to the uracil moiety of TPI in the active site.  However, these 
compounds exhibited no inhibitory effect, which could be attributed to many reasons. 
Firstly, the synthesized compounds have N-Me group instead of electron-withdrawing 
substituent at the C-5 position of the uracil ring. It is important to mention that 5-
chloro group at C5 of TPI accommodated in a hydrophobic pocket of active site. In 
addition, this chloro group, attributed to the increased acidity of the N1 of TPI, 
resulting in a better mimic of the zwitterionic resonance and tighter binding to the 
active site. Secondly, our synthesized compounds compared to TPI lack a methylene 
bridge and therefore, they could not interact with important amino acid residues in the 
active site as a consequence of steric constraints arising from inflexibility of 
substitutions at C6. Lastly, compared to TPI, there is an absence of (protonated) 
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amino group in the structure of compounds H1a-H1f, and therefore it could not form 
the hydrogen bonds with the water pocket associated with phosphate. 
Analogously, fused 1,2,4-triazolo[1,5-a][1,3,5]-triazin-2,4-dione viz. compound H2a, 
H2b having the aliphatic (SCH3) and aromatic (Ph) substituent at the position C2 
respectively, did not show any inhibitory potential at 100 µM. This result was not 
consistent with the previous report indicating that the homophthalimide group was a 
pharmacophoric requirement to impart inhibitory activity against TP
198
. The 
modification of H2a-H2b by replacing the oxygen atom at C7 with the bioisosteric 
sulphur exhibited no improvement in the activity. In addition, the introduction of 
thiomethyl group at C7 and consequently the removal of one active hydrogen at C6 in 
compounds H4a and H4b showed no activity, just like in the case of  H2a-H2b. 
Interestingly, with further modification of H3a and H3b by switching the positions of  
the  carbonyl and thiocarbonyl moieties, affording 5-thioxo-5,6-dihydro-4H-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-one analogues (H5a and H5b), exhibited 
moderate to weak TP inhibitory activity (IC50 value = 51.67 and 39.56 µM 
respectively). Further modification of H5a and H5b, by replacing thio-oxo moiety by 
thiomethyl group at the position C5 resulting in subsequent elimination of active 
hydrogen atom from N4, led to dramatic decrease in inhibition property as observed 
in compound H6a and H6b (IC50 = ˃ 100 and 95.05 µM respectively). The IC50 
values of the test compounds were compared with the positive control, 7-
deazaxanthine, that exhibited IC50 value of 42.63 µM in the same experimental 
conditions which was found to be in accordance with previous reported results
102
. 
Therefore, from the preliminary screening of different derivatives, it was revealed that 
a particular orientation of the C(=S)NHC(=O) moiety would be required to impart the 
inhibitory activity. In addition, it was also observed that lipophilic aromatic group was 
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compatible with higher binding affinity compared with aliphatic substitutions. These 
data clearly suggested that H5a and H5b could interact with binding site of the 
enzyme and thus exhibited inhibition property. It was assumed that the carbonyl 
group at C7, and its adjacent NH(6) group of H5a and H5b  would form strong 
hydrogen bonding contacts with the binding site. Moreover, thiocarbonyl moiety at 
C5 and substitution at C2 may place themselves into some hydrophobic space in the 
interaction site. It was postulated from the experimental data that the hydrogen bonds 
in between amino acid residue and carbonyl group at C7 and the hydrophobic 
interaction with the  thiocarbonyl moiety at C5 played a crucial role in inhibitory 
action. This explains why the modification of compounds H5a and H5b by switching 
the positions of the thiocarbonyl and carbonyl groups (in compounds H3a-H3b) and 
their corresponding thiomethyl compound (in compounds H4a-H4b) resulted in 
lowering inhibitory action. In addition, in compounds H2a-H2b, although the 
carbonyl group was retained at C7, the carbonyl group at C5 could not be properly 
accommodated in huge hydrophobic space due to its smaller atomic size as well as 
high polarity which may lead to misalignment of entire compound. The postulation of 
TP inhibitory activity of different 1,3,5-triazine and its fused analogues is based on 
the physicochemical properties of the different bioisosteric substituent (viz. C and S) 
present in the core ring structure. However, this postulation will still need to be 
further validated by modeling. 
To improve inhibitory effect of compounds H5b and H6b, further modification of 
lead structure was made by adopting two strategies. Firstly, in order to impart 
flexibility and subsequently removal of steric constraints in the lead structure, a 
methylene bridge was introduced in between aromatic phenyl and fused ring. It is 
noteworthy that recently 6-methylene bridged uracil derivatives was reported as 
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novel, orally active, TP inhibitors including TPI, most potent TP inhibitor, so far. 
Secondly, for the purpose of structural optimization, the N3 of H5b and H6b was 
replaced with  carbon atom, led to synthesis of pyrazolo[1,5-a][1,3,5]triazine. These 
two strategies resulted in generation of compounds H10-H13.  
Biological evaluation of these compounds with respect to TP inhibitory activity 
suggested that compound H8 (IC50 = 43.32 µM) and H11 (IC50 = 48.39 µM) were not 
able to improve binding affinity compared to lead H5b.  Therefore, it can be 
concluded that the introduction of methylene bridge in order to impart flexibility in 
lead structure and consequently removal of steric constrain could not enhance binding 
interaction for the enzyme. In addition, the presence of N3 moiety in H5b was proven 
to be essential as it could provide its lone pair of electron for hydrogen bond 
formation with amino acid residues of enzyme resulting in stronger inhibition pattern 
with respect to H11.  
The exploration of TP inhibitory activity of compound H9 and H12, the 
corresponding thiomethyl derivatives of H8 and H11 respectively, suggested that both 
of them exhibited lower inhibitory profile than their parent compound H8 and H11. 
Surprisingly, H12 (IC50 = 71.01 µM) showed better inhibitory activity than H6b. 
Interestingly, although two newly generated series did  not display improvement of 
relative potency of H5b, there are several general structure-activity similarities, 
including  the  following: (1) introduction of  the homophthalimide moiety in each 
series resulted in a complete loss  of  inhibitory potency, (2) isosteric replacement  of 
carbonyl moiety at C5 or C2 by the thiocarbonyl  moiety  significantly enhanced 
inhibitory potency, and (3) incorporation of  a thiomethyl moiety in C5 or C2 of fused 
ring decreases inhibitory activity compared to parent compound.   
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Table 5. Thymidine phosphorylase inhibitory activity of the synthesized compounds 
(H1-H13) 
 




IC50 (µM) (95% CI)
a
 
1 H1a CH3 > 100 
2 H1b C2H5 > 100 
3 H1c CH2Ph > 100 
4 H1d cyclopropyl > 100 
5 H1e morpholinyl > 100 
6 H1f pyrrolidinyl > 100 
7 H2a SCH3 > 100 
8 H2b Ph > 100 
9 H3a SCH3 > 100 
10 H3b Ph > 100 
11 H4a SCH3 > 100 
12 H4b Ph > 100 
13 H5a SCH3 51.67 (45.75 to 58.36)
 
14 H5b Ph 39.56 (38.32 to 40.84) 
15 H6a SCH3 > 100 
16 H6b Ph 95.05 (91.97 - 98.23) 
17 H7 Ph >100 
18 H8 Ph 43.32 (39.91 - 47.02) 
19 H9 Ph >100 
20 H10 Ph > 100 
21 H11 Ph 48.93 (46.54 - 51.44) 
22 H12 Ph 71.01 (64.64 - 77.99) 
23 H13 Ph 29.92 (25.74 - 34.77) 




experiments carried out at least in duplicate. 
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In order to explore further, the structure of pyrazolo[1,5-a][1,3,5]triazine was 
modified by introducing substitutions at both C7 and C8 using analogous synthetic 
methodology that resulted in generation of new di-substituted lead compound H13. 
The TP inhibitory property assessment of this compound identified it as most potent 
lead compound among all the synthesized compounds (IC50 = 29.92 µM). It was 
believed that the newly introduced thiourea moiety would form strong hydrogen bond 
with amino acid residues of the binding site of enzyme, whereas, benzyl group could 
impart some hydrophobic interaction resulting in augmentation of inhibitory potential 
of compound H13 (Table 5). 
3.4 Summary  
To summarize, an inexpensive and efficient method was optimized for the synthesis 
of 1,3,5-triazin-2,4-dione derivatives (H1a-H1f) with good yields. In addition, the use 
of intramolecular heterocyclization to generate the target compounds (H2-H13) was a 
practical synthetic approach. This preliminary study revealed that compounds having 
1,3,5-triazin-2,4-dione and its fused analogues bearing homophthalimide moiety 
surprisingly did not exhibit the inhibitory potential against TP. It is believed that due 
to the structural alteration of the lead compounds (TPI and 7-DX) by the insertion of 
the N moieties, the target compounds, in spite of having homophthalimide group, did 
not demostrate any inhibitory activity. However, among the  fused analogues, 
compounds having thiocarbonyl group and carbonyl group in particular orientation  
viz 5-thioxo-5,6-dihydro-4H-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-one, 2-thioxo-2,3-
dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one and their thiomethyl derivatives 




was identified as most active lead compound among all the synthesized compounds  
(IC50 = 29.92 µM). Herein, the derivatives having triazolo and/or pyrazolo fused 
triazines scaffold were established as a new class of potential thymidine 
phosphorylase inhibitors that might provide more leads in drug design and 
optimization of fused-ring TP inhibitors. In addition, it is revealed from the 
preliminary study that one aromatic ring is essential to impart better biological effect 
and with the  introduction of flexible chain in between aromatic and fused ring motif, 
compound can exhibit inhibitory property. Based on these promising results, further 
efforts are made to synthesize compounds with diverse structural modifications on the 
leads to enhance biological activities, and the results obtained from these efforts are  









































4.1 Craig plot directed structural optimization of the lead compounds and the 
evaluation of their anti-thymidine phosphorylase activity 
In the previous chapter, selected 1,3,5-triazin-2,4-dione and its fused bicyclic 
analogues viz. 1,2,4-triazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a][1,3,5]triazine 
were synthesized and evaluated for their anti-TP potential. This preliminary study 
revealed that monocyclic 1,3,5-triazin-2,4-dione derivatives surprisingly did not 
exhibit inhibitory property against TP. However, the fused bicyclic analogues of this 
monocyclic 1,3,5-triazine have demonstrated moderate TP inhibitory effects. Among 
the fused bicyclic analogues, 5-thioxo-5,6-dihydro-4H-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-one and 2-thioxo-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-
one  showed inhibitory activity against thymidine phosphorylase. Particularly, 
compounds H5b (IC50 = 39.56 µM), H8 (IC50 = 43.32 µM), H11 (IC50 = 48.93 µM), 
and H13 (IC50 = 29.92 µM) were identified as key lead structures with moderate 
inhibitory activity against TP (Figure 10). Therefore, further structural optimization of 
the lead compounds may lead to better enzyme inhibition activity. 
 
Figure 10. Structures of lead compounds and their IC50 values 
Several strategies can be employed in the process of lead optimization in medicinal 
chemistry. These strategies often may involve the synthesis of derivatives containing 
a range of substituents on an aromatic or heteroaromatic ring or derivatising 
accessible functional groups that can modify the physicochemical properties of lead 
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compound resulting in alteration of the distribution, metabolism, or receptor binding 
interactions. There are an infinite number of possible analogues or derivatives that can 
be made, using several substituents and combination of substituents having different 
physicochemical properties in terms of their electronic, steric and hydrophobic 
properties and thus selection of substituents to synthesize analogues in lead 
optimization process is always challenging. However, Craig plot guided 
optimization
215
 approach has often been employed to decide on the substituents to be 
selected for the study and such method has been proven to be extremely useful in 
tackling this stage of drug development.  
It is evident from the preliminary study that all the lead compounds possess one 
phenyl ring directly or indirectly (via a methylene bridge) attached to the fused ring. It 
is important to mention that the phenyl ring of compound H5b ensured better 
hydrophobic interaction into the active site resulting in improved activity compared to 
aliphatic substituted analogues H5a. Herein, it is assumed that Criag plot directed 
structural modification of the phenyl ring of the lead compounds (H5b, H8, H11 and 
H13) would exhibit improved inhibition properties against TP.  
 Therefore, the objective of this section was to synthesize derivatives of H5b, H8, 
H11 and H13 having different substituents on the phenyl ring (Figure 11). An 
evaluation of the influence of physiochemical properties of the substituents on TP 
inhibitory activity would be conducted. The libraries of the modified lead compounds 
were synthesized based on selected substituents found on the Craig plot. Substituents 
with a range of electronic properties, shapes and hydrophobicity were selected that are 
scattered around all four Craig plot quadrants. Guided by the Craig plot, 
representatives of substituents (F, Cl, Br, CF3) with increased hydrophobicity and 
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electron withdrawing properties (+π, +σ), substituents (OCH3, OH) with more 
hydrophilic and electron donating properties (-π, -σ), substituents (CH3) with positive 
hydrophobicity and negative σ values (+π, -σ), substituents (CN) with negative 
hydrophobicity and positive σ values (-π, +σ) were chosen for this study. 
In this study, an array of 28 aromatic acid chlorides was selected as starting materials 
to  generate a small library of 5-thioxo-5,6-dihydro-4H-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-one derivatives. These acid chlorides carried different substituents 
of varying hydrophobicity constant and Hammett constant at meta and/or para 
position in the phenyl ring. Analogous attempt was made to build 18 analogues of 
H11 and H13 starting from different substituted bromoacetophenone and aromatic 
aldehyde respectively. Consequently, the compounds synthesized were evaluated for 
in vitro enzyme assay.  
 
Figure 11. Planned Craig plot guided structural modification of lead compounds 
H5b, H8, H11 and H13  
4.1.1 Chemistry 
4.1.1.1 Synthesis of 5-thioxo-5,6-dihydro-4H-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-
one analogues 
Target compounds, H5bi-H5bxix and H8a-H8i, were prepared via (6+0) 
intramolecular heterocyclization of 1,2,4-triazoles having N-C-N-C appendages at 
N(5)3 as described in scheme 20. For the synthesis of the desired compounds, the 
synthetic methodology adopted here a four-step reaction sequence. The synthesis 
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started from the aryl acid chloride (103 and 104) or aryl acetic acid (105) derivatives 
which were reacted with aminoguanidine hydrochloride to yield arylamidoguanidine 
and its derivatives (85 and 106) which upon microwave irradiation led to the synthesis 
of the key intermediates, 1,2,4-triazole derivatives (87 and 91). The treatment of 87 
and 91 with ethoxycarbonyl isothiocyanate in DMF afforded the corresponding 
thiourea derivatives (88 and 93). In the presence of a base, the carbethoxythioureas 
underwent intramolecular heterocyclization, via an intermediate, resulting in the 
formation of the target compounds H5bi-H5bxix and H8a-H8i
26
. The compounds 




C NMR spectroscopy and mass 
spectrometry. The yield and melting points of compounds were evaluated and 
reported in Table 6. The purity of compounds was accessed by the use of HPLC. The 
purity of all compounds was above 95 %. 
By using different 3(5) substituted 1,2,4-triazole, this annulation reaction allowed a 
convenient means to introduce different substituents (substituted phenyl or benzyl) at 
the position C2 of the 1,2,4-triazolo fused triazine scaffold. The synthesis of 3(5) 
substituted 1,2,4-triazoles (87 and 91) was started by adopting the previously reported 
methods established in our laboratory
206,207
. This method comprised of two steps 
reaction sequences. In the first step, the synthesis of arylamidoguanidines (85 and 
106) was achieved from the reaction of corresponding hydrazides and S-methyl 
isothiourea. Following this step, 1,2,4-triazoles (87 and 91) were prepared from 85 
and 106 by using microwave irradiation in aqueous medium. Although the second 
step reaction was found to be clean and afforded almost quantitative yield with 
satisfactory purity of products, the first step of this method had several disadvantages. 
For example, this reaction needed prolonged reaction time to complete (3 days) and 
often afforded only low yield of the products because of a complicated workup during 
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the isolation of the products from the reaction mixture. Moreover, this reaction could 
not successfully proceed for all the different substituted hydrazide used. Thereafter, 
continuous efforts were employed to overcome the disadvantages of this reaction. 
Initially, attempts were made to synthesize arylamidoguanidines by heating acid 
chloride and aminoguanidine bicarbonate in refluxing water or aqueous-ethanol 
medium. However, this reaction condition was not successful to afford the desired 
product. Alternatively, heating of acid chloride and aminoguanidine bicarbonate at 
180 ºC without using any solvent was attempted.  In this reaction condition, the para-
substituted nitro arylacid chloride was readily converted to the corresponding triazole. 
However, the reaction with other substituted acid chlorides was unsuccessful. 
Interestingly, by using aminoguanidine hydrochloride, the desired products were 
achieved successfully. In other wards, arylamidoguanidines (85 and 106) could be 
formed  by fusion of aryl acid chloride (103 and 104) with aminoguanidine 
hydrochloride at 180 ºC for 20 minutes.  Some acid chlorides were readily cyclised to 
1,2,4-triazole under this reaction condition and therefore arylamidoguanidines were 
not isolated. In addition, it was observed that few substituted acid chlorides afforded a 
mixture of arylamidoguanidines and 1,2,4-triazole. The scope of the reaction was 
further explored using substituted (4-MeO, 4-NO2, 4-Me, 4-CN, 4-OH, 4-CF3, 4-Br 
and 3,4-di Cl) phenyl acetic acid (105) and it was observed that the reactions 
proceeded to give the desired product with excellent yield and purity. Theoretically, 
two possible tautomeric forms (85 and 106) and (85’ and 106’) for the 
arylamidoguanidines were observable (Scheme 20). The two signals of NH2 groups in 
1
H NMR spectra of compounds demonstrated that tautomeric form (85 and 106), 
rather than form (85’ and 106’), was preferred in DMSO solution. This phenomenon 
was reported earlier
206
. The intermediate arylamidoguanidines and its derivatives were 
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cyclised in the subsequent step upon microwave irradiation to afford the desired 1,2,4-
triazoles. 
Theoretically three annular tautomeric forms (A, B and C) are possible for prepared 
1,2,4-triazoles (87,91 and 88, 93) (Scheme 21)
207
. However, tautomeric study of the 1, 
2, 4-triazoles by 
1
H NMR revealed that forms A and B existed in the DMSO solution, 
while form C was not observed under the experimental conditions. Due to annular 
tautomerism, target compounds H5bi-H5bxix and H8a-H8i could also exist in 
dynamic equilibrium of A) 4-, B) 3- and C) 1H- forms (Scheme 20). The prototropic 
interconversion between these tautomeric forms resulted in broadening of the 4-N(H) 
signal in the 
1
H NMR spectra of compounds in DMSO. On heating, the broad signal 








Reagents and conditions: (a) Aminoguanidine hydrochloride, fusion at 180 ºC, 20 min, 5M NaOH (b) Water, MW irradiation, 180 ºC, 10 min  
(c) Ethoxycarbonyl isothiocyanate, DMF, r.t. (e) NaOH, 80% ethanol (aq.), 100 ºC.  





Scheme 21. Tautomerism of 1,2,4-triazoles 
Table 6. Synthesis of 5-thioxo-5,6-dihydro-4H-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-
one analogues 
 
Entry Cpd R %Yield mp (ºC) Entry Cpd R %Yield mp (ºC) 
1 H5bi 3-NO2 80 246-248 15 H5bxv 4-MeO 63 270-271 
2 H5bii 3-CF3 81 268-270 16 H5bxvi 4-CN 69 ˃300 
3 H5biii 3-Cl 65 266-267 17 H5bxvii (3,4)-Cl2 74 271-273 
4 H5biv 3-Br 75 262-264 18 H5bxviii (3,4)-F2 68 267-269 
5 H5bv 3-F 72 283-285 19 H5bxix 3-Me, 4-Br 77 278-281 
6 H5bvi 3-Me 80 259-261 20 H8a 4-CF3 67 280-281 
7 H5bvii 3-MeO 90 260 21 H8b 4-Cl 64 241-243 
8 H5bviii 3-CN 67 ˃300 22 H8c 4-Br 65 238-240 
9 H5bix 4-NO2 65 ˃300 23 H8d 4-F 72 260-262 
10 H5bx 4-CF3 69 280 24 H8e 4-Me 72 244-246 
11 H5bxi 4-Cl 66 281-282 25 H8f 4-MeO 78 243-244 
12 H5bxii 4-Br 73 292-293 26 H8g 4-OH 65 268-270 
13 H5bxiii 4-F 67 262 27 H8h 4-CN 60 ˃300 
14 H5bxiv 4-Me 78 296-297 28 H8i (3,4)-Cl2 57 265-267 
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4.1.1.2 Synthesis of 2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-a][1,3,5]triazin-4-one 
analogues 
To synthesize the target molecules, H11a-H11g and H13a-H13k, the two highly 
efficient and high yielding synthetic approaches (scheme 22 and 23 respectively) were 
adopted, that involved the heterocyclization of the pyrazole derivatives having 
attached with N-C-N-C appendages
41, 44
. These practical methods for the synthesis of 
the target compounds have generally proceeded with a four-step reaction sequence. 
In the synthesis of compounds H11a-H11g, the key intermediate, 3-substituted 
aminopyrazoles were synthesized via a two step reaction. In the first step, the 
synthesis of substituted cyanoacetophenone (95) from corresponding 
bromoacetophenone (94) was achieved via the reaction with sodium cyanide in 
aqueous ethanol in presence of dilute hydrochloric acid
209,210
. This reaction remained 
unsuccessful for 4-nitro substituted derivatives. Consequently, the 
cyanoacetophenones were treated with hydrazine hydrate in microwave irradiation to 






Reagents and conditions: (a) NaCN, HCl, aq-ethanol, r.t. (b) NH2NH2.H2O, methanol, MW, 140 ºC, (c) Ethoxycarbonyl isothiocyanate, DMF, 
r.t., 5 h (d) NaOH, 80% ethanol (aq.), 100ºC.  
Scheme 22. Synthesis of 2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-a][1,3,5]triazin-4-one analogues (H11a-H11g) 
 
Reagents and conditions: (a) Malononitrile, aq-ethanol, NaBH4, HCl, r.t. (b) NH2NH2.H2O, ethanol, reflux, 5-8 h (c) Ethoxycarbonyl 
isothiocyanate, DMF, r.t. , 5 h (d) NaOH, 80% ethanol (aq.), 100 ºC 
Scheme 23. Synthesis of (8- benzyl-4-oxo-2-thioxo-1,2,3,4-tetrahedro-pyrazolo[1,5-a][1,3,5]triazin-7-yl)-thiourea analogues (H13a-H13k)
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Analogously, the compounds H13a-H13k, were synthesized by preparing building 
block, 4-benzyl-1H-pyrazole-3,5-diamine (101) via a two-step process. The first step 
of the process comprised of the synthesis of  monosubstituted malononitriles (100) via 
reductive alkylation of malononitrile with aromatic aldehydes (99) which were readily 
converted to di-amino pyrazole (101) through simple reflux in ethanol in presence of 
hydrazine hydrate
212, 213
. The compounds (100 and 101) synthesized were 
characterized by using 
1
H NMR spectroscopy. The signals of methylene and methine 
proton appeared at around 3.33 and 5.11 ppm respectively and their splitting pattern 
in 
1
H NMR spectra suggested the formation of compound (100) while, the two amino 
groups of 101 observed at 4.25 ppm in the 
1
H NMR spectra as one broad signal. 
The reaction of 5-aminopyrazole (96) and 3,5-diaminopyrazole (101) with 
ethoxycarbonyl isothiocyanate afforded corresponding thiourea derivatives which 
underwent subsequent cyclization in presence of base affording target compounds 





C NMR and mass spectroscopy. The satisfactory purity (above 95%) was 
assessed by HPLC method. In addition, the physicochemical properties including % 












Entry Cpd R %Yield mp (ºC) Entry Cpd R %Yield mp (ºC) 
1 H11a 4-Cl 69 290-292 10 H13c 4-Br 82 222-224 
2 H11b 4-Br 66 ˃300 11 H13d 4-F 65 221-223 
3 H11c 4-F 74 270-272 12 H13e Ph 70 239-241 
4 H11d 4-Me 65 286-288 13 H13f OPh 81 210-212 
5 H11e 4-MeO 68 292-294 14 H13g 4-Me 76 254-256 
6 H11f 4-CN 61 ˃300 15 H13h 4-Et 73 228-230 
7 H11g (3,4)-Cl2 63 287-289 16 H13i 4-MeO 69 252-254 
8 H13a 4-CF3 71 189-191 17 H13j 4-OH 80 219-221 
9 H13b 4-Cl 78 243-245 18 H13k 4-CN 62 259-262 
 
4.1.2 Evaluation of anti-thymidine phosphorylase (Anti-TP) activity 
The compounds synthesized were spectroscopically tested for inhibitory activity 
against recombinant (expressed in E. coli) human thymidine phosphorylase. The 
inhibitory property of each tested compound was expressed in terms of IC50 values 
and compared with that of 7-DX (Tables 8, 9 and 10).   
 Thymidine phosphorylase activity of H5bi - H5bxix 
As shown in Table 8, the analogues of the lead H5b demonstrated a varying degree of 
TP inhibitory activities exhibiting a range of IC50 values (10.84 to 48.54 µM). The 
results also suggested that among the compounds H5bi-H5bxix, except meta-fluoro 
and meta-cyano substituted compounds (compound H5bv and H5bviii respectively), 
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the inhibitory activity of all compounds, no matter having electron-withdrawing or 
electron-donating substituents, were better compared to the lead H5b (IC50 value = 
39.56 µM) and the reference TP inhibitor, 7-DX (IC50 value = 42.63 µM). 
Interestingly, di-substituted analogues of H5b viz.compounds H5bxvii, H5bxviii and 
H5bxix showed improved activity pattern than the analogues with mono substitutions 
on phenyl ring. For example, compounds H5bxix constituted with electron-
withdrawing and electron donating substituents exhibited improved inhibitory activity 
with IC50 value 13.09 µM. In addition, compounds H5bxvii (IC50 = 10.84 µM) having 
Cl substituent in both meta and para position on the phenyl ring led to a 3.6 and 3.9-
fold improvement in activity as compared to non substituted compound, H5b (IC50 = 
39.56 µM) and 7-DX. The compound H5bxvii was identified as the most active 
inhibitor of this series. 
The results also demonstrated that the compounds with electron-donating and -π 
hydrophobicity exhibited better activity compared to the compounds with electron-
donating and +π hydrophobic substituents for both meta and para substituted 
compounds. In other words, the compounds H5bvii and H5bxv having a methoxy 
group imparted better activity than compounds H5bvi and H5bxiv which possessed a 
methyl substituent. However, among the compounds having (+π, +σ) substituents, 
compounds H5bii and H5bx with trifluoromethyl moiety exhibited improved 
inhibitory potential. This observation indicated that compounds having electron-
withdrawing substitutents with higher lipophilicity were compatible with improved 
hydrophobic interactions into the binding site.  
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Table 8. Thymidine phosphorylase inhibitory activity of H5bi - H5bxix 
 




IC50 (µM) (95% CI)
a
 
1 H5b - 39.56 (38.32 - 40.84) 
2 H5bi 3-NO2 22.63 (19.26 - 26.58) 
3 H5bii 3-CF3 22.14 (19.91 - 24.61) 
4 H5biii 3-Cl 30.29 (26.67 - 34.41) 
5 H5biv 3-Br 31.78 (29.37 - 34.40) 
6 H5bv 3-F 48.24 (41.98 - 55.42) 
7 H5bvi 3-Me 34.42 (32.23 - 36.77) 
8 H5bvii 3-MeO 23.18 (19.42 - 27.66) 
9 H5bviii 3-CN 48.54 (46.65 - 50.51) 
10 H5bix 4-NO2 36.56 (34.00 - 39.32) 
11 H5bx 4-CF3 22.68 (20.20 - 25.47) 
12 H5bxi 4-Cl 25.98 (23.09 - 29.23) 
13 H5bxii 4-Br 22.06 (19.16 - 25.41) 
14 H5bxiii 4-F 32.21 (29.00 - 35.77) 
15 H5bxiv 4-Me  31.58 (29.46 - 33.84) 
16 H5bxv 4-MeO 21.91 (20.37 - 23.56) 
17 H5bxvi 4-CN 33.06 (31.87 - 34.29) 
18 H5bxvii (3,4)-Cl2 10.84 (9.03 - 13.02) 
19 H5bxviii (3,4)-F2    21.90 (17.32 -27.69) 
20 H5bxix 3-Me, 4-Br 13.09 (11.85 to 14.47) 




experiments carried out at least in duplicate. 
 Thymidine phosphorylase activity of H8a - H8i and H11a - H11g 
The preliminary screening identified compounds H8 and H11 as potential new leads 
(IC50 values being 43.32 µM and 48.93 µM respectively). In an attempt to improve 
the inhibitory potency of leads H8 and H11, the modification of the para-position of 
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phenyl ring using various substituents from all four quadrants of the Craig plot was 
employed.  
The results of compound H8 series demonstrated that, except for cyano substituted 
compound H8h, inhibitory activity was improved with all substituents, irrespective of 
their electron-withdrawing or electron-donating properties, as compared to the leads 
H8 and H5b. As shown in table 9, the results suggested that compounds with 
substituents having electron-donating and less hydrophobic (-π) property, exhibited 
lower activity compared to compounds with electron-donating and more hydrophobic 
(+π ) substituents. In other words, the compound H8e having Me group imparted 
better activity than compound H8f and H8g bearing MeO and OH substituents 
respectively. This behaviour was not consistent as observed in compounds of H5b 
series. Therefore, it could be possible that with introduction of flexible methylene 
bridge MeO and OH moieties could impart steric effects resulting in reduction of 
binding affinities. In addition, among the compounds having +π and +σ substituents, 
compound H8a (with CF3) moiety exhibited improved inhibitory potential (IC50 value 
= 9.92 µM). It is noteworthy that within compounds H8a-H8d, except for compound 
H8b, the inhibitory effect on TP was decreasing in descending order of 
hydrophobicity of the substitutions at the para position of the phenyl ring. These 
observations indicated that hydrophobicity played an important role to impart high 
binding interaction and improved inhibitory activity. Interestingly, di-chloro 
substituted analogues of H8a, compound H8i was found to be the most potent 
inhibitor of this series with IC50 value 2.95 µM that showed 14.7, 13.4  and 14.5 fold 
enhancement of inhibitory activity compared to lead H8a, H5b and 7-DX 
respectively. The similar trend of inhibitory activity was observed in disubstituted 
analogues of H5b.  
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Within the H11 series, all the compounds substituted with varied range of electron-
donating and electron-withdrawing groups demonstrated improved inhibition property 
compared to the lead H11. In contrast to H8 series, the compounds with electron 
donating group having positive and negative hydrophobicity showed reverse pattern 
of TP inhibition profile. In other words, H11d (IC50 = 39.5 µM) bearing Me group 
showed almost 2 fold decreased in activity compared to H11e that have a methoxy 
substituent. Compounds H11a-H11c with +π and +σ substituents exhibited 
hydrophobicity dependent ascending order of inhibition profile. Analogously, di-
chloro substituted compound H11g exhibited the highest inhibitory activity with an 
IC50 value of 13.07 µM. 
In general, the di-chloro substituted analogues H5b, H8 and H11 demonstrated 
improved inhibitory activity compared to the mono-substituted derivatives. In 
addition, the structural modification in H5b by replacing one of the N atoms with 
carbon atom (giving rise to H11) resulted in no significant improvement in activity. 
Therefore, it is concluded that both N and C atoms are not crucial for better 







Table 9. Thymidine phosphorylase inhibitory activity of H8a - H8i and H11a - H11g 
 




IC50 (µM) (95% CI)
a
 
1 H8 - 43.32 (39.91 - 47.02) 
2 H8a 4-CF3 9.92 (8.03 - 12.25) 
3 H8b 4-Cl 8.54 (7.29 - 9.99) 
4 H8c 4-Br 13.71 (10.71 - 17.54) 
5 H8d 4-F 22.43 (20.61 to 24.41) 
6 H8e 4-Me 19.80 (15.98 - 24.54) 
7 H8f 4-MeO 33.95 (29.02 - 39.73) 
8 H8g 4-OH 33.78 (32.63 - 34.97) 
9 H8h 4-CN 64.33 (60.32 - 68.62) 
10 H8i (3,4)-Cl2 2.95 (2.47 - 3.52) 
11 H11 - 48.93 (46.54 - 51.44) 
12 
H11a 4-Cl 36.69  (32.76 - 41.08) 
13 
H11b 4-Br 26.54 (21.72 - 32.42) 
14 
H11c 4-F 46.45 (44.11 - 48.91) 
15 
H11d 4-Me 39.50 (32.88 - 47.45) 
16 
H11e 4-MeO 21.60 (18.09 - 25.79) 
17 H11f 4-CN 30.32 (28.45 - 32.32) 
18 H11g (3,4)-Cl2 13.07 (12.22 - 13.96) 




experiments carried out at least in duplicate. 
 Thymidine phosphorylase activity of H13a-H13k 
In a similar way, the lead structure H13 was modified by inserting different 
substituents to para-position of phenyl ring guided by Craig plot optimization 
approach. The results of the TP inhibitory activity of H13 analogues showed that all 
compounds suppressed the enzymatic reaction with IC50 values ranging in between 52 
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µM to 3 µM (Table 7).  The most pronounced TP inhibition (IC50 value = 3.82 µM) 
was observed for compound H13a, which contains a trifluoromethyl group at the para 
position of the phenyl ring. As shown in Table 7, except compounds bearing 
substituents from third and fourth quadrant of Craig plot, inhibitory activity was 
improved with all substituents, no matter having electron-withdrawing and electron-
donating group, as compared to the lead H13. In other words, compounds H13i, 
H13j, and H13k  having substituents with negative hydrophobic constant (-π) 
exhibited lower inhibitory activity compared to non substituted  H13 (IC50 value = 
29.92 µM). The results also demonstrated that compounds with electron-donating 
substituent having positive hydrophobic constant showed improved activity as 
compared to H13. Among them, compound H13h (IC50 value = 12.56 µM) having 
ethyl moiety exhibited inhibitory activity slightly better than compound H13g (IC50 = 
19.98 µM) having methyl substituent. In addition, it was evident from the results that 
among the compounds with (+π, +σ) substituents, compound H13a bearing CF3 
moiety was proven to be the most potent member in this series. It is interesting to note 
that substituent CF3 imparted higher hydrophobicity among other substitutions 
selected from first quadrant of Craig plot. Therefore, the above mentioned 
observations indicated that substitution with +π hydrophobicity at the para position of 
the phenyl ring seemed to play an important role in the binding interactions led to 
improved anti-TP effect of the compounds. Encouraged by these exciting findings, we 
were prompted to modify the compound H13 by introducing some hydrophobic 
substituents including biphenyl and phenoxyphenyl groups. Interestingly, such efforts 
generated compounds H13e and H13f and their anti-TP evaluation demonstrated a 4.9 
and 6.7 fold improvement in inhibitory activity over H13 respectively.   
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Table 10. Thymidine phosphorylase inhibitory activity of H13a-H13k 
 
Entry Cpd R 
TP Inhibition activity
b 
IC50 (µM) (95% CI)
a
 
1 H13 - 29.92 (25.74 - 34.77) 
2 H13a 4-CF3 3.82 (3.31 to 4.41) 
3 H13b 4-Cl 7.54 (5.97 - 9.51) 
4 H13c 4-Br 14.78 (13.52 - 16.15) 
5 H13d 4-F 22.65 (19.60 - 26.17) 
6 H13e Ph 6.11 (5.55 - 6.72) 
7 H13f OPh 4.46 (4.17 - 4.77) 
8 H13g 4-Me 19.98 (16.04 -24.90) 
9 H13h 4-Et 12.56 (11.53 - 13.69) 
10 H13i 4-MeO 51.44 (48.73 - 54.31) 
11 H13j 4-OH 37.38 (32.80 - 42.60) 
12 H13k 4-CN 51.53 (49.66 - 53.46) 




experiments carried out at least in duplicate. 
 4.2 Further miscellaneous structural modifications 
 As discussed in previous chapter, 2-(methylthio)-5-thioxo-5,6-dihydro-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one H5a exhibited moderate inhibitory 
activity against recombinant human thymidine phosphorylase (IC50 value = 51.67 
µM). However, replacing the thiomethyl group at the position C2 of this fused ring 
with aromatic phenyl ring led to an improvement of  TP inhibitory activity, suggesting  
that the bulky lipophilic moiety may increase  the hydrophobic interactions of  
compound H5b (IC50 value = 39.56 µM) in the binding site and thus the inhibitory 
activity of compound H5b against TP enzyme was augmented. Therefore, it was 
hypothesized that replacing the thiomethyl group by benzylthio, substituents with 
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higher flexible alkyl chain, and hydrophobic moiety at the position C2 might serve as 
a lipophilicity  modulator that might facilitate improvement of  interaction of lead 
compound with the binding site of enzyme. In addition, based on the structure of TPI, 
where the heterocycle pyrrolidine is attached to the pyrimidin-2,4-dione  ring, it is 
assumed  that heterocycle substituted fused ring scaffold would also fit well in the 
active site. Moreover, moderate TP inhibitory potential exerted by H11 (IC50 = 48.93 
µM) and H13 (IC50 = 29.92 µM), has led to the postulation that C8 substituted 
pyrazolo fused triazine scaffold would also exhibit anti-TP property.  
Therefore, the objective of the study was  to  synthesize a small series of compounds 
with phenylalkylthio groups introduced  at the position C2 of 5-thioxo-5,6-dihydro-
[1,5-a][1,3,5]triazin-7(4H)-one ring and to evaluate whether the increasing alkyl chain 
length  will be able to enhance binding affinity to TP. As  continuous efforts to 
develop potent TP inhibitors, lead compounds H5b and H11   were modified further 
by inserting a diphenyl group and t-butyl moiety at the position C2 and C7 
respectively as a lipophilic modulator. In addition, various heterocycles were 
introduced in the lead structures H5b and H13 by replacing phenyl ring using 
analogous synthetic methodology. Moreover, further modification of H11 was carried 
out by switching the position of phenyl ring from C7 to C8 in order to test above 
mentioned hypothesis.  
4.2.1 Chemistry 
The synthesis of all the target compounds (H5ai-H14) (Table 8) were conveniently 
achieved by a ring annulation reaction of carbethoxythioureas derivatives (88, 93, 98, 
and 102) having N-C-N-C appendages in alkali medium (Scheme 16, 17, 18 and 19). 
The nucleophilic reaction of ethoxycarbonyl isothiocyanate with various 1,2,4-
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triazoles (87 and 91) and pyrazole (96 and 101) having exocyclic amino group 
afforded corresponding carbethoxythioureas  derivatives with good yield in DMF. 
Herein, to synthesize 1,2,4-triazoles (87 and 91) and pyrazole (96 and 101) 
derivatives, several methods were adopted. For example, reported method was 
followed to prepare 5-phenylakylthio substituted-1,2,4-triazols by alkylation of 3-
amino-5-sulfanyl-1,2,4-triazole with benzyl bromide and its longer alkyl chain 
derivatives in DMF
208
. The furyl, thienyl and pyridyl substituted aminotriazole was 
synthesized via the preparation of (het)arylamidoguanidines from the reaction of 
appropriate hydrazides with S-methyl isothiourea in basic condition. Consequently, 
the cyclocondensation of (het)arylamidoguanidines in microwave irradiation led to 
formation of corresponding 1,2,4-triazoles with excellent yield and purity. For 
compound H5g, corresponding amino-1,2,4-triazole was synthesized by adopting 
alternative pathway of synthesis of arylamidoguanidines by using aryl acid chloride 
reacted with aminoguanidine hydrochloride and resulting product upon microwave 
irradiation led to synthesis of key intermediate 1,2,4-triazoles. In addition, to 
synthesize 4-substituted-pyrazol-3,5-diamine as a building block for preparation of 
H13l, H13m and H13o, the scheme 19 was directly utilized, starting from 
corresponding aromatic aldehyde. All other compounds (H5f, H11h and H14) were 
prepared by using commercially available aminotriazole or aminopyrazoles. The 
synthesized compounds were characterized by their % yield and melting points (Table 
11). The structures of these compounds were confirmed by using NMR spectroscopy 








Entry Cpd R %Yield mp (ºC) Entry Cpd R %Yield mp (ºC) 
1 H5ai SCH2Ph 89 249 8 H5g CH(Ph)2 63 210-212 
2 H5aii S(CH2)2Ph 94 232-234 9 H11h C(Me)3 55 268-270 
3 H5aiii S(CH2)3Ph 69 220-221 10 H13l 2-furyl 74 227-229 
4 H5c 2-furyl 62 292-294 11 H13m 2-thienyl 72 242-244 
5 H5d 2-thienyl 64 273 12 H13n 1-naphthyl 63 230-233 
6 H5e 2-pyridyl 63 280-282 13 H14 Ph 60 222-224 
7 H5f H 54 ˃300 
     
 
4.2.2 Evaluation of anti-thymidine phosphorylase (Anti-TP) activity 
The potency of the inhibition of thymidine phosphorylase (TP) by the synthesized 
compounds was spectrophotometriclly evaluated via in vitro enzyme assay method  
From the percentage of the enzymatic activity inhibition, IC50 values were calculated 
and reported in Table 12. The IC50 values of reference compound, 7-DX was 
determined under the same experimental conditions and the value was compared with 
our synthesized compounds. 
The preliminary study demonstrated that compounds H5a and H5b having 5-thioxo-
5,6-dihydro-4H-[1,2,4]triazole[1,5-a][1,3,5]triazin-7-one scaffold exhibited weak to 
moderate TP inhibitory activity. Herein, additional variation in substitution at C2 of 
the H5a and H5b was carried out via introducing phenyl ring through flexible alkyl 
chain and inserting heterocyclic rings instead of phenyl ring. The resultant compounds 
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(H5ai-H5aiii) and (H5c-H5e) showed varying degrees of TP inhibition with IC50 
values ranging between 22 and 38 μM (Table 12). The modification of compounds 
H5a and H5b by introducing longer flexible side chain and higher spacer length at the 
position C2 suggested that activity was increased with such kind of attempts. To 
illustrate, it should be mentioned that the compound H5ai, H5aii and H5aiii showed 
better binding interactions (IC50 = 38.19, 33.04, 27.64 µM respectively) with respect 
to H5a and H5b (IC50 = 51.67, 39.56 µM respectively). The replacement of phenyl 
ring with other aromatic ring like furan, thiophene and pyridyl motif produced 
compounds H5c, H5d and H5e that also exhibited improvement in enzyme affinity. 
In other words, the IC50 values of compounds H5c, H5d and H5e were 22.84 µM, 
30.95 µM and 24.53 µM respectively that were lower than the IC50 value of H5b. As 
depicted in the Table 9, compounds with aromatic substituents at the position C2 
demonstrated better interactions than the unsubstituted compound H5f which is 
considered as most structurally similar to the lead compound 7-DX (IC50 = 42.63 
µM). Compound H5c, 2-(furan-2-yl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7(4H)-one, was found to be the most active member of this  series 
(IC50 = 22.84 µM). 
The previous experimental data demonstrated that hydrophobicity of the substituents 
played an important role in enhancing inhibitory activity. Encouraged by this fact, 
bulky di-phenyl moiety and t-butyl group were introduced instead of phenyl ring at 
the position C2 and C7 of the lead compound H5b and H11 respectively. However, it 
could not able to impart significant improvement in inhibition potency suggesting 
such bulky group might present negative steric hindrance on the interaction to the 
binding site of the enzyme. 
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In addition, optimization of lead H13 was further extended by replacing phenyl ring 
by some aromatic heterocycles namely 2-furyl and 2-thienyl and naphthoyl 
substituents resulting in synthesis of compound H13l, H13m and H13n. Such effort 
demonstrated that although, compound H13n exhibited 6.8 fold enhancement of 
inhibition potential, H13m, H13n did not show any significant improvement of 
activity compared to lead H13. It was further proven that hydrophobicity of 
substituents might play significant role in improving interactions of compounds in the 
binding site. Moreover, it was observed that when the orientation of phenyl ring of 
pyrazolo[1,5-a][1,3,5]triazine was changed from C7 to C8, the enzyme affinity was 
augmented. In other word, the compound H14 showed lower IC50 value than all lead 
compounds identified (H5a, H5b, H8, H11 and H13). Therefore, a further structural 











Table 12. Thymidine phosphorylase inhibitory activity of the synthesized compounds 
(derivatives of H5, H11, H13 and compound H14) 
 




IC50 (µM) (95% CI)
a
 
1 H5ai SCH2Ph 38.19 (33.37 to 43.71) 
2 H5aii S(CH2)2Ph 33.04 (28.31 to 38.56) 
3 H5aiii S(CH2)3Ph 27.64 (23.21 to 32.91) 
4 H5c 2-furyl 22.84 (20.25 to 25.78) 
5 H5d 2-thienyl 30.95 (26.88 to 35.65) 
6 H5e 2-pyridyl 24.53 (21.30 to 28.25) 
7 H5f H 40.45 (32.36 to 50.57) 
8 H5g CH(Ph)2 36.37 (33.49 - 39.50) 
9 H11h C(Me)3 55.70 (52.19 - 59.45) 
10 H13l 2-furyl 36.72 (31.70 - 42.52) 
11 H13m 2-thienyl 27.69 (24.99 - 30.68) 
12 H13n 1-naphthyl 4.29 (3.714 - 4.953) 
13 H14 Ph 26.30 (28.3-24.3) 




experiments carried out at least in duplicate 
4.3 Summary    
To summarize, several compounds having 1,2,4-triazolo[1,5-a][1,3,5]triazine and  
pyrazolo[1,5-a][1,3,5]triazine ring structures were synthesized and their anti-TP effect 
was evaluated. The biological evaluation identified a number of new TP inhibitors 
bearing 5-thioxo-5,6-dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one, 2-thioxo-
2,3-dihydro-1H- pyrazolo [1,5-a][1,3,5]triazin-4-one scaffold. Among them, 
compounds H5bxvii and H8i, H11g and H13a exhibited the most promising 
inhibitory property against TP with low micromolar IC50 values (IC50 values = 10.84, 
2.95 and 13.07, 3.82 µM respectively). This study also provided evidence that the 
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potency of the active compounds strongly depends on physicochemical properties 
particularly on hydrophobic properties of the substituents at the different position of 
the phenyl ring. In addition, the biological evaluation demonstrated that several 
compounds of this series have shown significant TP inhibitory activity, in particular 
those that bear disubstitutions on the phenyl ring. Moreover, di-substituted pyrazolo 
[1,5-a][1,3,5]triazine derivatives, including H13e, H13f and H13n, demonstrated 
atteactive inhibition property against TP. 
In general, when the structural features of all fused 1,3,5-triazine compounds were 
considered with respect to their TP activity, a qualitative structure-activity 
relationship has emerged. Even though TPI and 7-DX were used as the leads for the 
design of this study, the structures of the new TP inhibitors from this study have 
deviated significantly from the lead compounds. As depicted in Figure 12, the bicyclic 
fused 1,3,5-triazines, having the homophthalimide group did not exhibit TP inhibitory 
activity. However, its replacement with the isosteric group –NH(S=S)NH(C=O) gave 
rise to good TP inhibitory activity in some derivatives. In addition, the incorporation 
of a thiomethyl group at either C5 or C2 of the fused ring scaffold, has led to a 
dramatic decrease in activity. It is evident from the data that a range of aromatic and 
aliphatic substituents (R = Ph, SCH3, CH(Ph)2, NH(C=S)NH2) and various aromatic 
heterocycles could be accommodated by the enzyme and exhibited good inhibitory 
effects. However, results also suggested that aromatic substitutions are essential for 
better inhibitory effect. The binding pocket of the enzyme appeared to tolerate 
substitutions such as the phenyl or benzyl group at C8/N3 and exhibited inhibitory 
effects. Moreover, the inhibitory potency of these synthesized compounds suggested 
that the introduction of different atoms including C or N at C8/N3 did not 













TP inhibitory activity  is better 
with R being Ph or thiourea
compared to aliphatic 
substituents
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Figure 12. A schematic diagram describing the structure-TP inhibitory activity 
relationship of the 1,2,4-triazolo and pyrazolo fused triazines  
Overall, the interesting TP inhibitory activity of the synthesized  compounds  make 
them suitable leads for further development of new chemical entities for potential use 
in the treatment of disease associated with TP. It is important to mention that the 
synthesis of these target compounds was achieved via intramolecular 
heterocyclization of key intermediate viz. substituted triazole and pyrazole 
derivatives. In this reaction pathway, it was noticed that these intermediates could 
generate different regioisomeric products depending on reaction conditions used. 
Therefore, in the following chapter, the regiochemistry of the synthetic intermediates 
































5.1 Synthesis and tautomerism study of the key intermediates, 3(5)-amino/ 
carbethoxythiourea-5(3)-aryl-1,2,4-triazoles 
The derivatives of 1,2,4-triazolo[1,5-a][1,3,5]triazine constitute an important class of 
heterocycles found in many compounds that are used in medicine and agriculture
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. 
Therefore, the synthesis of 1,2,4-triazolo fused 1,3,5-triazine analogues and the 
exploration of their diverse bioactivities draw increasing interest to organic and 
medicinal chemists. In an attempt to investigate the new biological properties of this 
scaffold, thio-oxo derivatives of 1,2,4-triazolo[1,5-a][1,3,5]triazine were established 
as potential TP inhibitors for the first time as described in previous chapter. The 
synthesis of these biologically active compounds was achieved via intramolecular 
heterocyclization of 1,2,4-triazoles having N-C-C-N appendage at C3(5) viz. N-(3(5)-
aryl-1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas which were generated from the 
reaction of substituted 3(5)-amino-1,2,4-triazoles and ethoxy carbonyl isothiocyanate. 
Therefore, 3(5)-amino-1,2,4-triazoles  and N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-
carbethoxythioureas were considered as valuable intermediates  for the construction 
of desirable thio-oxo analogues of 1,2,4-triazolo[1,5-a][1,3,5]triazine. In this synthetic 
pathway, it was observed that depending on reaction conditions used, the substituted 
1,2,4-triazole could afford different regioisomeric products. Among the different 
factors, the tautomerism is often considered as the most influencing factors in 
regioselectivity of reactions. Therefore, knowledge of the tautomeric preferences of 
intermediate compounds and the factors affecting the tautomeric equilibrium is 
essential to achieve desired compounds in chemical processes.  
Due to annular prototropic tautomerism, 1,2,4-triazole without substituents on the ring 
nitrogen atoms, can exist in three forms. Although several theoretical reports have 
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been published in the area of tautomerism in 1,2,4-triazole, the precise experimental 
data on the annular tautomerism in 1,2,4-triazoles is limited
218, 219
. Previously, our 
research group reported the annular tautomerism study of 3(5)-amino-5(3)-aryl-1,2,4-
triazoles
207
 and established a good correlation between the relative energies of 
individual tautomeric preferences and electronic property using limited number of 
para-substituted  3(5)-amino-5(3)-phenyl-1,2,4-triazoles. Herein, in continuation of 
our investigation on annular tautomerism, the tautomeric aspects of 3(5)-amino-1,2,4-
triazoles and related structure viz. N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-
carbethoxythioureas, considering a wide range of substitutions is studied  in  solutions 
(Figure 13). In addition, the various methods used to introduce different substituents 
at 3(5) position of 1,2,4-triazole will be summarized and the effects of  nucleophilicity 
of different substituents of 3(5)-amino-1,2,4-triazole on  reaction processes will be 
discussed. 
 
Figure 13. Structures of 1,2,4-triazole derivatives 
5.1.1 Synthesis of 3(5)-amino-5(3)-(het)aryl-1,2,4-triazoles (87, 91) 
The synthesis of 3(5)-amino-5(3)-(het)aryl-1,2,4-triazoles (87, 91) was achieved by 
adopting some environment friendly synthetic methods in which solvents like water 
and ethanol were selected for use, the energy was effectively utilized and the 
formation of by-products were minimized. The 5(3)-substituted-3(5)-amino-1,2,4-
triazoles (87, 91) were prepared by using four different reaction processes (Scheme 
24). Firstly, the condensation of substituted aryl hydrazide and  S-methyl isothiourea 
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produced arylaminoguanidines (85, 106) in alkali medium which upon microwave 
irradiation afforded 3(5)-amino-1,2,4-triazoles (87, 91)
206, 207
. The first step of this 
method had several limitations including prolonged reaction time and complicated 
work-up process that often led to decrease in the yield of the products. Alternatively, 
these (het)arylamidoguanidines (85, 106) were synthesized through the fusion of 
aminoguanidine hydrochloride with substituted benzoyl chloride (103, 104) by 
heating at high temperature (above 175 
º
C) followed by basification using 5M NaOH.  
The (het)arylamidoguanidines (85, 106) thus obtained were cyclised using microwave 
irradiation in water and subsequently afforded 3(5)-amino-5(3)-(het)aryl-1,2,4-
triazoles (87, 91). It gave quantitative yield and excellent purity of the products. The 
synthesis of compound 85, 106 was also achieved by the reaction of substituted (4-
MeO, 4-NO2, 4-Me, 4-CN, 4-OH, 4-CF3, 4-Br and 3,4-di Cl) phenyl acetic acid (105) 
and aminoguanidine hydrochloride and the products were proceeded successfully to 
afford corresponding benzyl substituted 3(5)-amino-1,2,4-triazoles upon microwave 
irradiation with excellent yield and purity. Thirdly, the reaction of dimethyl-N-
cyanodithiocarbonimidate (86) with hydrazine produced 3(methylthio)-amino-1,2,4-
triazoles
206
. Lastly, previously reported method was adopted to synthesize 5-
phenylalkylthio substituted-1,2,4-triazols via alkylation of commercially available 3-








Reagents and conditions: (a) Fusion at 180 ºC, 20 min, 5M NaOH (b) Water, MW  irradiation, 180 ºC, 10 min  (c) NaOH, r.t, 72 h (d) DMF, 
Et3N, r.t., 4 h (e) MeOH, 40 ºC, 5h. 





5.1.2 Tautomerism study of 3(5)-amino-5(3)-(het)aryl-1,2,4-triazoles  
Tautomerism is an intriguing phenomenon with a long history of investigation and the 
tautomerism in azoles has been a subject of discussion for many years
218, 219
. 
Theoretically three annular tautomeric forms are possible for prepared 3(5)-amino-
5(3)-(het) aryl-1,2,4-triazoles (Scheme 25) 
207
. The structures of these compounds, in 
particular their tautomerism were investigated using NMR spectroscopy, which is 
considered to be the most informative and accurate method for solutions. The 
tautomeric study by 
1
H NMR of the 1, 2, 4-triazoles revealed that forms A and B were 
exist in the DMSO solutions, while form C was not observed under the experimental 
conditions. The equilibrium between the tautomers was established rapidly and the 
compositions did not change with time. The identical spectra for the tautomeric 
system A and B was observed on dissolving the samples and after equilibration of the 
solution overnight. 
The tautomeric equilibrium constant (KT) was determined by integrating the  
characteristic NH and/or NH2 signals of tautomers A and B in the 
1
H NMR spectra 
and subsequently, the Gibbs free energies (ΔG298) of individual tautomers were 
calculated using equation, ΔG298 = -RTlnKT (Table 13). The 5-amino-1,2,4-triazoles 
(A) was identified as dominant in the equilibrium while form B was found to be 
minor. The substituents exhibited important role on the equilibrium. The study 
demonstrated that the ratio of predominant and thermodynamically most stable form 





Scheme 25. Tautomers of 3(5)-amino-1,2,4-triazoles 
It was observed that the KT and ΔG298 values correlated well with the Hammett 
constants
220
 of substituents on the phenyl or benzyl moiety of triazole, -ΔG298 = 
4.462σ + 5.217, R2 = 0.981 and -ΔG298= 1.768σ + 3.415, R
2
 = 0.972 (Figure 14A and 
14B respectively). Therefore, the thermodynamic stability of form A in comparison 
with B increased together with the electron-withdrawing properties of the 
substituents. Analogously, the tautomeric equilibrium constant and Gibbs free energy 
of individual tautomer were determined for some heterocyclic, that is, 2pyridyl, 3-
pyridyl, 4-pyridyl, 2-thienyl and 2-furyl  substituents at C3(5) of the 1,2,4-triazole 
ring. However, experimental results for these compounds were outside this 
correlation. In addition, the correlation could not be extended for compound 87j, 87r 
and 87zd. The calculated KT(A/B) for 87a and  87v  was found 16.8 and 19.01 whereas 
the ΔG298 was equal to 6.98 and -7.28 KJ/mol respectively. It was observed that 
introduction of longer flexible chain attached with sulphur moiety reduced electron 
donating property of this C3(5) position and thus form B was disfavoured and 





Table 13. Tautomerism in 3(5)-amino-1,2,4-triazoles in DMSO-d6 solution 
 
    
1
H NMR signal in DMSO-d6 (ppm)   
Entry Cpd R n Tautomer B Tautomer A KT -∆G298 
3(5)-NH2 N(1)-H 3(5)-NH2 N(1)-H 
1 87a CH3S 0 5.29 12.67 6.04 11.91 16.84 6.98 
2 87b Ph 0 5.35 13.24 6.12 12.08 7.75 5.06 
3 87c 3-NO2C6H4 0 5.47 13.60 6.26 12.34 27.62 8.21 
4 87d 3-CF3C6H4 0 5.45 13.50 6.23 12.29 19.84 7.39 
5 87e 3-ClC6H4 0 5.38 13.35 6.16 12.20 15.82 6.83 
6 87f 3-BrC6H4 0 5.40 13.35 6.17 12.22 15.67 6.81 
7 87g 3-FC6H4 0 5.42 13.38 6.19 12.21 13.91 6.51 
8 87h 3-MeC6H4 0 5.45 13.16 6.09 12.08 6.47 4.62 
9 87i 3-MeOC6H4 0 5.39 13.22 6.09 12.08 10.23 5.75 
10 87j 3-CNC6H4 0 5.37 13.34 6.12 12.14 14.25 6.57 
11 87k 4-NO2C6H4 0 5.54 13.69 6.30 12.45 33.33 8.67 
12 87l 4-CF3C6H4 0 5.53 13.55 6.24 12.32 22.42 7.69 
13 87m 4-ClC6H4 0 5.43 13.33 6.17 12.18 13.25 6.39 
14 87n 4-BrC6H4 0 5.40 13.33 6.15 12.17 13.50 6.44 
15 87o 4-FC6H4 0 5.36 13.24 6.13 12.10 10.30 5.77 
16 87p 4-MeC6H4 0 5.32 13.14 6.08 12.02 5.86 4.37 
17 87q 4-MeOC6H4 0 5.27 13.02 6.04 11.94 4.99 3.97 
18 87r 4-CNC6H4 0 5.50 13.60 6.26 12.37 25.58 8.02 
19 87s (3,4)-diClC6H3 0 5.43 13.42 6.21 12.28 22.78 7.73 
20 87t (3,4)-diFC6H3 0 5.41 13.33 6.19 12.21 18.28 7.19 
21 87u 3Me,4BrC6H3 0 5.35 13.27 6.11 12.15 12.06 6.16 
22 87v C6H5CH2S 0 5.19 12.69 6.08 11.96 19.01 7.28 
23 87w C6H5(CH2)2S 0 5.37 12.66 6.06 11.95 14.03 6.53 
24 87x C6H5(CH2)3S 0 5.21 12.66 6.03 11.90 13.04 6.35 
25 87y 2-Furyl 0 5.39 13.28 6.17 12.15 11.90 6.13 
26 87z 2-Thienyl 0 5.40 13.26 6.19 12.09 13.76 6.48 
27 87za 2-Pyridyl 0 5.45 13.55 6.22 12.41 1.68 1.29 
28 87zb 3-Pyridyl 0 5.52 13.51 6.29 12.34 19.92 7.40 
29 87zc 4-Pyridyl 0 5.53 13.65 6.28 12.42 29.15 8.34 
30 87zd (Ph)2CH- 0 5.42 12.62 5.92 11.75 7.27 4.91 
31 91a C6H5 1 5.08 12.52 5.85 11.68 3.70 3.23 
32 91b 4-CF3C6H4  1 5.16 12.55 5.88 11.74 5.75 4.33 
33 91c 4-NO2C6H4 1 5.14 12.62 5.92 11.78 6.70 4.70 
34 91d 4-ClC6H4  1 5.09 12.48 5.84 11.68 4.61 3.78 
35 91e 4-BrC6H4  1 5.11 12.47 5.83 11.67 5.01 3.98 
36 91f 4-FC6H4 1 5.10 12.51 5.87 11.70 4.41 3.67 
37 91g 4-MeC6H4 1 5.05 12.46 5.82 11.64 3.36 3.00 
38 91h 4-MeOC6H4 1 5.11 12.43 5.81 11.65 3.47 3.07 
39 91i 4-OHC6H4  1 5.10 12.53 5.76 11.57 2.99 2.71 
40 91j 4-CNC6H4 1 5.25 12.54 5.89 11.76 6.64 4.68 

















































































Figure 14. Correlation of ΔG for the tautomeric equilibrium of 3(5)-amino-1,2,4-







5.1.3  Synthesis of N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas (88, 
93) 
The nucleophilic reaction of ethoxycarbonyl isothiocyanate with various heterocyclic 
compounds having exocyclic amino group afforded addition product with good yield 
in polar aprotic solvent
221-223
. It was found that variations in substrate or reaction 
conditions produced isomeric derivatives of product
224
. Herein, to synthesize N-(3(5)-
aryl-1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas and their derivatives (88, 93),  the 
reactions of various substituted 3(5)-amino-5(3)-aryl-1,2,4-triazoles with ethoxy 
carbonyl isthiocyanate in dry DMF were performed and it was observed that at room 
temperature the reaction always preceded smoothly with satisfactory yield and purity 
(Scheme 26). 
 
Scheme 26.  Synthesis of N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas 
(88, 93) 
Interestingly, although there are several nucleophilic centres available in 87 and 91, 
ethoxycarbonyl isothocyanate attacked to exocyclic nitrogen and compounds (88, 93)  
were isolated exclusively and with good yields  except some heterocycles substituted 
3(5)-amino-1,2,4-triazoles. For example, the reaction of 3(5)-amino-5(3)-3-pyridyl-
1,2,4-triazoles (87zb) with ethoxy carbonyl isthiocyanate in the same reaction 
condition afforded corresponding thiourea derivative (88zb) (yield 45 %) and 5-
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amino-3-pyridin-3-yl-[1,2,4]triazole-1-carboxylic acid ethyl ester (88zb’) (yield 40 
%) after 5 hr. The formation of this two compounds (88zb and 88zb’) clearly 
indicated that the nucleophilic reactions of 87zb took place at the two electrophilic 
centres viz. isothiocyanato and carbonyl carbon atoms of ethoxycarbonyl 
isothiocyanate and resulted in addition reactions of isothiocyanato moiety with 
exocyclic amino group and nucleophilic substitution of carbonyl carbon atom at 
N(1)H of (5)-amino-5(3)-3-pyridyl-1,2,4-triazoles. Due to the strong electron-
attracting power of alkoxycarbonyl group enhances the reactivity of the adjacent 
isothiocyanato-function and promotes the nucleophilic addition at strong nucleophilic 
centre viz. exocyclic amino moiety of 87zb, whereas, the weak electrophile carbonyl 
carbon atom attack to weaker nucleophilic centre viz. at N(1)H resulting in formation 
of 88zb and 88zb’ respectively.  
To isolate compound 88zb exclusively from reaction mixture, several other reaction 
conditions were attempted using a wide range of polar aprotic solvents and varying 
reaction temperature. Initially, various polar solvents including dry acetonitrile, 
acetone, toluene and THF instead of DMF were used as reaction medium at room 
temperature. The reaction in acetonitrile (monitored by TLC) was found to complete 
after 24 hours. The products obtained from the reaction in dry acetone, were not pure 
enough and yield was also less. In addition, the reaction carried out in toluene and 
THF did not yield any products. Thereafter, to explore further, the reaction was 
carried out in both hot (100 ºC) and cold condition (0 ºC) in DMF. In both case the 
yields of product was unsatisfactory. Therefore, except the reaction in DMF at r.t., 
several other reaction conditions resulted in unsatisfactory, giving poor yield, or an 
impure product or both (Table 14).  Although the attempt to optimize the reaction 
condition was unsuccessful, the reaction of entry 1 gave the highest yield for 88zb and 
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this condition was used further The separation of two products was achieved by 
column chromatography using hexane:ethyl acetate (1:1) as eluent.  
Table 14. Optimization of reaction condition of  N-(3(5)-3-pyridyl-1,2,4-triazol-5(3)-
yl)-N’-carbethoxythioureas 
 
Entry Solvent Temp. Time (hr.) % yield 88zb % yield 88zb’ 
1 DMF r.t 5 hr. 45 40 
2 Acetonitrile r.t 24 hr. 29 11 
3 Acetone r.t 12hr. 30 16 
4 THF r.t 12hr. - - 
5 Toluene r.t 24 hr. - - 
6 DMF 100 3hr. 15 12 
7 DMF 0 12hr. 18 17 
 
To explore further, the reaction condition of entry 1 was applied on 3(5)-amino-5(3)-
2-pyridyl-1,2,4-triazoles (87za) and 3(5)-amino-5(3)-4-pyridyl-1,2,4-triazoles (87zc). 
Interestingly, although there are several nucleophilic centres available in 87za, 
ethoxycarbonyl isothocyanate attacked to exocyclic nitrogen viz. compounds 88za 
were isolated exclusively and with good yields (84%). The corresponding product 
88za obtained from the reaction of 3(5)-amino-5(3)-4-pyridyl-1,2,4-triazoles (87zc) 
and ethoxycarbonyl isothocyanate in DMF could not be characterized due to its poor 
solubility. 
In case of 3(5)-amino-5(3)-2-pyridyl-1,2,4-triazoles, due to mesomeric effect 
(Scheme 27), probably the lone pair electron of N(1)H was withdrawn by nitrogen 
atom of 2-pyridyl moiety resulted in transmission of δ+ and δ- charge at N(1)H and 
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pyridyl nitrogen respectively. Therefore, the nucleophilicity of N(1)H of 87za is 
decreased dramatically in respect to 87zb that leads to exclusively addition product 
88za in the reaction of 3(5)-amino-5(3)-2-pyridyl-1,2,4-triazoles and ethoxycarbonyl 
isothocyanate in DMF.  
 
Scheme 27. Nucleophilicity of 3(5)-amino-5(3)-2-pyridyl-1,2,4-triazoles 
5.1.4 Tautomerism study of N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-
carbethoxythioureas (88, 93) 
The tautomerism aspect of thiourea derivatives of 1,2,4-triazole was evaluated by the 
use of 
1
H NMR spectroscopy. This tool is believed to provide most reliable and 
comprehensive structural information in solution. Due to annular tautomerism, there 
is theoretical possibility for existence of three tautomeric forms viz. N-carbethoxy-N’-
(3-phenyl-1H-1,2,4-triazol-5-yl)thioureas (A), N-carbethoxy-N’-(5-phenyl-1H-1,2,4-
triazol-3-yl)thioureas (B), N-carbethoxy-N’-(3-phenyl-4H-1,2,4-triazol-5-yl)thioureas 
(C) (Scheme 26). To study tautomeric aspect of compounds (Table 15) in solution, 
DMSO-d6 was used as a solvent to disfavour a potential intramolecular hydrogen 
bonding in the compounds due to the presence of C=S and CO2Et hydrogen acceptors.  
Similarly to our results
207
 obtained previously for 3(5)-amino-5(3)-aryl-1,2,4-
triazoles, forms A and B were found to be present in the solutions of triazoles (88, 93) 
while form C was not observed under the experimental conditions (Scheme 26). The 
equilibrium between the tautomers was established rapidly and the compositions did 
not change with time. The identical spectra of the tautomeric system A-B were 
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observed instantaneously on dissolving the samples and after equilibration of the 
solution overnight. 
The N(1)H signals of tautomers A and B in the 
1
H NMR spectra in DMSO-d6 were 
quite distinct allowing calculation of KT values (Table 15). In comparison with parent 
5-amino-1,2,4-triazoles (87, 91), compounds (88, 93) had the mesomeric electron 
donating effect of amino group compromised by the thiocarbonyl attached, that 
resulted in rather similar electronic properties of the aryl and carbethoxythiourea 
groups. Therefore, electronic properties of the substituents on the phenyl ring changed 
the predominant tautomeric form. Thus, form B was predominant for R = MeO, Me, 
and H while form A is major in case of more electronegative R (Cl, Br, CF3 and NO2). 
The KT and ΔG298 values correlated well with the Hammett constant
206
 of the 
substituents on the phenyl ring of (88, 93) (Figure 15). Therefore, the thermodynamic 
stability of form A in comparison with B increased proportionally with increasing 
electron-withdrawing properties of the substituents R. This relation was not fit well 
for compound 88j, 88r and 88zd. The anomalous thermodynamic stability of 
tautomeric forms in solution for these compounds could not be explained properly by 
this limited study. Therefore, a detail investigation of the factors affecting tautomeric 















Table 15.  Tautomerism of N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas 
in DMSO-d6 solution 
 
    
1
H NMR signal in DMSO-d6 (ppm)   
Entry Cpd R n Tautomer A Tautomer B KT ∆G298 
NH NH N(1)H 2NH N(1)H 
1 88a CH3S 0 11.82 12.00 13.79 
11.41; 
11.52 
13.93 1.01 -0.02 
2 88b Ph 0 11.87 12.16 13.93 11.56 14.47 1.35 -0.74 
3 88c 3-NO2C6H4 0 11.89 12.13 14.18 11.61 14.81 0.42 2.15 
4 88d 3-CF3C6H4 0 11.89 12.13 14.11 11.56 14.69 0.57 1.39 
5 88e 3-ClC6H4 0 11.91 12.16 14.06 11.58 14.59 0.72 0.81 
6 88f 3-BrC6H4 0 11.89 12.14 14.05 11.57 14.57 0.74 0.75 
7 88g 3-FC6H4 0 11.89 12.15 14.04 11.58 14.59 0.78 0.62 
8 88h 3-MeC6H4 0 11.88 12.18 13.90 11.57 14.42 1.60 -1.16 
9 88i 3-MeOC6H4 0 11.88 12.16 13.93 11.56 14.48 1.48 -0.97 
10 88j 3-CNC6H4 0 11.87 12.11 14.12 11.56 14.62 0.64 1.09 
11 88k 4-NO2C6H4 0 11.89 12.13 14.25 11.58 14.86 0.32 2.82 
12 88l 4-CF3C6H4 0 11.88 12.12 14.13 11.57 14.74 0.47 1.87 
13 88m 4-ClC6H4 0 11.87 12.16 14.00 11.62 14.55 0.81 0.52 
14 88n 4-BrC6H4 0 11.86 12.13 14.00 11.59 14.55 0.79 0.58 
15 88o 4-FC6H4 0 11.85 12.10 13.92 11.52 14.44 1.08 -0.19 
16 88p 4-MeC6H4 0 11.86 12.13 13.85 11.53 14.24 1.89 -1.58 
17 88q 4-MeOC6H4 0 11.82 12.05 13.77 11.54 14.24 2.56 -2.33 
18 88r 4-CNC6H4 0 11.87 12.10 14.18 11.56 14.77 0.41 2.18 
19 88s (3,4)-diClC6H3 0 11.89 12.12 14.11 11.56 14.62 0.51 1.67 
20 88t (3,4)-diFC6H3 0 11.87 12.13 14.04 11.60 14.54 0.57 1.39 
21 88u 3Me,4BrC6H3 0 11.87 12.13 13.97 11.55 14.49 0.90 0.26 
22 88v C6H5CH2S 0 11.79 11.98 13.85 11.55 14.02 1.02 -0.05 
23 88w C6H5(CH2)2S 0 11.81 12.01 13.83 11.56 14.01 1.07 -0.16 
24 88x C6H5(CH2)3S 0 11.81 11.99 13.80 11-41-11.53 14.03 1.03 -0.06 
25 88y 2-Furyl 0 11.78 12.01 14.00 11.70 14.50 1.10 -0.25 
26 88z 2-Thienyl 0 11.85 12.07 13.90 11.47-11.55 14.45 0.86 0.37 
27 88za 2-Pyridyl 0 11.81 12.09 14.06 11.52 14.76 8.95 -5.42 
28 88zb 3-Pyridyl 0 11.87 12.11 14.10 11.56 14.66 0.56 1.45 
29 88zc 4-pyridyl 0 - - - - - - - 
30 88zd (Ph)2CH- 0 11.80 12.11 13.65 11.47 13.90 1.47 -0.96 
31 93a Ph 1 11.76 12.06 13.54 11.46 13.80 2.94 -2.67 
32 93b 4-CF3C6H4 1 11.80 12.08 13.61 11.47 13.86 1.95 -1.65 
33 93c 4-NO2C6H4 1 11.80 12.07 13.64 11.46 13.88 1.65 -1.23 
34 93d 4-ClC6H4 1 11.79 12.04 13.55 11.42 13.78 2.29 -2.05 
35 93e 4-BrC6H4 1 11.79 12.03 13.55 11.42 13.78 2.30 -2.06 
36 93f 4-FC6H4 1 11.78 12.05 13.54 11.44 13.78 2.55 -2.31 
37 93g 4-MeC6H4 1 11.78 12.05 13.49 11.42 13.75 3.11 -2.81 
38 93h 4-MeOC6H4 1 11.77 12.06 13.49 11.43 13.73 3.32 -2.96 
39 93i 4-OHC6H4 1 11.77 12.03 13.46 11.41 13.69 3.92 -3.38 
40 93j 4-CNC6H4 1 11.76 12.03 13.62 11.46 13.85 1.92 -1.62 





The signals of N(1)H in the 
1
H NMR spectra appeared at the same range and had 
similar line widths for some heterocyclic, that is 3-pyridyl, 2-pyridyl, and 2-thienyl, 2-
furyl substituent at C3(5) of the 1,2,4-triazole ring. The experimental results 
suggested that for compounds 88zb and 88z, form A was favoured whereas, for 
compounds 88y, 88za with 2-furyl and especially 2-pyridyl substituents at C3(5) of 
the 1,2,4-triazole ring, form B was predominant. Initially, it was believed that this 
observation could be attributed to possible intramolecular hydrogen bonding between 
N1–H and the nitrogen atom of the pyridyl and the oxygen atom of the furyl moieties 
[N1–H---X (X = O, N)] would prevent movement of the tautomeric equilibrium 
toward form A. However, this explanation was no longer existed by detailed analysis 
of further experiments. At elevated temperature, compounds 88za (with potential 
intramolecular hydrogen bonding) did not disfavour systems stabilized by 
intramolecular hydrogen bonding and did not change its KT value. Similar results 
were observed for compound 88b (without potential intramolecular hydrogen 
bonding). The signals of the tautomers A and B appeared clearly in the 
1
H NMR 
spectra in DMSO-d6 solution and coalesced only on heating. With the introduction of 
S moiety in between triazole and benzyl moiety decrease electron donating property 
of this C3(5) position, disfavour B form. Similar tautomeric preference was observed 
in compound 88a. 
Replacement of benzyl group at C3(5), the tautomeric form B was predominated, and 
an attempt to establish a relation between the electronic properties (σ) of substituents 
and relative Gibbs free energy (ΔG) of tautomeric preference demonstrated that there 
is a good correlation between two parameters with R
2
































































Figure 15. Correlation of ΔG for the tautomeric equilibrium of N-(3(5)-aryl-1,2,4-
triazol-5(3)-yl)-N’-carbethoxythioureas (88, 93) (A. phenyl, B. benzyl moiety) with 




5.2 Synthesis of 4-carbethoxy-1-[4-(N,N-
dimethylamino)benzoyl]thiosemicarbazide 
To broaden the scope of nucleophilic substitution reaction of ethoxycarbonyl 
isothiocyanate with heterocyclic compounds and to observe the preferable site of 
electrophilic attachment, a similar reaction condition was performed using 4-(N,N-
dimethylamino)benzhydrazide (108) as strating material in DMF.  In this reaction, it 
was observed that the ethoxycarbonyl isothiocyanate attacked to hydrazino amino  
group and resulted in the formation of 4-carbethoxy-1-[4-(N,N-





Scheme 28: Synthesis of 4-carbethoxy-1-[4-(N,N-
dimethylamino)benzoyl]thiosemicarbazide (109) 
The crystal structure of 4-carbethoxy-1-[4-(N,N-
dimethylamino)benzoyl]thiosemicarbazide suggested that the structure is stabilized by 
intramolecular N-H---O=C hydrogen bonding arranged in an S(6) graph-set motif. In 
this crystal, the inversion dimers were connected via intermolecular N-H---S=C 
hydrogen bonds [R
2
2(8) graph-set motif] for sheets parallel to the (121) plane. The 
dimers were also formed by the molecules via weak intermolecular N-H---S=C 
hydrogen bonds [R
2




Figure 16. X-ray structure of 4-carbethoxy-1-[4-
(N,Ndimethylamino)benzoyl]thiosemicarbazide 
5.3  Summary 
To summarize, various optimized and highly efficient conditions to synthesize 3(5)-
amino-1,2,4-triazoles and N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas 
were discussed and some aspect of the tautomerism of these compounds have been 
investigated using NMR spectroscopy. The triazoles were found to exist in 
equilibrium of 1H and 2H-forms whereas the 4H-form was not identified in solution. 
In addition, the tautomeric equilibrium of triazoles was greatly influenced by 
electronic properties of substituents presents, however, some exceptions from the 
established relationship were observed. Following this study, continuous investigation 
has been employed to explore pharmacophoric requirement of our synthesized TP 
inhibitors, and the results obtained from these efforts will be reported and discussed in 








































6.1 CoMFA based 3D-QSAR study of synthesized TP inhibitors 
Many laboratories, including our own, have devoted significant efforts in the design 
and synthesis of a variety of TP inhibitors. Most of the inhibitors generated by this 
process are mainly the analogues of its natural substrate and primarily belong to the 
uracil type molecules with various substituents at C-5 and / or C-6 positions. Among 
them, TPI was identified as the most potent inhibitor, so far, exhibiting a substantial 
suppression of the tumour growth by inhibiting angiogenesis. Moreover, based upon 
the crystal structure of E. coli TP, purine based compounds viz. 7-DX has been 
investigated for TP inhibition. In addition, multisubstrate inhibitors have designed and 
evaluated as well. Meanwhile, N-phenyl homophthalimide derivatives and purine 




In the search for promising TP inhibitors, we have synthesized a few series of  thio-
oxo analogues of 1,2,4-triazolo[1,5-a][1,3,5]triazines and pyrazolo[1,5-
a][1,3,5]triazines bearing aromatic or aliphatic side chains as TP inhibitors. Structural 
diversity was generated by modifying aromatic phenyl ring using a range of 
substituents scattered over different quadrants of the Craig plot. Furthermore, it was 
revealed that modification of the lead structure with introduction of methylene bridge 
in between the lipophilic aromatic and the fused ring system resulted in an 
improvement of TP inhibitory activity. An attempt to investigate the effects of di-
substitution (C7 and C8) in the pyrazolo[1,5-a][1,3,5]triazine scaffold demonstrated 
their propensity to better inhibition property. Among different compounds 
synthesized, compounds H5bxvii, H5bxix, H11i, H8g, and H13a exhibited excellent 
inhibition potential towards TP with recorded IC50 values in the low micro molar 
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range. At this stage of investigation, the exploration of structural requirements of 
these new fused TP inhibitors in order to improve the inhibitory activity is needed. 
 Quantitative structure activity relationship (QSAR) studies are examples of the 
application of chemometrics, to collect useful information for the design of new 
compounds acting on specific targets. QSAR study attempts to derive meaningful 
relationship between biological activity and molecular properties. Thus, QSAR 
models can be used to predict the activity of new compounds and many successful 
applications in medicinal chemistry have proven its importance in drug discovery and 
development. There are several meaningful approaches available to relate chemical 
structure to biological activity in quantitative terms
226
. Nowadays, comparative 
molecular field analysis (CoMFA), a 3D-QSAR method, is widely used tool as it 
provides information on structural complementarity between the ligand and its 
binding site, in a 3D arrangement of all relevant molecular properties essential for 
specific interaction
180
. As the derivatives of 1,2,4-triazolo[1,5-a][1,3,5]triazines and 
pyrazolo[1,5-a][1,3,5]triazines were identified as novel thymidine phosphorylase 
inhibitors, it is assumed that 3D-QSAR study would able to investigate the structural 
requirements for the future development of promising TP inhibitors.  
Therefore, to elucidate a ligand-based pharmacophore and in order to fine-tune the 
structural requirements, a 3D-QSAR approach using CoMFA analysis was adopted. In 
addition, same experimental data was analyzed for better understanding of the 
structural basis for activity particularly for positions 2(C)/ C(7) and 3(N)/ C(8) of the 
1,2,4-triazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a][1,3,5]triazine template 
respectively. In this study, the compounds possessing aromatic phenyl ring attached 
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directly or indirectly to the fused ring were used in the experiment. To-date, no QSAR 
report using CoMFA is available on this class of compounds as a TP inhibitor. 
6.2 3D-QSAR study design 
6.2.1 Dataset 
A total of 43 structurally related compounds (training set) were selected and used to 
generate a CoMFA model. They consisted of six classes of fused bicyclic compounds. 
Among them, 5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-(4H)-one 
(H5) and its derivatives , 5-(methylthio)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(6H)-one 
(H6), 2-thioxo-2,3-dihydro-pyrazolo[1,5-a][1,3,5]triazin-4(1H)-one (H11) and its 
derivatives, 2-(methylthio)-pyrazolo[1,5-a][1,3,5]triazin-4(3H)-one (H12), 1-(8-
phenyl-4-oxo-2-thioxo-1,2,3,4-tetrahydro-pyrazolo[1,5-a][1,3,5]triazin-7-yl)thiourea 
(H13) and its derivatives and 8-phenyl-2-thioxo-2,3-dihydro-pyrazolo[1,5-
a][1,3,5]triazin-4(1H)-one (H14), all of which bearing phenyl moiety were selected as 
training set. On the other hand, to examine the predictability of the model generated 
from training set, 2-benzyl-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-
(4H)-one (H8) and its derivatives and its related compounds were considered as 
testing set (Figure 17) 
 
Figure 17. Structures of synthesized TP inhibitors used in CoMFA study (red portion 
indicated common structural feature) 
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The rationale behind selecting  seven different groups of derivatives for our QSAR 
study was based on three main considerations: (1) these groups of compounds 
comprise similar bicyclic 1,2,4-triazolo and pyrazolo fused 1,3,5-triazine ring which 
are planar in shape; (2) these derivatives share similar substituents at the 
corresponding C2/C7 position of the bicyclic nuclei such as (un)substituted phenyl 
ring (ph), (un)substituted benzyl moiety (PhCH2), and benzylthio groups (PhCH2S) 
allowing investigation on the significance of steric and electrostatic effects; (3) most 
importantly, the majority of these compounds bear a similar (C=O)NH(C=S) motif. 
This last aspect enables the evaluation of importance of the (C=O)NH(C=S) motif to 
exhibit inhibitory activity against TP, which represents the first attempt to identify the 
structural requirements for bicyclic inhibitors of TP.  
6.2.2 Preparation of dataset  
The CoMFA analysis was performed using SYBYL-X 1.3 molecular modeling 
software. The partial atomic charges required for the electrostatic interaction were 
computed using the Gasteiger-Huckel method. The structures were then energy 
minimized using the standard Tripos force field with a distance dependent dielectric 
function until a root mean square (rms) deviation of 0.001 kcal/mol Å was achieved. 
6.2.3 Alignment 
The superimposition of the molecules is considered as the most crucial step in 
CoMFA analysis. The alignment of the molecules was performed by the database 
alignment method implemented in SYBYL-X 1.3. The most active compound (H13a) 
was chosen as the template molecule and shared backbone or core structure was 
identified on which rest of the molecules were aligned.  
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6.2.4 CoMFA analysis  
The CoMFA steric and electrostatic interaction fields were calculated at each lattice 
intersection point of a regularly spaced grid of 2.0 Å. The grid pattern, generated 
automatically by the Sybyl/CoMFA routine, extended 4.0 Å units in X, Y and Z 
directions beyond the dimensions of each molecule. The steric term that represented 
van der Waals (Lennard-Jones) interaction, and the coulombic term, which 
represented electrostatic interactions, were calculated with the standard Tripos force 
field. A sp
3
 carbon atom with a van der Waals radius of 1.52 Å and +1.0 charge was 
used as the probe to calculate the steric and electrostatic fields. The values of the 
steric and electrostatic fields were truncated at 30 kcal/mol. The SYBYL default 
energy cut-off of 30 kcal mol
-1 
was used. The minimum sigma (column filtering) was 
set to 2.0 kcal/mol to improve the signal to noise ratio by eliminating those points 
whose energy variation was below this threshold.  
To generate statistically significant 3D QSAR models, partial least squares (PLS) 
regression analysis was used. In this analysis, the CoMFA descriptors were used as 
independent variables, whereas the pIC50 (nM) values were considered as dependent 
variables. Initially, the optimal number of components was determined by using 





cv) values that indicate the predictive power of the models.  
Subsequently, using this optimum number of components, a final QSAR model was 
derived that yielded the conventional correlation coefficient (r
2
), and its standard error 
(s) of estimation. Finally, the CoMFA results were graphically represented by field 
contour maps. In addition, the CoMFA model generated from training set was applied 
to predict the pIC50 of test set.  
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6.3 Results and discussion 
The results of the CoMFA analysis are presented in Tables 16, 17 and 18. To evaluate 
the predictive power of QSAR model, several statistical parameters including cross-
validated correlation coefficient (q
2
), non-cross-validated correlation coefficient (r
2
), 
and standard error of estimate, F-statistic values as well as the optimum number of 
components were determined.  





) value of 0.545 with optimum component 
number of 8. The high value of these two parameters indicated a proper internal 
predictive capacity of the model. Thereafter, the non-cross-validated PLS analysis 
was conducted using this optimum number of components to generate an r
2
 of 0.960. 
The r
2
 value, which tended to one suggested self-consistency in the study. Moreover, 
the relatively small estimated standard error of 0.063 and a high F-test value of 
100.95 produced from the non-cross-validated analysis also indicated a high degree of 
confidence in the analysis. In term of the relative contributions, the steric and 
electrostatic field accounts for 46.5% and 53.5% contributions respectively for the 
compounds in the training set demonstrated that the electrostatic property was 
relatively more predominant for the optimal interaction of these inhibitors to the 







Table 16. Training set compounds with observed and predicted pIC50 values 
 
Entry Cpd R R1 X 
pIC50 value (nM) 
Observed Predicted Residual 
1 H5aiii S(CH2)3Ph - N 4.559 4.595 0.036 
2 H5b Ph - N 4.403 4.283 -0.120 
3 H5bi 3-NO2C6H4 - N 4.645 4.677 0.032 
4 H5bii 3-CF3C6H4 - N 4.655 4.601 -0.054 
5 H5biii 3-ClC6H4 - N 4.519 4.546 0.027 
6 H5biv 3-BrC6H4 - N 4.498 4.525 0.027 
7 H5bv 3-FC6H4 - N 4.317 4.376 0.059 
8 H5bvi 3-MeC6H4 - N 4.463 4.516 0.053 
9 H5bvii 3-MeOC6H4 - N 4.635 4.574 -0.061 
10 H5bviii 3-CNC6H4 - N 4.314 4.376 0.062 
11 H5bix 4-NO2C6H4 - N 4.437 4.489 0.052 
12 H5bx 4-CF3C6H4 - N 4.644 4.667 0.023 
13 H5bxi 4-ClC6H4 - N 4.585 4.589 0.004 
14 H5bxii 4-BrC6H4 - N 4.656 4.629 -0.027 
15 H5bxiii 4-FC6H4 - N 4.492 4.497 0.005 
16 H5bxiv 4-MeC6H4 - N 4.501 4.544 0.043 
17 H5bxv 4-MeOC6H4 - N 4.659 4.684 0.025 
18 H5bxvi 4-CNC6H4 - N 4.481 4.536 0.055 
19 H5bxvii (3,4)-Cl2C6H3 - N 4.965 4.826 -0.139 
20 H5bXviii (3,4)-F2C6H3 - N 4.660 4.597 -0.063 
21 H5bxix 3-Me, 4-BrC6H3 - N 4.883 4.835 -0.048 
22 H6b Ph - N 4.022 4.023 0.001 
23 H11 Ph H C 4.310 4.204 -0.106 
24 H11a 4-ClC6H4 H C 4.436 4.512 0.076 
25 H11b 4-BrC6H4 H C 4.576 4.528 -0.048 
26 H11c 4-FC6H4 H C 4.333 4.435 0.102 
27 H11d 4-MeC6H4 H C 4.403 4.453 0.050 
28 H11e 4-MeOC6H4 H C 4.666 4.614 -0.051 
29 H11f 4-CNC6H4 H C 4.518 4.481 -0.037 
30 H11g (3,4)-Cl2C6H3 H C 4.884 4.878 -0.006 
31 H12 Ph H C 4.149 4.133 -0.016 
32 H13 H2N(C=S)NH- PhCH2 C 4.524 4.592 0.068 
33 H13a H2N(C=S)NH- 4-CF3C6H4CH2 C 5.418 5.430 0.012 
34 H13c H2N(C=S)NH- 4-BrC6H4CH2 C 4.830 4.768 -0.062 
35 H13d H2N(C=S)NH- 4-FC6H4CH2 C 4.645 4.594 -0.051 
36 H13e H2N(C=S)NH- 4-PhC6H4CH2 C 5.214 5.214 0.000 
37 H13f H2N(C=S)NH- 4-OPhC6H4CH2 C 5.351 5.382 0.031 
38 H13g H2N(C=S)NH- 4-MeC6H4CH2 C 4.699 4.743 0.044 
39 H13h H2N(C=S)NH- 4-EtC6H4CH2 C 4.901 4.827 -0.074 
40 H13i H2N(C=S)NH- 4-OMeC6H4CH2 C 4.289 4.302 0.013 
41 H13j H2N(C=S)NH- 4-OHC6H4CH2 C 4.427 4.501 0.074 
42 H13k H2N(C=S)NH- 4-CNC6H4CH2 C 4.288 4.235 -0.053 




Table 17. Statistical results from CoMFA analysis 
 
Parameters Statistical values 
No. of compounds 43 











Standard error of estimate 0.063 
Steric contribution 0.465 
Electrostatic contribution 0.535 
 
Although high value of q
2 
derived from internal validation via cross-validation is 
considered as necessary requisite, it is not sufficient to confirm the high predictive 
power of model. In fact, external validation is considered fundamental to establish a 
reliable QSAR model. Therefore, to verify the efficacy of the CoMFA model 
generated, thirteen compounds of 2-benzyl-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-(4H)-one (H8) analogues and and its related compounds were 
included as external validated set which were not used in the training set during the 
model development. The actual and predicted TP activities for this external testing set 
were shown in Table 18. Consistently, the CoMFA model has shown a reasonable 
predictability of the test set compounds. As shown in Table 18, except compound H8, 
H8h and H8i, the residual values of all compounds are below 0.5, which further 
confirmed the reliability of the model.  
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Table 18. Test set compounds with observed and predicted pIC50 values 
 
Entry Cpd R 
pIC50 value (nM) 
Observed Predicted Residual 
44 H8 C6H5CH2 4.363 4.896 0.533 
45 H8a 4-CF3-C6H5CH2 5.004 4.978 -0.026 
46 H8b 4-Cl-C6H5CH2 5.069 4.939 -0.130 
47 H8c 4-Br-C6H5CH2 4.863 4.922 0.059 
48 H8d 4-F-C6H5CH2 4.649 4.965 0.316 
49 H8e 4-Me-C6H5CH2 4.703 4.875 0.172 
50 H8f 4-MeO-C6H5CH2 4.469 4.921 0.452 
51 H8g 4-OH-C6H5CH2 4.471 4.953 0.482 
52 H8h 4-CN-C6H5CH2 4.192 5.049 0.857 
53 H8i (3,4)-Cl2C6H5CH2 5.530 4.905 -0.625 
54 H5ai SCH2Ph 4.418 4.812 0.394 
55 H5aii S(CH2)2Ph 4.481 4.822 0.341 
56 H5g CH(Ph)2 4.439 4.920 0.481 
 
The CoMFA results are usually represented as 3D ‘coefficient contour’ maps.  They 
usually indicate the regions where the variation of steric and electrostatic nature in the 
structural features of the different training set molecules lead to increase or decrease 
in the biological activity.  The overall graphical representations of the analysis 
comprising both the electrostatic and steric contour plots were depicted in Figure 18 
and to aid visualization, compound H13a (most active compound in training set) and 
H6b (least active compound in training set) is displayed in the maps. For CoMFA 
steric contour, the green colour indicates the region where the bulky groups are 
associated with enhanced enzyme interaction while the yellow contour suggested the 
region where increased steric bulk is unfavourable for activity. In the case of 
electrostatic contour, the regions where more positive charge is favourable to 
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inhibitory activity are indicated in blue, while those where increased negative charge 
is favourable to activity were indicated in red.  
As shown in Figures 18c and 18e, the biggest yellow contour surrounding the R and 
R1 substituents, suggests that the modification of the compounds with the bulky group 
in this region would lead to decrease in activity. The yellow colour near R2 indicated 
that bulky group was not compatible for this region. The IC50 values of H6b and H12 
supported this finding. It is noteworthy that with the introduction of the bulky group 
at R2, H6b and H12 exhibited dramatic decrease of inhibition potential compared to 
parent H5b and H11. However, a small green contour near the para and meta 
substituents of the phenyl ring of H5b and H13 series also suggests that bulkiness is 
indeed favoured to certain extent. Thus, the size of substituent at this site should be 
neither too large nor too small. This finding is supported by the high activity of 













Figure 18. CoMFA analysis. (a). structural alignments of all compounds. (b). structure of the 
template compound H13a. (c, e and d, f). steric and electrostatic contour plots of compounds 
H13a and H6b . Green areas correspond to favoured steric bulk, yellow areas indicate bulky 
groups are disfavoured, blue contours refer to regions where electron-donating groups are 
favoured; red contours indicate regions where electron-withdrawing groups are favoured. 
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On the other hand, the blue contour near the atom connecting R1, indicates that a more 
electropositive or in other words a lesser electronegative atom at this site will enhance 
the activity of the molecules. This finding is clearly supported by the improved 
activity of compounds H13f having OPh moiety compared to compound H13e 
bearing Ph group at the site in question. The red contour surrounding the thiourea 
moiety and connected to R substituent and para position of phenyl ring of H5b and 
H11 series suggested that greater electron density at this site is important for 
improvement of enzyme affinity.  
6.4 Summary 
To summarize, the CoMFA analysis was conducted to study the effect of steric and 
electrostatic properties of the different substituents on TP inhibition exhibited by the 
series of 1,2,4-triazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a][1,3,5]triazine 
derivatives. The electrostatic descriptor of the molecules was found to be the more 
predominant factor for optimal TP interaction. Moreover, this study derived QSAR 
model with good predictive capacity for TP inhibition exerted by the new fused 
triazine analogues with acceptable accuracy; therefore, it has provided structural 
requirements for the development of newer TP inhibitors. The results may aid in 
designing new TP inhibitors with improved biological potencies. The CoMFA study 
together with the SAR study from Chapter 4 provided good evidence that with 
appropriate substitution on the pyrazolo and triazolo triazine, TP inhibitory activity 
can be better than 7-DX which is also a bicyclic heterocycle. Following this study, 
further investigation has been conducted to explore TP associated biological activities 




























7.1 Investigation of enzyme inhibition kinetics and TP associated antiangiogenic 
activity of synthesized compounds 
Intensive research has been devoted to the development of TP inhibitors with diverse 
structures. Consequently, numerous TP inhibitors disclosed over the past few years 
were found to be mainly competitive inhibitors. However, limited number of 
compounds was designed as multi-substrate, mixed-type competitive type and non-
competitive inhibitors of TP. Although, several potent inhibitors were generated and 
have been tested preclinically and clinically, to-date, there is no TP inhibitor clinically 
available. It is believed that the development of TP inhibitors with potent 
antiangiogenic activity may improve future TP-targeted therapy. 
In this thesis, continuous efforts in exploring new TP inhibitors have identified thio-
oxo analogues of 1,2,4-triazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-
a][1,3,5]triazine scaffolds as new lead compounds exhibiting promising TP inhibition 
profiles. Among them, compounds H5bxvii, H5bxix, H8i, H11g, H13a, H13e, H13f 
and H13n have demonstrated good inhibitory activities against TP with IC50 values in 
the low micro molar range (Figure 19). The good inhibitory profile of the compounds 
has prompted the need to investigate the enzyme inhibition kinetics in order to 
determine the interaction mechanism against the enzyme. In addition, the exciting 
outcome from the in vitro enzyme assay has led to the question of whether these novel 
inhibitors would inhibit the TP associated downstream mediation of various 
angiogenic factors such as matrix metalloproteinase (MMPs), interleukins (IL) and 
vascular endothelial growth factor (VEGF). If the new inhibitors were to exhibit such 
functions, it would mean that these compounds might exhibit antiangiogenic property. 
At the same time, the likelihood of these compounds exhibiting antiproliferative and 
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antimetastatic properties would be evaluated so as to determine their potential use in 
chemotherapy.  
To investigate these potentials, the experiments that demonstrate inhibition of the 
expression of MMP-9, VEGF, IL-8 in breast cancer cell line, MDA-MB-231, were 
performed. In addition, to verify their antiproliferative and antimetastatic properties, 
the cell viability and migration assay were employed respectively. In this study, initial 
investigation was tested on selected compounds from the H5b series. The compounds, 
which exhibited attractive in vitro TP enzyme inhibition profile with IC50 values less 
than 30 µM, were  screened for their antiproliferative and MMP-9 inhibitory activity. 
Based on the results of these experiments, compounds which showed positive 
response were chosen for further investigations. Similarly, selected compounds from 
libraries H8, H11, and H13 were subjected to the same screens for their effects on 
specific biological assays as were tested on the H5b series compounds. Moreover, the 
enzyme kinetic study was performed to evaluate the inhibitory mechanism of the 
synthesized compounds using the most active compounds from each series.  
In this study, the gelatine zymography was employed to determine MMP expression 
on the said cell line whereas to quantify VEGF and IL-8 expression colorimetric 
enzyme-linked immunosorbent assay (ELISA) method was adopted. In addition, the 
MTT colorimetric assay and the cell invasion assay were conducted using the same 
cell line in order to determine the cytotoxicity and antimetastatic properties of 
selected compounds respectively. Furthermore, in vitro enzyme assay was performed 
to study the inhibition kinetics. The statistical significance between treatment and 
control groups was analyzed using ANOVA test. The values of p ˂ 0.05 were 




Figure 19. Structures of synthesized TP inhibitors with low micromolar IC50 values 
7.2 Results 
7.2.1 Enzyme inhibition kinetics characterization  
To elucidate the mechanism of enzyme inhibition, a kinetic study was attempted using 
compound H5bxix at different inhibitor concentrations (0, 2, 15, 20, 30 µM) in the 
presence of variable thymidine (dThd) and phosphate (kpi) concentration. In this 
study, both thymidine and phosphate are considered as substrates because the 
structural features of E. coli TP suggests that there are two distinct places namely the 
nucleoside and the phosphate binding sites in the active pocket of the enzyme. The 
data obtained was analyzed by the Lineweaver–Burk plot (the double reciprocal plot) 
(Figure 20). The results demonstrated that compound H5bxix exhibited mixed type 
inhibition for both dThd and kpi as a variable substrate (Figure 20a and 20b) since the 
straight lines corresponding to different concentrations of the inhibitor intersected in 
the second quadrant of the reciprocal plot. This was further confirmed by the fact that 
increasing inhibitor concentration was accompanied by the increase of Km values 
whereas the Vmax values decreased gradually (Figure 20). Therefore, the compound 
could directly interact with enzyme as well as enzyme-substrate complex by weak 
142 
 
bonds at, near, or inside the active site which inactivated the enzyme but does not 
affect the binding of substrate. Similar pattern of enzyme inhibition kinetics was 
observed for the other selected compounds viz. H5bxvii, H8i, H11g and H13a in the 
presence of varying concentration of thymidine and phosphate as substrates (Figures 
21, 22, 23, and 24 respectively).  
As the compounds exhibited mixed type enzyme inhibition pattern, it was expected 
that these inhibitors would bind to the free enzyme, E, as well as to the enzyme-
substrate complex, ES. For mixed-type inhibitors, the following model is adopted 
(Scheme 29): 
 
Scheme 29.  Mixed type inhibition model 
The enzyme-inhibitor complex (EI) has lower affinity for substrate (S) than free 







In order to analyze the mixed type inhibition kinetics, the Lineweaver-Burk equation 





where Km is the Michaelis constant, Vmax is the maximum enzymatic reaction 
velocity, [S] is the substrate concentration, [I] is the concentration of inhibitors, Ki is 
the inhibition constant for free enzyme and inhibitor, and αKi represents the inhibition 
constant for enzyme-substrate complex and inhibitor. Replots of slopes and intercepts 

















































































































Figure 20. Lineweaver-Burk plots of TP inhibition by H5bxix, in the presence of 
variable concentrations of dThd (a) and phosphate (b) demonstrating mixed type 
enzyme inhibition and response of kinetic parameters Vmax and Km with increasing 
concentration of H5bxix in variable concentrations of dThd (c, d) and phosphate (e, 











































































































Figure 21. Lineweaver-Burk plots of TP inhibition by H5bxvii, in the presence of 
variable concentrations of dThd (a) and phosphate (b) demonstrating mixed type 
enzyme inhibition and response of kinetic parameters Vmax and Km with increasing 
concentration of H5bxvii in variable concentrations of dThd (c, d) and phosphate (e, 














































































































Figure 22. Lineweaver-Burk plots of TP inhibition by H8i, in the presence of variable 
concentrations of dThd (a) and phosphate (b) demonstrating mixed type enzyme 
inhibition and response of kinetic parameters Vmax and Km with increasing 
concentration of H8i in variable concentrations of dThd (c, d) and phosphate (e, f). 

















































































































Figure 23. Lineweaver-Burk plots of TP inhibition by H11g, in the presence of 
variable concentrations of dThd (a) and phosphate (b) demonstrating mixed type 
enzyme inhibition and response of kinetic parameters Vmax and Km with increasing 
concentration of H11g in variable concentrations of dThd (c, d). and phosphate (e, f). 





































































































Figure 24. Lineweaver-Burk plots of TP inhibition by H13a, in the presence of 
variable concentrations of dThd (a) and phosphate (b) demonstrating mixed type 
enzyme inhibition and response of kinetic parameters Vmax and Km with increasing 
concentration of H13a in variable concentrations of dThd (c, d) and phosphate (e, f). 










Table 19. A summary of the enzyme inhibition kinetics parameters 
 
Cpd Substrate Ki value (µM) α Type of inhibition 
H5bxix 
dThd 24.21 ± 0.53 2.48 Mixed type 
KPi 5.58 ±0.91 15.47 Mixed type 
H5bxvii 
dThd 20.09 ± 1.25 2.12 Mixed type 
KPi 21.12 ± 1.18 9.47 Mixed type 
H8i 
 
dThd 19.57 ± 5.62 5.41 Mixed type 
KPi 14.52 ± 4.178 2.74 Mixed type 
H11g 
 
dThd 2.00 ± 0.37 1.57 Mixed type 
KPi 7.08 ±1.68 1.94 Mixed type 
H13a 
 
dThd 1.19 ± 0.13 3.07 Mixed type 
KPi 4.14 ± 0.85 5.94 Mixed type 
 
7.2.1 Antiangiogenic activity determination 
 Compounds inhibited PMA-stimulated MMP-9 secretion and expression in 
breast cancer cell  
The MMP-9 and MMP-2 have been reported to play  key roles in the degradation and 
remodelling of the basement membrane, and therefore they promote tumour cell 
invasion, migration, and metastasis. MMPs have been shown to be up regulated by the 
activity of TP
227
. To demonstrate inhibition profile towards MMP-9 by the 
synthesized TP inhibitors, the test compounds were subjected to gelatine zymography 
screening using MDA-MB-231 cells. Initially, the exploration of TP associated 
biological activities was started with the H5 series compounds. The thirteen 
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compounds from H5 series, which showed promising TP inhibitory activity with IC50 
values less than 30 µM, were selected. The cells were treated with 100 and 200 µM of 
the test compounds along with PMA (80 nM) for 24h. The conditioned medium from 
the cell culture was collected and the secreted form of MMP-9 was analysed using 
gelatine zymography. As shown in Figure 25a, the proteolytic activity of MMP-9 
(band corresponded to the MW of 92 kDa) was not significantly inhibited by any of 
the test compounds at concentration of 100 µM. Interestingly, an obvious change in 
band intensity, compared to vehicle control, was detected for compounds H5bii, 
H5bxvii and H5bxix at 200 µM indicating inhibition of proteolytic activity of MMP-
9 at a higher concentration (Figure 25b). Therefore, identified compounds H5bii, 
H5bxvii and H5bxix were subjected to further investigations. 
To study the dose response of extracellular expression of MMP-9, the conditioned 
medium of MDA-MB-231 cells exposed to PMA and different doses of the selected 
test compounds was examined and the results suggested that a PMA-induced 
elevation of MMP-9 expression was attenuated dose dependently by all compounds 
tested (Figure 26a). It is noteworthy that by visual inspection of the results, TPI, the 
most potent TP inhibitor reported so far and 7-DX, reference TP inhibitor, did not 
show significant reduction in the activity of MMP-9 even at 200 µM. When the band 
intensities of gelatine zymography of the corresponding doses were quantified by 
using the Image Gauge 4.0 software and subsequent densitometric analysis of these 
results revealed that compounds H5bxvii and H5bxix at 100 and 200 µM 
significantly (p < 0.05) inactivated the MMP-9 activity. Moreover, compounds 
H5bxix and H5bxvii exhibited 43 and 32 fold stronger inhibition profile towards 
MMP-9 expression at 200 µM compared to TPI respectively (Figure 26b). However, 
the proteolytic activity of MMP-2 (band corresponded to the MW of 62 kDa) was not 
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significantly affected by combining treatment with the synthesized compounds and 
PMA using lung cancer cell line A549 (Data not shown here). 
Using similar technique, a total of twenty compounds from the H8, H11 and H13 
series that showed TP inhibition with IC50 values of less than 30 µM was examined 
for inhibitory effects of MMPs production. They were subjected to gelatine 
zymography screening at 100 µM for 24 h using the same cell line. The level of 
MMP-9 expression was determined from the conditioned media. Interestingly, the 
visual analysis of the zymograms (Figure 27a) revealed that the basal MMP-9 
secretion levels were significantly inhibited by H11g, H8i, H13a, H13e, H13f and 
H13n at 100 µM compared with the control. Therefore, to study the dose response on 
PMA-induced MMP-9 activity, compounds H11g, H8i, H13a, H13e, H13f and H13n 
were selected. The treatment of the compounds (from 25 to 100 µM) decreased the 
expression level of MMP-9 in MDA-MB-231 cell line in a dose-dependent fashion 
(Figure 27b). The densitometric analysis of the band intensity of the corresponding 
dose of compounds suggested that except for compounds H8i and H13a, all the other 
selected compounds significantly inhibited the MMP-9 expression at 50 and 100 µM 
(p < 0.05) (Figures 28a and 28b). It is noteworthy that even though compounds H8i 
(IC50 = 2.95 µM) and H13a (IC50 = 3.82 µM) were identified as most active TP 
inhibitors in their corresponding series, they did not show promising inhibitory 
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Figure 25. Screening of compounds (IC50TP ˂ 30 µM) (series H5 and reference compounds) based on their inhibitory effect of MMP expression 
on breast cancer cell line, MDA-MB-231 (a). screening of inhibitory potential of compounds (series H5, compound H14 and reference 
compounds) towards PMA induced MMP-9 expression after 24 h treatment at 100 µM (b). screening of inhibitory potential of compounds 
(series H5, compound H14 and reference compounds) towards PMA induced MMP-9 expression after 24 h treatment at 200 µM. 
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Figure 26. Antiangiogenic effect (MMP-9 expression) of compounds (series H5 and reference compounds) on breast cancer cell line (a). 
suppressive effects of selected compounds (H5bxix, H5bii, H5bxvii, TPI and 7-DX) on PMA-induced MMP-9 expression and their dose 
response. (b). densitometry analysis of band intensities of corresponding dose of compounds, normalized to respective vehicle controls. Results 
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Figure 27. Antiangiogenic potential (MMP expression) of selected synthesized compounds (series H11, H8 and H13) on breast cancer cell line 
(a). screening of inhibitory potential of compounds (IC50TP ˂ 30 µM) (series H11, H8 and H13) towards PMA induced MMP-9 expression after 
24 h treatment at 100 µM (b). suppressive effects of selected compounds (H11g, H8i, H13a, H13e, H13f and H13n) on PMA-induced MMP-9 





























































Figure 28. Densitometry analysis of MMP expression of selected synthesized compounds (series H11, H8 and H13) on breast cancer cell line 
(a). compound H11g and H8i. (b). compound H13a, H13e, H13f and H13n. Results are presented as means ± SD; SD denoted by error bars 






 Compounds inhibited  VEGF secretion and expression in breast cancer cell  
Several studies suggested that TP and its metabolite 2DDR stimulate the secretion 
and/or expression of the angiogenic molecules VEGF and induce endothelial cell 
migration. The effect of compounds H5bii, H5bxvii and H5bxix on vascular 
endothelial growth factor (VEGF) protein secretion was determined by treating  
MDA-MB-231 cells for 24 hours either without the test compounds or in the presence 
of the indicated dose of the compounds (10, 25, 50, 100, and 200 µM). The 
expression of VEGF protein levels in the conditioned cell medium was measured 
using an enzyme linked immunosorbent assay. As shown in Figure 29, all compounds 
at dose ranging between 25 µM to 200 µM markedly inhibited VEGF expression 
compared to vehicle control (p < 0.05). The secretion of the protein normalized to the 
corresponding number of cells seeded after treatment with H5bxix was inhibited in a 
dose dependent manner (Figure 29a).  
Similarly, an attempt to study the effects of the synthesized compounds H11g, H8i, 
H13a, H13e, H13f and H13n on VEGF expression in the breast cancer cells was 
conducted using the ELISA technique. After a 24-hour treatment of this cell line with 
the test compounds at concentrations of 10, 25, 50 and 100 µM, the assay revealed a  








































































































































Figure 29. Antiangiogenic potential (VEGF expression) of selected synthesized 
compounds on breast cancer cell line (a). effect of selected compounds (H5bxix, 
H5bii and H5bxvii) on VEGF expression in indicated dose on MDA-MB-231 cells 
after 24 h treatment. (b and c). effect of selected compounds (H11g, H8i, H13a, 
H13e, H13f and H13n) on VEGF expression in indicated dose on MDA-MB-231 
cells after 24h treatment. Results are presented as means ± SD; SD denoted by error 
bars (Experiments carried out at least in triplicate). * p˂0.05. 
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7.2.2 Antimetastasis activity determination  
 Compounds did not inhibit in vitro breast cancer cell invasion and induce IL-8 
secretion and expression in breast cancer cell 
The significant inhibitory effect against MMP-9 and VEGF expression demonstrated 
by some of the test compounds encouraged further exploration of other biological 
effects of the active compounds. To correlate the functional relevance of MMP-9 
expression and cell invasion, the invasive capability of MDA-MB-231 cells that were 
treated with different doses of compounds H5bii, H5bxvii and H5bxix was 
investigated. The in vitro effect of the selected compounds on cell migration was 
assessed by using Matrigel-coated, porous polycarbonate filters. Figure 30a indicated 
that compounds were not able to suppress FBS-induced invasiveness of MDA-MB-
231 even at 200 µM, thus demonstrating that the test compounds did not have in vitro 
antiinvasive effects. 
The inability to exhibit anti-invasive effects by compounds H5bii, H5bxvii and 
H5bxix prompted further exploration of IL-8 expression via enzyme linked 
immunosorbent assay. The IL-8 protein expression in MDA-MB-231 cells, upon 
exposure to different concentrations of the test compounds, is shown in Figure 30b. 
Pre-treatment with the test compounds for 24 hour was found to gradually induce IL-8 
protein expression in a dose-dependent manner. Therefore, the study concerning the 
exploration of antimetastatic properties and IL-8 protein expression was not attempted 



















































Figure 30. Antimetastasis potential of selected synthesized compounds on breast cancer cell line (a). effect of compounds (H5bxix, H5bii and 
H5bxvii) (at 200 µM) on MDA-MB-231 cell invasion. (b). effect of IL-8 induction on MDA-MB-231 cell after 24 h treatment with different 
dose of selected compounds (H5bxix, H5bii and H5bxvii). Results are presented as means ± SD; SD denoted by error bars (Experiments carried 
out at least in duplicate). * p˂0.05. 
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7.2.3 Antiproliferative activity determination  
In order to ascertain the inhibition of MMP-9 and VEGF expression by the 
compounds on breast cancer cell was not the consequence of its cytotoxic effect, the 
inhibitory effect of the test compounds on MDA-MB-231 cell growth was determined 
by means of the MTT assay. Using the analogous basis of selecting compounds for 
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Figure 31. Antiproliferative  effect of the test compounds on breast cancer cell line (a). cell viability (%) of 
MDA-MB-231 cells  after 72 h treatment of the test compounds (series H5) exhibiting TP inhibition (IC50 ˂ 
30 µM) and reference TP inhibitors (TPI and 7-DX) at concentration of 200 µM. (b and c). cell viability of 
MDA-MB-231 cells after 72 h treatment of compounds (series H8, H11 and H13) exhibiting TP inhibition 
(IC50 ˂30 µM) at concentration of 100 µM.  Results are presented as means ± SD; SD denoted by error bars 
(Experiments carried out at least in duplicate). * p˂0.05. 
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As shown in Figure 31, except for some compounds from series H13, all compounds 
exhibited cell viability at around 80-100 % after 72 h exposure. In particular, only 
compound H13e, exhibited attractive cell viability (40.30 ± 10.35 %) compared to 
vehicle control (p < 0.05). 
7.3 Discussion 
Breast carcinoma is the leading cause of cancer-related death in world. Due to the 
rapid advancement in cancer diagnosis and therapy options, the life expectancy and 
survival rate of cancer patients have shown improvement, however, the overall 
clinical outcome of breast cancer is still unsatisfactory for its highly invasive and 
metastatic properties. The exact molecular mechanism associated with metastatic 
nature of this cancer remains largely unclear. However, several studies demonstrated 
that thymidine phosphorylase (TP), an angiogenic protein, is overexpressed in many 
solid tumours including breast cancer and it is believed that TP would play a crucial 
role in breast cancer angiogenesis and metastasis
228, 229
. TP exerts angiogenesis via 
release of metabolic product 2-deoxy-D-ribose that stimulates the secretion and or 
expression of many angiogenic factors viz. MMP-9, MMP-2, VEGF, IL-8 and others 
resulting in endothelial cell migration, angiogenesis accompanied by tumour growth 
and metastasis. Pioneering research in this field has generated several potent TP 
inhibitors having pyrimidin-2,4-dione as core structure including TPI, which mostly 
binds at the substrate active site of the target enzyme and exert competitive inhibition 
with respect to natural substrate. 
In this study, thio-oxo analogues of 1,2,4-triazolo[1,5-a][1,3,5]triazine and 
pyrazolo[1,5-a][1,3,5]triazine scaffolds were discovered as new TP inhibitors and  
among these derivatives, compounds H5bxvii, H5bxix, H8i, H11g, H13a, H13e, 
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H13f and H13n exhibited exciting TP inhibition profiles (Figure 19). Therefore, in 
this section, attempts were made to evaluate the enzyme inhibition kinetics of the 
most active candidates from each series. In addition, TP-induced anti-angiogenenic 
activity of the synthesized bicyclic TP inhibitors was also investigated. The anti-
angiogenesis property of the compounds was assessed via their inhibitory potential 
against the expression of different angiogenic markers in the breast cancer cell line, 
MDA-MB-231. Moreover, the antimetastatic and antiproliferative activities of these 
compounds were determined as well.  
In the experiments conducted, the most active TP inhibitors H5bxvii, H5bxix, H8i, 
H11g and H13a were found to demonstrate mixed type of enzyme inhibition kinetics 
in the presence of varying concentrations of thymidine and phosphate as the 
substrates.  Therefore, this inhibition pattern suggested that these compounds would 
interact with the free enzyme (E) and/or enzyme substrate (ES) complex. The values 
of dissociation constants (Ki and αKi) (Table 19) indicated that the inhibitor has 
stronger affinity towards the free enzyme than enzyme substrate complex (α ˃ 1). 
Moreover, the enzyme-inhibitor complex would exhibit lower affinity for substrate 
compared to free enzyme (α ˃ 1) (Scheme 29). The mixed-type inhibitors of enzymes 
may offer some advantages when compared to compounds interacting at the substrate-
binding site. The mixed inhibitors may be safer and more efficacious by overcoming 
selectivity issues and substrate competition. In addition, by interacting with both free 
enzyme and enzyme-substrate complex, it could make both E and ES complex non-
productive. Indeed, the kinetic results demonstrated that the synthesized compounds 
exhibited different kinetic pattern compared to TPI and 7-DX. It is interesting to 
mention that, TPI behaved as competitive inhibitors with respect to thymidine
145
 as 
substrate, while 7-DX exhibited non-competitive inhibition with respect to phosphate 
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and competitive or mixed type inhibition in presence of variable thymine/thymidine 
concentration
154
. The difference in enzyme inhibition kinetic behaviour with respect 
to TPI and 7-DX is probably due to the structural modification of the core ring 
structure via the introduction of additional nitrogen atoms and the incorporation of 
other substituted functional groups around the fused ring system. Therefore, it is 
believed that the modified molecule might interact with the enzyme differently and 
consequently demonstrated mixed type inhibition.  
The studies that were intended to explore the anti-angiogenic properties showed that 
the test compounds exhibited inhibitory effect on PMA induced MMP-9 expression of 
the MDA-MB-231 breast carcinoma cells. Among the selected compounds tested, 
compounds H11g, H13e, H13f and H13n having pyrazolo[1,5-a][1,3,5]triazine 
scaffold, demonstrated higher inhibition against MMP-9 suggesting that pyrazolo[1,5-
a][1,3,5]triazine analogues were suitable for better activity than compounds having  
1,2,4-triazolo[1,5-a][1,3,5]triazine ring. It is noteworthy that with the introduction of 
substitutions at positions C7 and C8, as evident in series H13, the inhibitory activity 
against MMP-9 was improved compared to mono substituted (at C7 only) 
pyrazolo[1,5-a][1,3,5]triazine analogues (H11g). Particularly, the compounds H13e, 
H13f and H13n, having lipophilic bulky group at the position C8, demonstrated 
almost complete attenuation of MMP-9 expression and activity at 100 µM. On the 
other hand, although compounds H8i and H13a identified as the most active TP 
inhibitors (IC50 = 2.95 µM and 3.82 µM respectively) in their corresponding series, 
could not establish themselves as the most active candidates in reducing MMP-9 
expression. This observation could suggest that MMP-9 expression was not directly 
correlated to the potency of in vitro anti-TP activity. Analysis of gelatine zymography 
of TPI (IC50 = 35 nM), the most potent TP inhibitor, revealed that under the condition 
164 
 
of PMA stimulation, MMP-9 activity was not significantly inhibited by  TPI even at 
concentration  of 200 µM. Analogously, the prototype TP inhibitor, 7-DX did not 
demonstrate any inhibition of MMP-9 expression under similar experimental 
condition as well. 
Most reported TP inhibitors including TPI are substituted uracil analogues that 
compete mostly with the substrate binding site of TP. However, based on the 
structural features, the synthesized compounds represented very unusual TP 
inhibitors. Therefore, it is assumed that these compounds might interact with a 
completely different site at the enzyme, which would abrogate the angiogenic (MMP-
9) activity of TP. The kinetic behaviour of these compounds also strongly supported 
this assumption.  
Matrix metallopeptidase 9 (MMP-9), a Zn
+2
 dependent endopeptidase, is involved in 
the breakdown of extracellular matrix surrounding tumour and endothelial cells 
facilitating tumour cell invasion, migration, and metastasis
230
. Several studies have 
suggested that MMP-9 expression is well correlated with cancer cell migration and 
invasion and agents that down-regulate MMP-9 have also been demonstrated to 
inhibit tumour invasion
231
. In addition, the experimental data provided evidence that 
in the selected breast cancer cell line, TP was associated with higher levels of 
activated MMP-9
227
. Indeed, in the study, the synthesized compounds being TP 
inhibitors exhibited down-regulation of the MMP-9 expression and therefore, these 
compounds would serve as promising anti-angiogenic lead compound for future 
development.  
Another important finding of this study was that selected compounds inhibited VEGF 
expression in the breast cancer cell line. It is reported that most of the solid tumour 
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cells overexpressed vascular endothelial growth factor (VEGF) which plays a crucial 
role in tumour angiogenesis by inducing endothelial cell proliferation, migration and 
survival
232
. As depicted in Figure 29, all compounds irrespective of having 1,2,4-
triazolo[1,5-a][1,3,5]triazine and  pyrazolo[1,5-a][1,3,5]triazine scaffold  exhibited 
similar pattern of inhibition profile at higher dose (200 µM, 100 µM,  and 50 µM). 
However, in lower doses (25 µM and 10 µM) the inhibition rates among the selected 
compounds were significantly varied. In addition, compounds H5bxix, H5bii, 
H5bxvii and H11g demonstrated around three fold differences in response between 
lower and higher dose. It is important to indicate that all these compounds possess an 
aromatic ring directly attached to the fused ring system. In contrast, the difference of 
VEGF suppressive effect exhibited by lower and higher dose was reduced to around 
1.5 fold for compound H8i, H13a, H13f and H13n. It is noteworthy that for all these 
compounds the aromatic ring attached with fused ring via a methylene bridge. It is 
important to mention that there is a significant correlation between expression of 
VEGF and TP in many solid tumours. Various studies suggested that both pro-
angiogenic factors share same transcription site
81, 233
.  
Indeed, the synthesized TP inhibitors showed anti-angiogenic property, through 
inhibition of MMP-9 and VEGF expression. Therefore, it is expected that compounds 
would inhibit the growth of tumour by cessation of several biomarkers. For example, 
it could prevent the extracellular matrix degradation essential for cancer cell 
migration and prevent the formation of new blood vessels leading to cessation of 
supply of necessary oxygen and nutrients to malignant cells. In addition, these 
compounds inhibit the TP enzyme activity.  
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Encouraged by the promising MMP-9 and VEGF expression inhibition potential, an 
attempt to investigate the invasive ability of H5bxix, H5bii and H5bxvii on the same 
cell line using a cell invasion assay kit was carried out. However, the results indicated 
that these compounds were not able to exhibit anti-invasive property even at 200 µM 
concentration. To explore further, the effect of IL-8 expression pattern after treating 
by different doses of compound H5bxix, H5bii and H5bxvii were investigated. 
Interestingly, the experimental data suggested that the compounds induced the 
expression of IL-8 in a dose dependent manner.  
It was established by a different studies that human mononuclear phagocytes 
(macrophage cells) regulate the remodelling of extracellular matrix by producing 
metalloproteinases including MMP-9 as well as the tissue inhibitor of 
metalloproteinases (TIMP)
234
. In addition, several evidences suggested that 
interleukin and other inflammatory cytokines released from activated T lymphocytes 
co-ordinately suppress metalloproteinase biosynthesis in macrophages without 
affecting TIMP production
235
. Therefore, from the data presented in this report, it is 
assumed that the synthesized compounds could activate T lymphocytes resulting in 
elevated expression of IL-8 leading to attenuation of MMP-9 activity. Furthermore, an 
increasing number of studies have implicated that cytokines and growth factors 
including interleukins induce the transcription of many intracellular protein involved 
in  cell cycle progression, apoptosis, and tumour cell invasion
236, 237
. Hence, it is 
postulated that the inability of the active test compounds to show anti-invasive 
potential is a consequence of their induction of IL-8 expression. However, further 
investigation to explore the exact mechanism in molecular level to explain the diverse 
biological effects exerted by our compounds is strongly recommended. 
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The viability study demonstrated that most of these compounds showed weak 
cytotoxic effects towards breast cancer cell. Some compounds from series H13 
significantly reduced the cell viability at the concentration of 100 µM. Among them, 
compound H13e bearing lipophilic biphenyl moiety exhibited lowest cell viability. 
Therefore, these compounds could be used as template compounds for future 
development of anti-angiogenic agent, which exert inhibition towards angiogenic 
marker without producing substantial cytotoxicity. 
7.4 Summary  
In summary, the series of experiments conducted has provided general information on 
the biological charecteristics of the active TP inhibitors. Firstly, it was demonstrated 
that the new bicyclic fused triazines exhibited mixed type of enzyme inhibition 
kinetics with respect to both substrates. It is noteworthy that structural modification of 
lead compound 7-DX by inserting additional nitrogen atom in core ring structure and 
incorporating different substitutents around the fused ring scaffolds have led to TP 
inhibitors that could interact with the enzyme in different orientations and exhibit 
mixed type inhibition kinetics. Secondly, some of the compounds reduced VEGF and 
MMP-9 expression without exhibiting significant cytotoxicity in breast cancer cell 
line, which would explain the potential anti-angiogenesis effect of the test 
compounds. However, TPI and 7-DX did not demonstrate significant antiangiogenic 
property with respect to attenutation of MMP-9 expression. Therefore, it is postulated 
that the synthesized compounds bearing different structural features compared to lead 
compound 7-DX, may interact distinctly with TP and which is sufficient for 
suppression of angiogenic property exerted by TP. Interestingly, compounds H8i and 
H13a that exhibited 14.5 and 11.2 fold improvement in TP inhibitory property with 
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respect to 7-DX, were identified as the most active compounds in their corresponding 
series. Moreover, compounds H13e, H13f and H13n having di-substituted 
pyrazolo[1,5-a][1,3,5]triazine scaffold, demonstrated antiangiogenic effect by 
suppressing expression of MMP-9 and VEGF in breast cancer cell line. Since, these 
compounds showed inhibition towards multiple targets including TP and important 
angiogenenic markers, they might be very useful for the design of efficacious 
anticancer drugs. However, further studies are necessary to reveal the detail 




































The derivatives of 1,3,5-triazine and its fused analogues viz. 1,2,4-triazolo[1,5-
a][1,3,5]triazine and pyrazolo[1,5-a][1,3,5]triazine are commonly found in several 
biologically active chemical compounds. Despite a wide spectrum of biological 
activities exhibited by 1,3,5-triazine derivatives and the compounds having 1,2,4-
triazolo and pyrazolo fused triazine scaffolds, no unequivocal study has been 
conducted to explore their activity associated with TP inhibition. Therefore, the focus 
of this thesis was to synthesize different types of 1,3,5-triazin-2,4-diones and their 
fused analogues and investigate their thymidine phosphorylase inhibitory activity. In 
addition, the inhibitory effect of the selected compounds towards MMP-9 and VEGF 
expression on breast cancer cell line was also determined. This project also dealt with 
the exploration of cell migration and relevant IL-8 expression pattern exerted by the 
target compounds. Moreover, pharmacophore elucidation for new series of TP 
inhibitors was performed via comparative molecular field analysis-based quantitative 
structure activity relationship studies. The motivation of conducting this whole project 
came from the gaps of previous works reported in the literature. An increasing 
number of studies discovered several potent thymidine phosphorylase inhibitors, most 
of which are derivatives of pyrimidin-2,4-dione with only a few that are fused bicyclic 
heterocycles having homophthalimide moiety assumed to be essential for binding to 
the active site of this enzyme. Among the previously disclosed TP inhibitors, TPI and 
7-DX have emerged as leading TP inhibitor candidates. Although TPI and 7-DX were 
identified as prototypic TP inhibitors in long back, further extensive structural 
exploration by isosteric replacement in different positions of  the core structures along 
with introduction of different substituents has never been synthesized nor have their 
antiproliferative activity, inhibitory effect of MMP-9, VEGF and IL-8 expression  as 
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well as anti-metastasis activity been investigated before. Collectively, the significant 
gaps from pioneering studies have led us to investigate the hypothesis that derivatives 
of 1,3,5-triazin-2,4-dione and its fused analogues viz. substituted 1,2,4-triazolo[1,5-
a][1,3,5]triazines and pyrazolo[1,5-a][1,3,5]triazines would exhibit TP inhibitory 
activity. 
To address the hypotheses, a total of eighty-two compounds having the 1,3,5-triazin-
2,4-dione, 1,2,4-triazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a][1,3,5]triazine as the 
core scaffold were synthesized. The use of ring transformation and intra-molecular 
annulation of appropriately substituted staring material to afford the target compounds 
was found to be practical and flexible. Undoubtedly, the objective of developing 
convenient synthetic methodologies to generate target compounds was successfully 
achieved. Among the different scaffolds synthesized, 5-thioxo-5,6-dihydro-4H-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-one and 2-thioxo-2,3-dihydropyrazolo[1,5-
a][1,3,5]triazin-4(1H)-one and their corresponding thiomethyl derivatives showed TP 
inhibitory activity. Therefore, these findings proved the hypothesis to be true.  
In this study, it was revealed that compounds having homophthalimide moiety did not 
exhibit TP inhibition property which turned out to be inconsistent with previous 
reported studies
101
. However, the compounds having keto group (C=O) and thioketo 
group (C=S) in particular orientation demonstrated inhibitory activity. This study also 
suggested that the introduction of flexible chain in between aromatic and fused ring 
system imparted better biological effects towards TP inhibition. In addition, structural 
modification by incorporating substituents at the both C8 and C7 of pyrazolo[1,5-
a][1,3,5]triazine exhibited improvement of inhibitory potential as evident in series 
H13. Furthermore, structural diversity of compounds generated based on Craig plot 
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optimization, suggested that hydrophobicity and electronic effects of substituent are 
important influencing factors for improvement of inhibition property. The TP active 
compounds exhibited varying degree of thymidine phosphorylase inhibitory activity 
with IC50 values recorded in the range of 3 - 95 µM. Compounds H5bxvii, H5bxix, 
H8i, H11g, and H13a were identified as most active TP inhibitors in their respective 
series, exhibiting low micromolar IC50 values (IC50 = 10.84, 13.09, 2.95, 13.07 and 
3.82 µM respectively).  
With the aim to clarify the structural basis, the 3D-QSAR studies based on CoMFA 
method was employed on a series of 1,2,4-triazolo and pyrazolo fused triazine 
derivatives that showed different extent of anti-TP activity, with IC50 values ranging 
from 2.95 µM to 95.05 µM. The models turned out satisfactorily based on the 
statistical validation results and contour map analysis. Moreover, the excellent 
predictive abilities of these model observed for the test set of compounds suggested 
that these CoMFA models could be successfully employed for predicting the IC50 
values of other TP inhibitors. Furthermore, the CoMFA contour maps provided 
enough information to understand the structure–activity relationship and identify 
structural features influencing the inhibitory activity. 
In order to investigate the inhibition mechanism of these test compounds, enzyme 
inhibition kinetics studies of selected compounds were conducted and it was revealed 
that these compounds exhibited mixed type inhibition against the enzyme in the 
presence of variable substrates concentrations. It was believed that due to unique 
structural features, these compounds would interact with the enzyme in different 
pattern and hence, it demonstrated different enzyme kinetic behaviour compared to 
TPI and 7-DX. This finding has led to an important assumption that these compounds 
173 
 
would exhibit TP associated anti-angiogenic property via interacting in different 
orientation. To prove these postulations, the experiments were carried out to explore 
anti-angiogenic effects of the selected compounds and it was found that these 
compounds demonstrated TP associated antiangiogenic potential as they attenuate the 
expression of VEGF and MMP-9 in breast cancer cell line without exerting 
cytotoxicity. Therefore, the hypothetical statements were proven to be true.  It is 
noteworthy that the compounds did not inhibit cell migration as a consequence of 
their interleukin induction.  
Overall, this study has established the fused bicyclic triazolo and pyrazolo triazines 
and their derivatives to be a new class of potential thymidine phosphorylase 
inhibitors, which demonstrated mixed type enzyme inhibition kinetics with respect to 
thymidine and phosphate as substrate. As depicted in Table 20, the difference in 
kinetic behaviour compared to reference compounds is probably due to structural 







Table 20. A summary of biological activities of reference compounds (TPI and 7-DX) and synthesized TP inhibitors 
 
 





(% cell viability) IC50 (µM) Kinetic behaviour MMP-9  expression (%) VEGF  expression (%) 
TPI 0.035 competitive insignificant - 90.48 
7-DX 42.63 competitive/mixed insignificant - 86.73 
H8i 2.95 mixed 48.97 22.27 79.82 
H11g 13.07 mixed 2.29 18.95 89.66 
H13a 3.82 mixed 24.58 37.36 89.27 
H13e 6.11 mixed 1.61 31.15 40.30 
H13f 4.46 mixed 0 23.99 74.10 
H13n 4.29 mixed 0 23.29 68.21 
a
comparison of antiangiogenic effects (MMP-9 and VEGF expression (%) with respect to Veh. ctrl (100 %)) at 100 µM, 
b
cell viability (%) of 




Although, the synthesized compounds exhibited weaker inhibition activity against TP 
compared to TPI, these inhibitors would provide some added advantages as they 
demonstrated mixed type of enzyme kinetic behaviour. Firstly, in the presence of 
sufficiently high concentration of substrate, the effectiveness of mixed inhibitors 
could not alter significantly in contrast to competitive inhibitors. Secondly, as the 
mixed inhibitors would bind to both free enzyme and enzyme substrate complex, 
these inhibitors could make the enzyme non-productive by forming EI and ESI 
complex. In addition, these synthesized TP inhibitors suppress the expression of some 
biological markers including MMP-9 and VEGF that are closely associated with 
angiogenesis whereas the reference compounds did not exhibit significant inhibitory 
effects (Table 20). Moreover, compound 13e exhibited significant antiproliferative 
effect (% cell viability = 40.30 ) which is better compared to lead compounds, 7-DX 
and TPI. It is important to mention that compounds having  pyrazolo[1,5-
a][1,3,5]triazine scaffold exhibited better inhibition response against all these assays 
compared to the compounds bearing 1,2,4-triazolo[1,5-a][1,3,5]triazine ring. It was 
also evident that di-substituted compounds H13e, H13f and H13n having lipophilic 
bulky group at the position C8, significantly attenuated the expression of angiogenic 
markers including MMP-9 and VEGF and also exhibited remarkable inhibitory 
property against TP. Therefore, these compounds would be used as lead for future 
development of potent TP inhibitors. Moreover, CoMFA model established in this 
investigation would contribute molecular basis in designing novel fused TP inhibitors. 
Therefore, this dissertation demonstrated the foundation for further design and 
optimization of fused-ring TP inhibitors that may lead to development of 
chemotherapeutic agents, as it can overcome the pathological effects of TP such as 
tumour progression via angiogenesis.  
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8.2 Future work 
Although this comprehensive study has shown some promising results, there is still 
room for further improvement of this project and thus the following studies need to be 
investigated. 
Undoubtedly, this study has revealed that the compounds having 1,2,4-triazolo[1,5-
a][1,3,5]triazine and pyrazolo[1,5-a][1,3,5]triazine exhibited anti-TP and anti-
angiogenic effects. However, most of the compounds did not demonstrate 
antiproliferative property except for compound H13e that showed around 40 % cell 
viability at 100 µM. It is assumed that the bi-phenyl group of compound H13e 
attached at the position C8 of fused ring is responsible for this property. Therefore, 
further structural modification of this compound by introducing bulky lipophilic 
groups with an aim to generate TP inhibitor with antiproliferative potential is crucial.  
In order to investigate the anti-angiogenic effects, the synthesized compounds were 
found to inhibit the expression and/or activity of MMP-9 and VEGF. However, the 
molecular mechanism through which these TP inhibitors exert these biological effects 
is still largely unclear. Therefore, to identify the detailed signal transduction cascades 
inhibited by the synthesized TP inhibitors, more research needs to be performed. In 
addition, to prove potency of the synthesized compounds in angiogenesis, in vivo 
experiments of angiogenesis and detailed exploration of inhibitory potential toward 
other angiogenenic biomarkers are still to be revealed. This knowledge would help 




In this study, the identified mixed type TP inhibitors, which are structurally entirely 
unrelated to the natural substrates of the enzyme, has opened up interesting 
perspectives for further development of new classes of TP inhibitors. As part of the 
lead finding and optimization program in our laboratory, continuous efforts with a 
view to enhancing the biological activity, will be employed to modify the lead 
compounds H14 (IC50 = 26.30 µM). In addition, it is believed that introduction of 
thiourea chain in compound H14 would generate some potent inhibitors of TP.  
Taking these hypotheses into consideration, a series of compounds is proposed to be 
synthesized where flexibility can be made by using different R group to generate a 
range of libraries and thereafter it will be evaluated for the TP inhibitory activity to 
explore better lead in drug design against TP (Figure 32). Such compounds may also 
be employed to reveal TP associated angiogenesis and other biological processes such 
as apoptosis and tumour cell metastasis. 
 
Figure 32. Structures of proposed compounds 
Structures could be further improved by another QSAR study using a wider range of 
molecular properties. The results obtained after QSAR study could be helpful in 
designing new series of fused analogues as novel TP inhibitors. The study can be 
extended with advanced techniques including CoMSIA, 3-D-QSAR method, and 
docking etc which may further lead to design of novel and potent TP inhibitors having 
better therapeutic index with low toxicity, higher oral bioavailability and solubility. 
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It is very interesting and encouraging that the most potent TP inhibitor, TPI has now 
entered clinical trials in the combination with TFT, designated as TAS-102
150
. The 
outcome of these studies will be extremely helpful to establish the clinical relevance 
of a potent TP inhibitor. Similarly, it is essential to establish the synergism of our 
synthesized compounds with TFT for applications in cancer therapy.  
The potential use of TP inhibitors is not limited to cancer as TP is also involved in 
many inflammatory diseases, such as rheumatoid arthritis
82
. Therefore, it is worth-
trying to explore the potential effects in TP associated inflammatory diseases using 



































9.1 Chemistry  
9.1.1 Reagents and general methods 
All reagents were purchased from Sigma-Aldrich or Alfa Aesar and were used 
without further purification. Melting points were determined on a Gallenkamp 
melting point apparatus and were uncorrected. The 
1
H NMR and 
13
C NMR spectra 
were recorded on a Bruker DPX-300 spectrometer at 300 MHz and 75 MHz 
respectively using DMSO-d6 as solvent and TMS as internal standard. Mass spectra 
were obtained on a Finnigan MAT LCQ LC-MS mass spectrometer using 
electrospray ionization (ESI) mode. Reactions were monitored by TLC on silica gel 
(60 F254) coated aluminium plate. 
 HPLC 
HPLC analysis was carried out using Hewlett-Packard series 1050 HPLC system 
equipped with a HP-1050 quaternary pump, a degasser, diode array detector, a HP-
1100 autosampler, and a LiChrosorb reversed phase C18 (5 µm) column (4.6×250 
mm). All the samples were prepared by dissolving them in methanol to form a 25 
µg/ml solution. The analysis was performed at 30°C using isocratic elution with a 
suitable mobile phase, consisting of water (50%) and acetonitrile (50%) (method A). 
or methanol (50%) and acetonitrile (50%) (method B). The total run time was set for 
20 minutes. In addition, another two gradient elution methods (method C and D) were 
adopted to determine the purity of compounds. In method C, the analysis was.started 
with a mobile phase composition of 95:5 (aqueous phase (0.1% acetic 
acid):acetonitrile) and it gradually changed to 60:40 within first 10 min. For the next 
30 min, the composition of the mobile phase was changed from 60:40 to 0:100. 
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Alternatively, another mobile phase system composed of water (with 0.1 % formic 
acid) and acetonitrile (with 0.1 % formic acid) was selected for method D. In this 
method, the experiment started using mobile phase composition of 95:5 (aqueous 
phase :acetonitrile) which gradually changed to 0:100 within 7 minutes. The flow rate 
was set at 1 ml/ minute and the ultraviolet detection was made at wavelength 254 nm. 
The injection volume was 5 µL.  
9.1.2 General procedure for the synthesis of 1,3,5-triazin-2,4-dione (H1a-H1f)  




In well-stirred suspension of cyanoguanidine (8.4 g, 10 mmol) in acetone (70 ml), 
potassium hydroxide pellets (11 g, 20 mmol) and carbon disulphide (6.64 ml, 11 
mmol) were added at -10 to -5 ºC. The temperature was then allowed gradually to rise 
to 15 ºC and stirring was continued for another 3.5 hours. The yellow coloured 
intermediate dipotassium ω-cyanoguanidinodithiocarbonate was filtered off, washed 
with acetone and dried. This intermediate was dissolved in water, and acetic acid 
added to make it neutral. The precipitated product was filtered off, washed with water, 
and dried. 
Yield 55%; mp > 300ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 8.03 and 8.30 (two s, 2H, 
NH2), 8.67 and 8.81 (two s, 2H, NH2); 
13
C NMR (75 MHz, DMSO-d6): δ 162.6 (C-4), 









4, 6-Diamino-2H-1,3,5-thiadiazine-2-thione (1.6 g, 10 mmol) was suspended in 
dimethylformamide (DMF, 5 ml). To it, methylamine (1.3ml, 10 mmol) was added 
and stirred the reaction mixture for 30 minutes. 10 ml of 2M NaOH solution was then 
added and allowed it to stand at room temperature for 1 day. The precipitated product 
was filtered, washed well with water and dried.  
Yield 44%; mp 275ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 3.68 (s, 3H, NMe), 6.85 
and 7.11 (two s, 2H, NH2), 7.55 (s, 2H, NH2); 
13
C NMR (75 MHz, DMSO-d6): δ 35.5 
(NMe), 158.1 (C-6), 161.1 (C-4), 184.4 (C-2). 




A suspension of 1-methyl-4,6-diamino-1,3,5-triazin-2-thione (314 mg, 2 mmol) in 50 
ml of 6N hydrochloric acid on heating under reflux for 2 hours gave a clear solution, 
which upon cooling deposited a solid. The acidic filtrate obtained after removing the 
solid, on concentration and cooling afforded another solid, which upon 
recystallization from water gave 1-methyl-6-thioxo-1,3,5-triazin-2,4-dione. 
 Yield 15%; mp 272-270ºC (water); 
1
H NMR (300 MHz, DMSO-d6): δ 3.68 (s, 3H, 
NMe), 11.86 (s, 1H, NH), 12.55 (s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 35.8 








To a stirred solution of 1-methyl-6-thioxo-1,3,5-triazin-2,4-dione (1.6 g, 10 mmol) in 
8 ml of 2.5 M NaOH, iodomethane ( 933 µl, 15 mmol) was added, the stirring was 
continued for 30 minutes. A solid precipitate was afforded by acidification (pH 1-3) 
with 2.5 M HCl of resulting reaction mixture. The precipitated solid was filtered, 
washed with ice cold water and recrystallized from water-ethanol system. 
 Yield 60%; mp 220-222ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): δ 2.50 
(s, 3H, SMe), 3.27 (s, 3H, NMe), 11.42 (s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): 
δ 15.1 (SMe), 30.4 (NMe), 147.0 (C-4), 148.9 (C-2), 179.4 (C-6). 
 General procedure for the synthesis of 1-methyl-6-substituted-1,3,5-triazin-2,4-
dione (H1a- H1f)  
In methanolic (30 ml) suspension of 1-methyl-6-methylthioxo-1,3,5-triazin-2,4-dione 
(865 mg, 5 mmol) , a secondary amine (10 mmol) or a primary amine (7.5 mmol) was 
added. The reaction mixture was heated under reflux for 3-5 hours. The products were 
obtained by removing the solvent under vacuum and recrystallizing the residue with 
ethanol.  
1-Methyl-6-(methylamino)-1,3,5-triazin-2,4(1H,3H)-dione (H1a) 




H NMR (300 MHz, 
DMSO-d6): δ 2.78 (s, 3H, NHMe), 3.16 (s, 3H, NMe), 7.63 (s, 1H, NHMe), 10.65 (s, 
1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 28.4 (NHMe), 28.9 (NMe), 151.4 (C-2), 








H NMR (300 MHz, 
DMSO-d6): δ 1.11 (t, 3H, CH2CH3, J = 7.1 Hz), 3.16 (s, 3H, NMe), 3.32 (q, 2H, CH2, 
J = 6.9 Hz), 7.61 (s, 1H, NHCH2), 10.62 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-
d6): δ 14.8 (Me), 28.39 (NMe), 36.7 (NHCH2), 151.5 (C-2), 155.1 (C-4), 156.1 (C-6). 
6-(Benzylamino)-1-methyl-1,3,5-triazin-2,4(1H,3H)-dione (H1c) 




H NMR (300 MHz, 
DMSO-d6): δ 3.25 (s, 3H, NMe), 4.53 (s, 2H, -CH2Ph), 7.21-7.33 (m, 5H, Ph), 8.20 
(s, 1H, NHCH2), 10.71 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 28.6 (NMe), 
44.7 (NHCH2), 127.4 (C’4), 127.6 (C’2 & C’6) 128.7 (C’3 & C’5), 139.1 (C’1), 151.5 
(C-2), 155.1 (C-4), 156.7 (C-6). 
6-(Cyclopropylamino)-1-methyl-1,3,5-triazin-2,4(1H,3H)-dione (H1d) 




H NMR (300 MHz, 
DMSO-d6): δ 0.61-0.71 (m, 4H, two H-2’ and H-3’), 2.78 (s, 1H, H-1’), 3.13 (s, 3H, 
NMe), 7.53 (s, 1H, NH), 10.69 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 6.5 
(C-2’ and 3’), 25.3 (C-1’), 26.6 (NMe), 151.4 (C-2), 155.1 (C-4), 157.8 (C-6). 
1-Methyl-6-(morpholino)-1,3,5-triazin-2,4(1H,3H)-dione (H1e) 
Yield 85%; mp 240-242ºC (Ethanol); ESI-MS m/z 212.9 (M-1)
+; purity ˃ 95%; 1H 
NMR (300 MHz, DMSO-d6): δ 3.21 (s, 3H, NMe), 3.32-3.36 (m, 4H, two H-2’ and 
H-6’), 3.65-3.68 (m, 4H, two H-3’ and H-5’), 10.98 (s, IH, NH); 13C NMR (75 MHz, 
DMSO-d6): δ 34.7 (NMe), 48.7 (C-2’ and C-6’), 66.0 (C-3’ and C-5’), 153.0 (C-2), 




Yield 23%; mp 220ºC (Ethanol); purity ˃ 95%; 1HNMR (300 MHz, DMSO-d6): δ 
1.81-1.85 (m, 4H, two H-3’ and H-4’), 3.26 (s, 3H, NMe), 3.49-3.52 (m, 4H, two H-2’ 
and 2H-3’) 10.63 (s, 1H, NH). 13C NMR (75 MHz, DMSO-d6): δ 25.6 (C-3’ and C-
5’), 33.8 (NMe), 50.6 (C-2’ and C-5’), 153.0 (C-2), 154.7 (C-4), 158.9 (C-6).  
9.1.2 General procedure for the synthesis of 1,2,4-triazolo[1,5-a][1,3,5]triazine 
(H2-H6) 
 General procedure for the synthesis of 3(5)-amino-1,2,4-triazoles (87) 
Method A 
206,207
 In well-stirred suspension of s–methylisothiourea sulfate (2.8 g, 10 
mmol) in 20 ml 1M NaOH, corresponding hydrazides (3.0 g, 20 mmol) was added at 0 
ºC. The stirring was continued for 48 hours at room temperature. The reaction mixture 
was allowed to heat at 50 ºC for another 3 hours. After cooling, the precipitated 
product was filtered, washed with ice cooled water and recrystallized from water. The 
obtained (het)arylamidoguanidines (5mmol) were heated with fixed microwave 
irradiation power (100W) using water (10 ml) as solvent for 3 to 5 minutes. After 
cooling, the precipitated products were filtered, washed with ice-cold water and 
recrystallized. 
Method B: A mixture of aryl acid chloride (10 mmol) and aminoguanidine HCl (20 
mmol) were heated in an oil bath for 20 minutes to at 180-185 ºC. After cooling, 
water (25 ml) was added with continuous stirring to make a homogeneous suspension. 
To it, 2 ml 5 M NaOH was added to basify the suspension. The precipitated products 
((het)arylamidoguanidines) was filtered, washed with water and dried. The 
(het)arylamidoguanidines (5 mmol) were treated with microwave irradiation power 
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(100W) for 5 to 8 minutes in water. After cooling, the precipitated products were 




 To a stirred suspension of 3-amino-5-sulfanyl-1,2,4-triazole 1 (1.8 g, 
15.5 mmol) in  DMF (25 ml), Et3N (2.2 ml, 17 mmol) was added drop wise and 
stirred for few minutes. To this mixture, benzyl bromide and its longer chain analogue 
(17 mmol) was added, and the mixture was stirred at room temperature for 4 hours. 
The resulting reaction mixture was partitioned between ethyl acetate (150 ml) and 
water (100 ml). The organic layer was washed with brine (50 ml), dried by using 
magnesium sulphate (MgSO4). The resulting organic layer was concentrated under 
reduced pressure and recrystallized with suitable solvent. 
Method D 
206
:To a stirred solution of dimethyl-N-cyanodithiocarbonimidate (2.9 g, 20 
mmol) in methanol (20 ml), hydrazine hydrate (98%, 1.1 ml, 22 mmol) was added. 
The stirring was continued for 5 hours at 40 ºC. After stirring, the solvent was 
removed under vacuum. The solid was recrystallized from ethyl acetate. 
 Synthesis of 3(5)-amino-1,2,4-triazoles and their 1H NMR spectral data (* signals 
of the minor tautomeric form 3-amino-1,2,4-triazoles). 
 
3-(Methylthio)-1H-1,2,4-triazole-5-amine (87a)  
Yield 68 % (method D); mp 123-125ºC (EA); 
1
HNMR (300 MHz, DMSO-d6): δ 2.42 
(s, 3H, SMe), 5.29* and 6.04 (s, 2H, NH2), 11.91 and 12.67* (s, 1H, NH). 
187 
 
3-Phenyl-1H-1,2,4-triazole-5-amine (87b)  
Yield 97 % (method A); mp 186-187 ºC (water); 
1
H NMR (300 MHz, DMSO-d6): δ 
5.35* and 6.11 (two s, 2H, NH2), 7.31-7.90 (m, 3H, H-3’, H-4’ and H-5’), 7.91 (d, 
2H, H-2’ and H -6’, J = 7.1 Hz), 12.08 and 13.24* (two s, 1H, NH). 
3-(3-Nitrophenyl)-1H-1,2,4-triazole-5-amine (87c)  
Yield 94 % (method B); mp 268 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): 
δ 5.47* and 6.26 (two s, 2H, NH2), 7.73 (t, 1H, H-5’,
 
J = 7.9 Hz), 8.21 (dd, 2H, H-
4’and H-6’ J = 8.2, 1.5 Hz), 8.65 (s, 1H, H-2’), 12.34 and 13.60* (two s, 1H, NH). 
3-(3-(Trifluromethyl)phenyl)-1H-1,2,4-triazole-5-amine (87d)  
Yield 93 % (method B); mp 208-210 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.45* and 6.23 (two s, 2H, NH2), 7.62-7.77 (m, 2H, H-4’ and H-5’), 
8.14-8.25 (m, 2H, H-2’ and H-6’), 12.29 and 13.50* (two s, 1H, NH). 
3-(3-Chlorophenyl)-1H-1,2,4-triazole-5-amine (87e)  
Yield 93 % (method B); mp 192 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): 
δ 5.38* and 6.16 (two s, 2H, NH2), 7.38-7.47 (m, 2H, H-4’ and H-5’), 7.83-7.7.87 (m, 
2H,  H-6’ and H-2’), 12.20 and 13.35* (two s, 1H, NH). 
3-(3-Bromophenyl)-1H-1,2,4-triazole-5-amine (87f)  
Yield 92 % (method B); mp 199-200 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.40* and 6.17 (two s, 2H, NH2), 7.38 (t, 1H, H-5’,
 
J = 7.8 Hz), 7.54 (d, 
1H, H-4’, J = 7.8 Hz), 7.87-7.93 (m, 1H, H-6’), 8.04 (s, 1H, H-2’), 12.22 and 13.35* 




3-(3-Fluorophenyl)-1H-1,2,4-triazole-5-amine (87g)  
Yield 92 % (method B); mp 189-190 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.42* and 6.19 (two s, 2H, NH2), 7.14-7.22 (m, 1H, H-5’), 7.46 (dd, 
1H, H-4’, J = 14.2, 7.9 Hz), 7.76 (d, 1H, H-2’, J = 7.8 Hz), 7.74-7.78 (m, 1H, H-6’), 
12.21 and 13.38* (two s, 1H, NH). 
3-(3-Methylphenyl)-1H-1,2,4-triazole-5-amine (87h)  
Yield 80 % (method B); mp 147-148 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 2.34 (s, 3H, Me), 5.45* and 6.09 (two s, 2H, NH2), 7.15 (d, 1H, H-4’, J 
= 7.0 Hz), 7.29 (t, 1H, H-5’, J = 7.5 Hz), 7.71 (d, 1H, H-6’, J = 7.6 Hz), 7.75 (s, 1H, 
H-2’), 12.08 and 13.16* (two s, 1H, NH). 
3-(3-Methoxyphenyl)-1H-1,2,4-triazole-5-amine (87i) 
Yield 83 % (method A); mp 166-168 ºC (water); 
1
H NMR (300 MHz, DMSO-d6): δ 
3.79 (s, 3H, OMe), 5.39* and 6.09 (two s, 2H, NH2), 6.92 (d, 1H, H-4’, J = 7.5 Hz), 
7.32 (t, 2H, H-5’, J = 7.9 Hz), 7.44 (s, 1H, H-2’), 7.49 (d, 1H, H-6’, J = 7.5 Hz), 12.08 
and 13.22* (two s, 1H, NH). 
3-(3-Cyanophenyl)-1H-1,2,4-triazole-5-amine (87j) 
Yield 75 % (method B); mp 246-248 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.37* and 6.12 (two s, 2H, NH2), 7.39-8.60 (m, 4H, Ar-H), 12.14 and 






Yield 98 % (method B); mp 263-265 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.54* and 6.30 (two s, 2H, NH2), 8.15 (d, 2H, H-3’ and H-5’, J = 9.0 
Hz), 8.29 (d, 2H, H-2’ and H-6’, J = 9.0 Hz), 12.45 and 13.69* (two s, 1H, NH). 
3-(4-(Trifluoromethyl)phenyl)-1H-1,2,4-triazole-5-amine (87l) 
Yield 93 % (method B); mp 207-208 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.53* and 6.24 (two s, 2H, NH2), 7.78 (d, 2H, H-3’ and H-5’, J = 8.1 
Hz,), 8.13 (d, 2H, H-2’ and H-6’, J = 8.0 Hz,), 12.32 and 13.55* (two s, 1H, NH). 
3-(4-Chlorophenyl)-1H-1,2,4-triazole-5-amine (87m) 
Yield 94 % (method B); mp 229-230 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.43* and 6.17 (two s, 2H, NH2), 7.47 (d, 2H, H-3’ and H-5’, J = 8.0 
Hz), 7.92 (d, 2H, H-2’ and H-6’, J = 8.5 Hz,), 12.18 and 13.33* (two s, 1H, NH) 
3-(4-bromophenyl)-1H-1,2,4-triazole-5-amine (87n) 
Yield 98 % (method B); mp 213-215 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.40* and 6.15 (two s, 2H, NH2), 7.60 (d, 2H, H-3’ and H-5’, J = 8.5 
Hz,), 7.85 (d, 2H, H-2’ and H-6’, J = 8.5 Hz,), 12.17 and 13.33* (two s, 1H, NH). 
3-(4-Fluorophenyl)-1H-1,2,4-triazole-5-amine (87o) 
Yield 95 % (method B); mp 188-189 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.36* and 6.13 (two s, 2H, NH2), 7.23 (t, 2H, H- 3’ and H -5’, J = 8.7 





Yield 98 % (method B); mp 209 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): 
δ  2.32 (s, 3H, Me), 5.32* and 6.08 (two s, 2H, NH2), 7.20 (d, 2H, H-3’ and -5’, J = 
7.8 Hz), 7.80 (d, 2H, H-2’ and -6’, J = 8.1 Hz), 12.02 and 13.14* (two s, 1H, NH). 
3-(4-Methoxyphenyl)-1H-1,2,4-triazole-5-amine (87q) 
Yield 96 % (method B); mp 226 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): 
δ 3.78 (s, 3H, OMe), 5.27* and 6.04 (two s, 2H, NH2), 6.96 (d, 2H, H-3’ and -5’, J = 
8.4 Hz), 7.83 (d, 2H, H-2’ and -6’, J = 8.8 Hz), 11.94 and 13.02* (two s, 1H, NH). 
3-(4-Cyanophenyl)-1H-1,2,4-triazole-5-amine (87r) 
Yield 76 % (method B); mp 226 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): 
δ 5.50* and 6.26 (two s, 2H, NH2), 7.88 (d, 2H, H-3’ and H-5’, J = 8.3 Hz), 8.07 (d, 
2H, H-2’ and H-6’, J = 8.5 Hz), 12.37 and 13.60* (two s, 1H, NH). 
3-(3,4-Dichlorophenyl)-1H-1,2,4-triazole-5-amine (87s) 
Yield 94 % (method B); mp 243-245 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.43* and 6.21 (two s, 2H, NH2), 7.67 (d, 1H, H-5’, J = 8.4 Hz), 7.86 
(dd, 1H, H-6’, J = 8.4, 1.9 Hz), 8.03 (d, 1H, H-2’ J = 1.6 Hz),12.28 and 13.42* (two s, 
1H, NH). 
3-(3,4-Difluorophenyl)-1H-1,2,4-triazole-5-amine (87t) 
Yield 92 % (method B); mp 189-190 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.41* and 6.19 (two s, 2H, NH2), 7.41-7.53 (m, 1H, H-5’), 7.70-7.84 




Yield 96 % (method B); mp 185-187 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 2.39 (s, 3H, Me), 5.35* and 6.11 (two s, 2H, NH2), 7.58-7.86 (m, 2H, 
H-5’ and -6’), 7.86 (s, 1H, H-2’), 12.15 and 13.27* (two s, 1H, NH).
 
3-(Benzylthio)-1H-1,2,4-triazole-5-amine (87v) 
Yield 80 % (method C); mp 85-87 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): 
δ 4.23(s, 2H, CH2), 5.19* and 6.08 (s, 2H, NH2), 7.10-7.47 (m, 5H, Ph),
 11.96 and 
12.69*(S, 1H, NH). 
3-(Phenethylthio)-1H-1,2,4-triazole-5-amine (87w) 
Yield 82 % (method C); mp 103 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ  
2.93 (t, 2H, CH2Ph, J = 8.0 Hz), 3.20 (t, 2H, SCH2, J = 7.2 Hz), 5.37* and 6.06 ( s, 
2H, NH2), 7.20-7.31 (m, 5H,  Ph), 11.95 and 12.66*
  (s, 1H, NH). 
3-((Phenylpropyl)thio)-1H-1,2,4-triazole-5-amine (87x) 
Yield 82 % (method C); mp 103 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 
1.92 (q, 2H, CH2CH2CH2, J = 7.4 Hz), 2.67 (t, 2H, CH2Ph, J = 7.5 Hz), 2.94 (t, 2H, 
SCH2, J = 7.2 Hz), 5.21* and 6.03 (s, 2H, NH2), 7.14-7.32 (m, 5H, H-4’, Ph), 11.90 
and 12.66* (s, 1H, NH). 
3-(Furan-2-yl)-1H-1,2,4-triazole-5-amine (87y) 
Yield 95 % (method B); mp 211-212 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-
d6): δ 5. 39* and 6.17 (two s, 2H, NH2), 6.46-6.64 (m, 1H, H-4’), 6.65-6.91 (m, 1H, 




Yield 97 % (method B); mp 211-212 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.40* and 6.19 (two s, 2H, NH2), 7.09 (t, 1H, H- 4’, J = 4.3 Hz ), 7.44 
(d, 1H, H-3’, J = 3.1 Hz,), 7.47 (d, 1H, H-5’, J = 5.0 Hz), 12.09 and 13.26* (two s, 
1H, NH). 
3-(Pyridin-2-yl)-1H-1,2,4-triazole-5-amine (87za) 
Yield 92 % (method A); mp 220-221 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.45* and 6.22 (two s, 2H, NH2), 7.37-7.44 (m, 1H, H-5’), 7.86-7.98 
(m, 2H, H-3’ and H-4’), 8.63-8.64 (m, 2H, H-6’), 12.41 and 13.55* (two s, 1H, NH). 
3-(Pyridin-3-yl)-1H-1,2,4-triazole-5-amine (87zb) 
Yield 98 % (method A); mp 224-225 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.52* and 6.29 (two s, 2H, NH2), 7.47 (dd, 1H, H-5’, J = 7.8, 4.8 Hz), 
8.25 (dt, 1H, H-4’, J = 7.9, 1.9 Hz), 8.59 (d, 1H, H-6’, J = 3.5 Hz), 9.13 (d, 1H, H-2’, 
J = 1.4 Hz), 12.34 and 13.51* (two s, 1H, NH). 
3-(Pyridin-4-yl)-1H-1,2,4-triazole-5-amine (87zc) 
Yield 98 % (method A); mp 272-274 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.53* and 6.28 (two s, 2H, NH2), 7.81-7.83 (m, 2H, H- 3’ and H-5’), 







Yield 78 % (method B); mp 211-212 ºC (water-ethanol); 
1
H NMR (300 MHz, 
DMSO-d6): δ 5.28 (s, 1H, CH), 5.42* and 5.92 (two s, 2H, NH2), 7.12-7.39 (m, 10H, 
Ph), 11.75 and 12.62* (two s, 1H, NH). 




3(5)-amino-5(3)-(het)aryl-1,2,4-triazoles (3 mmol) was suspended in anhydrous 
dimethylformamide (DMF, 4 ml) and ethoxycarbonyl isothiocyanete (3.3 mmol)  was 
then added . By stirring the mixture for 4.5-5 hours at room temperature, 50-60 ml 
water was added to it to get more precipitated product. The product was filtered and 










Table 21. Synthesis of N-(3(5)-aryl-1,2,4-triazol-5(3)-yl)-N’-carbethoxythioureas and 
their 
1
















H NMR (300 MHz, DMSO-d6) 
CO2Et Ar 
tautomer A tautomer B 
NH NH N(1)H 2NH N(1)H 
88a CH3S- 
% yield: 73, 
mp: 169-170 
ºC (Ethanol) 
1.26, t, 3H, 
J = 7.1 Hz; 
4.22, q, 2H, 
J = 7.1 Hz 






% yield: 85     
mp: 180-181 
ºC (Ethanol) 
1.27, t, 3H, 
J = 7.1 Hz; 
4.24, q, 2H, 
J = 7.1 Hz 
7.51-7.52, m, 3H; 
7.97- 7.99, m, 2H 
 
11.87 12.07 13.88 11.67 14.47 
88c 3-NO2-C6H4- 
% yield: 73, 
mp: 211-212 
ºC , (Ethanol) 
1.29, t, 3H, 
J = 7.2 Hz; 
4.25 q, 2H, J 
= 7.2 Hz 
7.81, br.t, 1H, J = 
7.9 Hz; 8.31, br.d, 
1H, J = 7.9 Hz; 
8.39, d, 1H, J = 
7.9 Hz; 8.72, br.s, 
1H 
11.89 12.13 14.18 11.61 14.81 
88d 3-CF3-C6H4- 
% yield: 78, 
mp: 239-241 
ºC , (Ethanol) 
1.28, t, 3H, 
J = 7.0 Hz; 
4.25, q, 2H, 
J = 7.0 Hz 
7.67-7.96, m, 2H; 
8.16-8.37, m, 2H 
11.89 12.13 14.11 11.56 14.69 
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H NMR (300 MHz, DMSO-d6) 
CO2Et Ar 
tautomer A tautomer B 
NH NH N(1)H 2NH N(1)H 
88e 3-Cl-C6H4- 
% yield: 98, 
mp: 195-196 
ºC (Ethanol) 
1.30, t, 3H, 
J = 7.1 Hz; 
4.26, q, 2H, 
J = 7.1 Hz 
7.43-7.69, m, 2H; 
7.89-8.09, m, 2H 
11.91 12.16 14.06 11.58 14.59 
88f 3-Br-C6H4- 
% yield: 89, 
mp: 196-197 
ºC (Ethanol) 
1.29, t, 3H, 
J = 7.2 Hz; 
4.25, q, 2H, 
J = 7.2 Hz 
7.39-7.58m, 1H; 
7.59-7.80, m, 1H; 
7.99, d, 1H, J = 7.9 
Hz; 8.13, br.s, 1H 
11.89 12.14 14.05 11.57 14.57 
88g 3-F-C6H4- 
% yield: 80       
mp: 192-193  
ºC (Ethanol) 
1.29, t, 3H, 
J = 7.0 Hz; 
4.26, q, 2H, 
J = 7.0 Hz 
7.21-7.44, m, 1H; 
7.48-7.67, m, 1H; 
7.73, d, 1H, 
3
JHF = 
9.8 Hz;  7.85, d, 1H, 
J = 7.9 Hz 
11.89 12.15 14.04 11.58 14.59 
88h 3-Me-C6H4- 
% yield: 87 
mp: 175-176 
ºC (Ethanol) 
1.28, t, 3H, 
J = 7.0 Hz; 
4.25, q, 2H, 
J = 7.0 Hz 
2.40, s, 3H, Me; 
7.18-7.52, m, 2H; 
7.80, d, 1H, J = 7.9 
Hz;7.83, s, 1H 
11.88 12.18 13.90 11.57 14.42 
88i 3-MeO-C6H4- 
% yield: 76 
mp: 188-189  
ºC (Ethanol) 
1.29, t, 3H, 
J = 7.2 Hz; 
4.25, q, 2H, 
J = 7.2 Hz 
3.85, s, 3H, 
OMe;6.94-7.17, m, 
1H; 7.33-7.51, m, 
1H; 7.51, s, 1H;7.59, 
d, 2H, J = 7.5 Hz 
11.88 12.16 13.93 11.56 14.48 
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1H NMR (300 MHz, DMSO-d6) 
CO2Et Ar 
tautomer A tautomer B 
NH NH N(1)H 2NH N(1)H 
88j 3-CN-C6H4- 
% yield: 75, mp: 
182-184 ºC, 
(Ethanol) 
1.27, t, 3H, J = 
7.0 Hz; 4.24 q, 
2H, J = 7.0 Hz 
7.49-8.71, m, 
4H 
11.87 12.11 14.12 11.56 14.62 
88k 4-NO2-C6H4- 
% yield: 97, mp: 
200-201ºC, 
(Ethanol) 
1.28, t, 3H, J = 
7.0 Hz; 4.26 q, 
2H, J = 7.0 Hz 
8.23, d, 2H, J 
= 8.7 Hz; 
8.29-8.48, m, 
2H 




% yield: 79, mp: 
194-195 ºC , 
(Ethanol-water) 
1.28, t, 3H, J = 
7.0 Hz; 4.25, q, 
2H, J = 7.0 Hz 
7.76-8.04, m, 
2H; 8.19, d, 
2H, J = 8.3 
Hz 
11.88 12.12 14.13 11.57 14.74 
88m 4-Cl-C6H4- 
% yield: 94 mp: 
192-193 ºC , 
(Ethanol) 
1.29, t, 3H, J = 
7.2 Hz; 4.26, q, 
2H, J = 7.2 Hz 
7.43-7.77, m, 
2H; 8.01, d, 
2H, J = 8.3 
Hz 
11.87 12.16 14.00 11.62 14.55 
88n 4-Br-C6H4- 
% yield: 88, mp: 
220-221 ºC , 
(Ethanol) 
1.28, t, 3H, J = 
7.0 Hz; 4.25, q, 
2H, J = 7.0 Hz 
7.61-7.85, m, 
2H; 7.92, d, 
2H, J = 8.3 
Hz 
11.86 12.13 14.00 11.59 14.55 
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1H NMR (300 MHz, DMSO-d6) 
CO2Et Ar 
tautomer A tautomer B 
NH NH N(1)H 2NH N(1)H 
88m 4-Cl-C6H4- 
% yield: 94 mp: 
192-193 ºC , 
(Ethanol) 
1.29, t, 3H, J = 
7.2 Hz; 4.26, 
q, 2H, J = 7.2 
Hz 
7.43-7.77, m, 
2H; 8.01, d, 
2H, J = 8.3 Hz 
11.87 12.16 14.00 11.62 14.55 
88n 4-Br-C6H4- 
% yield:  88, 
mp:220-221 ºC , 
(Ethanol) 
1.28, t, 3H, J = 
7.0 Hz; 4.25, 
q, 2H, J = 7.0 
Hz 
7.61-7.85, m, 
2H; 7.92, d, 
2H, J = 8.3 Hz 
11.86 12.13 14.00 11.59 14.55 
88o 4-F-C6H4- 
% yield: 86 mp: 
209-210 ºC , 
(Ethanol-water) 
1.27, t, 3H, J = 
7.0 Hz; 4.24, 
q, 2H, J = 7.0 
Hz 
7.22-7.50, m, 
2H; 8.01, dd, 
2H, J = 8.7 Hz, 
3
JHF = 5.3 Hz 
11.85 12.10 13.92 11.52 14.44 
88p 4-Me-C6H4- 
% yield:  80      
mp: 215-216  ºC 
, (Ethanol) 
1.27, t, 3H, J = 
7.0 Hz; 4.24, 
q, 2H, J = 7.0 
Hz 
7.21-7.46, m, 
2H; 7.87, d, 
2H, J = 7.9 Hz 
11.86 12.13 13.85 11.53 14.24 
88q 4-MeO-C6H4- 
% yield: 84 mp: 
212 ºC , 
(Ethanol) 
1.27, t, 3H, J = 
7.0 Hz; 4.23, 
q, 2H, J = 7.0 
Hz 
6.98-7.20, m, 
2H; 7.91, d, 
2H, J = 8.7 Hz 
11.82 12.05 13.77 11.54 14.24 
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1H NMR (300 MHz, DMSO-d6) 
CO2Et Ar 
tautomer A tautomer B 
NH NH N(1)H 2NH N(1)H 
88r 4-CN-C6H4- 
% yield: 85, mp: 
198-200 ºC, ( 
Ethanol) 
1.27, t, 3H, 
J = 7.0 Hz; 
4.24 q, 2H, 
J = 7.0 Hz 
7.95-8.14, m, 4H 11.87 12.10 14.18 11.56 14.77 
88s 3,4 Di Cl- C6H3 
% yield: 79, mp: 
190-191 ºC , ( 
Ethanol) 
1.28, t, 3H, 
J = 7.0 Hz; 
4.25, q, 2H, 
J = 7.0 Hz 
7.69-7.89, m, 1H; 
7.94, dd, 1H, J = 
8.3, 1.5 Hz; 8.04-
8.24, m, 1H 
11.89 12.12 14.11 11.56 14.62 
88t 3,4 Di F- C6H3 
% yield: 83, mp: 
196-198  ºC , 
(Ethanol) 
1.29, t, 3H, 
J = 7.0 Hz; 
4.26, q, 2H, 
J = 7.0 Hz 
7.47-7.71, m, 1H; 
7.76-8.03, m, 2H 
11.87 12.13 14.04 11.60 14.54 
88u 3 Me, 4Br  C6H3 
% yield: 88, 
mp:189-190 ºC  
( Ethanol) 
1.28, t, 3H, 
J = 7.0 Hz; 
4.24, q, 2H, 
J = 7.0 Hz 
2.42, s, Me;7.60-
7.83, m, 2H; 7.95, 
s, 1H 
11.87 12.13 13.97 11.55 14.49 
88v C6H5CH2S- 
%yield:76, mp: 
141-142 ºC , 
(Ethanol-water) 
1.26, t, 3H, 
J = 7.0 Hz; 
4.22, q, 2H, 
J = 7.0 Hz
 
4.35, s, 2H, 
CH2;7.23-7.45, m, 
5H, Ph 
11.79 11.98 13.85 11.55 14.02 
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1H NMR (300 MHz, DMSO-d6) 
CO2Et Ar 
tautomer A tautomer B 




ºC , (Ethanol) 
1.25, t, 
3H, J = 
7.0 Hz; 
4.22, q, 
2H, J = 
7.0 Hz
 
2.97, t, 2H, 
CH2Ph, J = 7.3 
Hz; 3.34, m, 2H, 
SCH2; 7.19-7.33, 
m, 5H, Ph 
11.81 12.01 13.83 11.56 14.01 
88x C6H5(CH2)3S-





3H, J = 
7.0 Hz; 
4.22, q, 
2H, J = 
7.0 Hz
 
1.95, q, 2H, 
CH2CH2CH2, J = 
7.3 Hz; 2.70, t, 
2H, CH2Ph, J = 
7.5; 3.08, m, 2H, 
SCH2; 7.18, t, 
2H, Ph, J = 7.5 
Hz; 7.20, d, 1H, 
Ph, J = 7.2 Hz; 
7.28, t, 2H, Ph, J 
= 7.3 Hz 
11.81 11.99 13.80 11.41;11.53 14.03 
88y 2-furyl- 
% yield: 80, 
mp: 173 ºC , 
(Ethanol) 
1.27, t, 
3H, J = 
7.0 Hz; 
4.24, q, 





7.98, m, 1H 
11.78 12.01 14.00 11.70 14.50 
88z 2-thiophenyl- 
% yield: 85, 
mp: 182-183 
ºC , (Ethanol) 
1.27, t, 
3H, J = 
7.0 Hz; 
4.24 q, 










% yield: 84, 
mp: 168-170 
ºC , (Ethanol) 
1.26, t, 
3H, J = 
7.0 Hz; 
4.22 q, 




m, 2H; 8.71, d, J 
= 3.7 
11.81 12.09 14.06 11.52 14.76 
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Ethyl 5-amino-3-(pyridine-3-yl)-1H-1,2,4-triazole-1-carboxylate (88zb’) 
 
Yield 40 %; mp 157-159 ºC (ethanol); 
1
H NMR (300 MHz, DMSO-d6), δ 1.38 (t, 3H, 
CH3, J = 7.0 Hz), 4.46 (q, 2H, CH2, J = 7.0 Hz), 7.50-7.57 (m, 3H, Ar-H), 8.27 (d, 






1H NMR (300 MHz, DMSO-d6) 
CO2Et Ar 
tautomer A tautomer B 
NH NH N(1)H 2NH N(1)H 
88zb 3-pyridyl- 
% yield: 50, mp: 262-
264 ºC , (Ethanol) 
1.27, t, 
3H, J = 
7.0 Hz; 
4.24 q, 
2H, J = 
7.0 Hz 
7.45-7.65, m, 
1H; 8.30, d, 
1H, J = 7.9; 
8.59-8.74, 
m,1H; 9.14, 
d, 1H, J = 1.5 






3H, J = 
7.0 Hz; 
4.20, q, 
2H, J = 
6.8 Hz 
5.65, s, CH, 
7.13-7.49, m, 
10H 
11.80 12.11 13.65 11.47 13.90 
88ze H 




3H, J = 
7.1 Hz; 
4.21, q, 
2H, J = 
7.1 Hz 
7.90 & 8.54, 
s, 1H 







Yield 89 %; mp 201ºC (PhMe); 
1
H NMR (300 MHz, DMSO-d6): δ 1.26 (t, 3H, J = 
7.1 Hz, CH3), 2.99 (s, 6H, N(CH3)2), 4.21 (q, 2H, J = 7.1 Hz, CH2), 6.73 (d, 2H, J = 
9.0 Hz, H-3’ & H-5’), 7.76 (d, 2H, J = 9.0 Hz, H-2’ & H-6’), 10.55 (s, 1H, NH), 
11.34 (s, 1H, NH), 11.39 (s, 1H, NH) 




To a stirred solution of NaOH (9 mmol) in ethanol (80%, 20 ml), N-(1,2,4-triazole-
3(5)-yl)-N’-carbethoxythiourea was added and heated on water bath for 20 minutes 
with continuous stirring. After cooling, the solvent was evaporated under vacuum, and 
the residue was suspended in water (25 ml). The resulting suspension was acidified up 
to pH 1-3 using 2.5 M HCl. The precipitated product was filtered off, recrystallized 
with suitable solvent and dried under vacuum. 
2-(Methylthio)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one 
(H5a) 
Yield 64%; mp 263 ºC (Ethanol-water); ESI-MS m/z 214.0 (M-1)
+; purity ˃ 95%;  tR 
2.11 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 2.56 (s, 3H, SMe), 13.03 (s, 1H, 
NH), 14.10 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 13.9 (SMe), 141.0 (C-





Yield 89%; mp 249 ºC  (EtOH-water); ESI-MS m/z 290.1 (M-1)
+; purity ˃ 95%; tR 
14.77 min (C); 
1
H NMR (300 MHz, DMSO-d6): δ 4.40 (s, 2H, SCH2Ph), 7.25-7.35 
(m, 3H, H-3’, H-4’ and H-5’), 7.44 (d, 2H, H-2’ and H-6’, J = 6.8 Hz) 13.03 (s, 1H, 
NH), 14.30 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 35.0 (CH2), 127.9 (C-
4’), 129.0 (C-2’and C-6’), 129.4 (C-3’ and C-5’), 137.5 (C-1’), 141.0 (C-2), 151.9 (C-
9), 164.0 (C-7), 175.7 (C-5). 
2-(Phenethylthio)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-
one (H5aii) 
Yield 94%; mp 232-234ºC (EtOH-water); ESI-MS m/z 304.1 (M-1)
+; purity ˃ 95%; tR 
2.18 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 3.01 (t, 2H, CH2Ph, J = 7.3 Hz), 
3.37 (t, 2H, SCH2, J = 7.3 Hz), 7.21-7.34 (m, 5H, Ph), 13.03 (s, 1H, NH), 14.21 (br. s, 
1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 32.5 (SCH2), 35.3 (PhCH2), 126.9 (C-
4’), 128.9 (C-2’and C-6’), 129.1 (C-3’ and C-5’), 140.3 (C-1’), 141.0 (C-2), 151.8 (C-
9), 164.2 (C-7), 175.6 (C-5). 
2-((3-Phenylpropyl)thio)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H5aiii) 
Yield 69%; mp 220-221 ºC (EtOH-water); ESI-MS m/z 318.2 (M-1)
+; purity ˃ 95%; 
tR 18.57 min (C); 
1
H NMR (300 MHz, DMSO-d6): δ 2.01 (q, 2H, CH2CH2CH2, J = 
7.3 Hz), 2.72 (t, 2H, CH2Ph, J = 7.7 Hz), 3.12(t, 2H, SCH2, J = 7.2 Hz), 13.01 (s, 1H, 
NH), 14.12 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 30.7 (CH2CH2CH2), 
203 
 
30.9 (SCH2), 34.4 (PhCH2), 126.4 (C-4’), 128.8 (C-2’and C-6’), 128.9 (C-3’ and C-
5’), 141.0 (C-1’), 141.5 (C-2), 151.8 (C-9), 164.2 (C-7), 175.6 (C-5). 
2-Phenyl-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one 
(H5b) 
Yield 78%; mp 258-259 ºC (EtOH); ESI-MS m/z 244.1 (M-1)
+; purity ˃ 95%; tR 2.16 
min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.53-7.55 (m, 3H, H-3’, H-4’ and H-5’), 
8.04-8.07 (m, 2H, H-2’ and H-6’), 13.12 (s, 1H, NH), 14.31 (br. s, 1H, NH); 13C 
NMR (75 MHz, DMSO-d6): δ 127.1 (C-2’ and C-6’), 129.5 (C-3’ and C-5’), 129.7 
(C-4’), 131.3 (C-1’), 141.7 (C-2), 151.9 (C-9), 162.4 (C-7), 175.8 (C-5). 
2-(3-Nitrophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-
one (H5bi) 
Yield 80%; mp 246-248 ºC (acetic acid), ESI-MS m/z 289.1 (M-1)
+; purity ˃ 95%; tR 
13.15 min (C); 
1
H NMR (300 MHz, DMSO-d6): δ 7.86 ( t, 1H, H-5’, J = 8.1 Hz,), 
8.39 (dd, 1H, H-4’, J = 8.1, 1.3  Hz), 8.47 (d, 1H, H-6’, J = 7.5 Hz), 8.74 (s, 1H, H-
2’), 13.19 (s,1H, NH), 14.51 (br. s, 1H, NH); 13C NMR (75 MHz, DMSO-d6): δ 120.9 
(C-2’), 125.2 (C-4’), 130.6 (C-5’), 130.9 (C-6’), 132.4 (C-1’), 141.0 (C-3’), 148.1 (C-
2), 151.7 (C-9), 160.0 (C-7), 175.3 (C-5). 
5-Thioxo-2-(3-(trifluoromethyl)phenyl)-5,6-dihydro-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7(4H)-one (H5bii) 
Yield 81%; mp 268-270 ºC (EtOH-water); ESI-MS m/z 312.1 (M-1)
+; purity ˃ 95%; 
tR 2.15 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.81 (t, 1H, H-5’, J = 7.7 Hz), 
7.93 (d, 1H, H-4’, J = 7.9 Hz), 8.27 (s, 1H, H-2’), 8.35 (d, 1H, H-6’, J = 7.5 Hz), 
13.18 (s,1H, NH), 14.40 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 122.6 (q, 
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CF3, J = 4.1 Hz), 123.8 (q, C-2’, J = 272.5 Hz), 127.2 (q, C-4’, J = 3.4 Hz), 129.7 (q, 
C-5’, J = 32.0 Hz), 130.2 (C-6’), 130.3 (C-3’), 130.5 (C-1’), 141.1 (C-2), 151.6 (C-9), 
160.5 (C-7), 175.3 (C-5). 
2-(3-Chlorophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H5biii) 
Yield 65%; mp 266-267ºC (acetic acid); ESI-MS m/z 278.0 (M-1)
+; purity ˃ 95%; tR 
14.63 min (C); 
1
H NMR (300 MHz, DMSO-d6): δ 7.55-7.63 (m, 2H, H-4’and H-5’), 
8.00-8.02 (m, 2H, H-2’ and H-6’), 13.16 (s, 1H, NH), 14.26 (br. s, 1H, NH); 13C 
NMR (75 MHz, DMSO-d6): δ 125.7 (C-6’), 126.6 (C-2’), 131.1 (C-5’) 131.6 (C-4’), 
134.2 (C-3’), 141.6 (C-1’), 141.6 (C-2), 152.0 (C-9), 161.2 (C-7), 175.8 (C-5). 
2-(3-Bromophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H5biv) 
Yield 75%; mp 262-264 ºC (acetic acid), ESI-MS m/z 324.0 (M-1)
+; purity ˃ 95%; tR 
2.19 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.52 (t, 1H, H-5’, J = 7.9 Hz), 7.74 
(d, 1H, H-4’, J = 7.9 Hz), 8.05 (d, 1H, H-6’, J = 7.9 Hz), 8.14 (s, 1H, H-2’), 13.18 
(s,1H, NH), 14.22 (br.s,1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 122.6 (C-3’), 
126.0 (C-6’), 129.4 (C-2’) 131.9 (C-5’), 131.9 (C-4’), 133.9 (C-1’), 141.6 (C-2), 
152.0 (C-9), 161.0 (C-7), 175.8 (C-5). 
2-(3-Fluorophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H5bv) 
Yield 72%; mp 283-285 ºC (acetic acid); ESI-MS m/z 262.3 (M-1)
+; purity ˃ 95%; tR 
2.15 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.39 (td, 1H, H-5’, J = 8.5, 2.3 Hz), 
7.60 (dd, 1H, H-4’, J =  7.9, 13.9 Hz), 7.75 (d, 1H, H-2’, J =  9.8 Hz), 7.90 (d, 1H, H-
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6’, J = 7.9 Hz), 13.13 (s,1H, NH), 14.33 (br. s, 1H, NH); 13C NMR (75 MHz, DMSO-
d6): δ 13C NMR (75 MHz, DMSO-d6): δ 114.1 (d, C-2’, J = 23.3 Hz), 118.7 (d, C-4’, 
J = 21.1 Hz), 122.7 (d, C-6’, J = 1.5 Hz), 131.3 (d, C-5’, J = 8.0 Hz), 131.5 (d, C-1’, J 
= 8.0 Hz), 141.1 (C-9), 151.5 (C-7), 160.7 (d, C-2, J = 2.9 Hz), 162.2 (d, C-3’, J = 
244.1 Hz), 175.3 (C-5).  
2-(3-Methylphenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H5bvi) 
Yield 80%; mp 259-261ºC (EtOH-water); ESI-MS m/z 258.1 (M-1)
+; purity ˃ 95%; tR 
2.17 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 2.40 ( s, 3H, Me), 7.34 (d, 1H, H-4’, 
J = 7.5 Hz), 7.42 (t, 1H, H-5’, J = 7.5 Hz), 7.84 (d, 1H,  H-6’, J = 7.9 Hz), 7.88 (s, 
1H, H-2’), 13.09 (s,1H, NH), 14.24 (br. s, 1H, NH); 13C NMR (75 MHz, DMSO-d6): 
δ 20.9 (Me), 123.7 (C-6’), 127.0 (C-2’), 128.8 (C-5’), 129.0 (C-4’), 131.3 (C-1’), 
138.2 (C-3’), 141.2 (C-2), 151.3 (C-9), 161.9 (C-7), 175.2 (C-5). 
2-(3-Methoxyphenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H5bvii) 
Yield 90%; mp 260 ºC (acetic acid), ESI-MS m/z 274.1 (M-1)
+
; purity ˃ 95%; tR 2.15 
min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 276.6. 3.84 (s, 3H, OMe), 7.11 (dd, 1H, 
H-4’, J = 8.1, 2.1 Hz), 7.45 (t, 1H, H-5’, J = 7.9 Hz), 7.54 (s, 1H, H-2’), 7.64 (d, 1H, 
H-6’, J = 7.5 Hz), 13.10 (s,1H, NH), 14.32 (br. s, 1H, NH); 13C NMR (75 MHz, 
DMSO-d6): δ 55.1 (OMe), 111.2 (C-2’), 116.6 (C-4’), 118.9 (C-6’), 130.1 (C-5’), 






Yield 67 %; mp ˃300 ºC (acetic acid); ESI-MS m/z 287.0 (M-1)+; purity ˃ 94%; tR 
3.84 min (D); 
1
H NMR (300 MHz, DMSO-d6): δ 7.48-8.57 (m, 4H, Ar-H), 13.10 
(s,1H, NH), 14.38 (br. s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 126.5 (C-3’), 
129.7 (CN), 129.8 (C-2’), 130.0 (C-5’), 130.1 (C-1’), 135.6 (C-6’), 141.9 (C-4’), 
152.2 (C-2), 162.1 (C-9), 168.1 (C-7), 176.0 (C-5). 
2-(4-Nitrophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-
one (H5bix) 
Yield 65%; mp > 300 ºC (basification followed by acidification); ESI-MS m/z 289.1 
(M-1)
+; purity ˃ 95%; tR 2.13 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 8.29 (d, 
2H, H-3’ and H-5’ J = 8.7 Hz), 8.39 (d, 2H, H-2’ and H-6’ J = 9.0 Hz), 13.21 (s, 1H, 
NH), 14.28 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 124.3 (C2’ and C-6’), 
127.7 (C-3’and C-5’), 135.0 (C-4’), 141.1 (C-1’), 148.5 (C-2), 151.7 (C-9), 160.1 (C-
7), 175.3 (C-5). 
5-Thioxo-2-(4-(trifluoromethyl)phenyl)-5,6-dihydro-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7(4H)-one (H5bx) 
Yield 69%; mp 280 ºC (EtOH-water); ESI-MS m/z 312.0 (M-1)
+; purity ˃ 95%; tR 
2.15 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.91 (d, 2H, H-3’ and H-5’, J = 8.3), 
8.26 (d, 2H, H-2’ and H-6’, J = 8.3), 13.18 (s, 1H, NH), 14.36 (br. s, 1H, NH); 13C 
NMR (75 MHz, DMSO-d6): δ 123.9 (q, CF3, J = 272.2 Hz), 125.9 (q, C-3’ and C-5’, 
J = 3.4 Hz), 127.3 (C-2’ and C-6’), 130.5 (q, C-4’, J = 32.0 Hz), 133.0 (C-1’), 141.1 





Yield 66%; mp 281-282 
º
C (EtOH-water); ESI-MS m/z 278.0 (M-1)
+; purity ˃ 95%; 
tR 2.18 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.61 (d, 2H, H-3’ and H-5’, J = 
8.3), 8.05 (d, 2H, H-2’ and H-6’, J = 8.3), 13.14 (s, 1H, NH), 14.31 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 128.01 (C-4’) 128.26 (C2’ and C-6’), 129.08 (C-3’ 
and C-5’), 135.32 (C-1’), 141.08 (C-2), 151.46 (C-9), 160.89 (C-7), 175.22 (C-5). 
2-(4-Bromophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H5bxii) 
Yield 73%; mp 292-293 ºC (acetic acid); ESI-MS m/z 324.0 (M-1)
+; purity ˃ 95%; tR 
2.21 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.75 (d, 2H, H-3’ and H-5’ J = 8.3), 
7.98 (d, 2H, H-2’ and H-6’ J = 8.3), 13.13 (s, 1H, NH), 14.35 (br. s, 1H, NH). 13C 
NMR (75 MHz, DMSO-d6): δ 124.8 (C-4’), 128.9 (C-1’), 129.1 (C2’ and C-6’), 
132.6 (C-3’and C-5’), 141.7 (C-2), 152.0 (C-9), 161.6 (C-7), 175.8 (C-5). 
2-(4-Fluorophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H5bxiii) 
Yield 67%; mp 262 ºC (EtOH-water); ESI-MS m/z 262.3 (M-1)
+; purity ˃ 95%; tR 
2.13 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.37 (dd, 2H, H-3’ and H-5’ J = 8.9, 
8.9 Hz), 8.09 (dd, 2H, H-2’ and H-6’ J = 8.7, 5.7 Hz), 13.12 (s, 1H, NH), 14.20 (br. s, 
1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 116.0 (d, C-3’ and C-5’, J = 21.8 Hz), 
125.7 (d, C-1’, J = 2.9 Hz), 128.9 (d, C-2’ and C-6’, J = 8.7 Hz), 141.1 (C-2), 151.4 





Yield 78%; mp 296-297 ºC (EtOH-water);  ESI-MS m/z 258.1 (M-1)
+; purity ˃ 95%; 
tR 2.19 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 2.38 (s, 3H, ArMe), 7.34 (d, 2H, 
H-3’ and H-5’ J = 7.9), 7.94 (d, 2H, H-2’ and H-6’ J = 7.9), 13.07 (s, 1H, NH), 14.26 
(br. s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 20.95 (Me), 126.38 (C-4’) 126.46 
(C2’ and C-6’), 129.45 (C-3’and C-5’), 140.44 (C-1’), 141.11 (C-2), 151.22 (C-9), 
161.86 (C-7), 175.14 (C-5). 
2-(4-Methoxyphenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H5bxv) 
Yield 63%; mp 270-271 
º
C (acetic acid); ESI-MS m/z 288.1(M-1)
+; purity ˃ 95%; tR 
2.15 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 3.84 (s, 3H, OMe), 7.08 (d, 2H, H-
3’ and H-5’ J = 8.7 Hz), 7.99 (d, 2H, H-2’ and H-6’ J = 9.0 Hz), 13.07 (s, 1H, NH), 
14.11 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 55.25 (MeO), 114.29 (C2’ 
and C-6’), 121.52 (C-4’), 128.17 (C-3’and C-5’), 141.13 (C-1’), 151.20 (C-2), 161.12 
(C-9), 161.75 (C-7), 175.12 (C-5). 
4-(7-Oxo-5-thioxo-4,5,6,7-tetrahydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-
yl)benzonitrile (H5bxvi) 
Yield 69%; mp ˃ 300 ºC (EtOH-water); ESI-MS m/z 287.0 (M-1)+; purity ˃ 88%; tR 
3.73 min (D); 
1
H NMR (300 MHz, DMSO-d6): δ 8.02 (d, 2H, H-3’ and H-5’, J = 8.4 
Hz), 8.12 (d, 2H, H-2’ and H-6’, J = 8.4 Hz), 13.11 (s, 1H, NH), 14.44 (br. s, 1H, 
NH); 
13
C NMR (75 MHz, DMSO-d6): δ 126.3 (C-3’ and C-5’), 128.1 (C-2’and C-6’), 
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Yield 74%; mp 271-273 ºC (acetic acid); ESI-MS m/z 314.0 (M-1)
+; purity ˃ 95%; tR 
2.23 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.82 (d, 1H, H-6’, J = 8.3 Hz), 8.01 
(dd, 1H, H-5’, J = 8.3 Hz, J = 1.9 Hz,), 8.16 (d, 1H, H-2’, J = 1.9 Hz), 13.17 (s, 1H, 
NH), 14.35 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 127.1 (C-6’), 128.5 
(C-2’), 130.3 (C-5’) 132.0 (C-4’), 132.4 (C-3’), 133.9 (C-1’), 141.6 (C-2), 152.2 (C-
9), 160.4 (C-7), 175.9 (C-5). 
2-(3,4-Difluorophenyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H5bxviii) 
Yield 68%; mp 267-269 ºC (acetic acid); ESI-MS m/z 280.3 (M-1)
+; purity ˃ 95%; tR 
2.16 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.57-7.66 (m, 1H, H-5’), 7.89-8.00 
(m, 1H, H-2’ and H-6’), 13.17 (s, 1H, NH), 14.40(br. s, 1H, NH); 13C NMR (75 MHz, 
DMSO-d6): δ 115.5 (d, C-3’, J = 18.9 Hz), 118.4 (d, C-5’, J = 17.4 Hz), 123.8 (dd, C-
6’, J = 6.9, 3.3 Hz), 126.7 (dd, C-1’, J = 6.5, 3.6 Hz), 141.1 (C-2), 149.6 (dd, C-4’, J = 




Yield 77%; mp 278-280 ºC (acetic acid); ESI-MS m/z 338.0 (M-1)
+; purity ˃ 95%; tR 
6.1 min (D); 
1
H NMR (300 MHz, DMSO-d6): δ 2.44 (s, 3H, Me), 7.72-7.79 (m, 2H, 
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H-5’ and H-6’), 8.00 (s, 1H, H-2’), 13.13 (s, 1H, NH), 14.30 (br. s, 1H, NH); 13C 
NMR (75 MHz, DMSO-d6): δ 22.9 (Me), 126.4 (C-4’), 127.2 (C-6’), 129.2 (C-2’) 




Yield 62%; mp 292-294 ºC (EtOH-water); ESI-MS m/z 234.1 (M-1)
+; purity ˃ 95%; 
tR 3.95 min (D); 
1
H NMR (300 MHz, DMSO-d6): δ 6.62-6.74 (m, 1H, H-4’), 7.12 (d, 
1H, J = 3.0, H-3’), 7.83-7.96 (m, 1H, H-5’), 13.13 (s, 1H, NH), 14.17 (br. s, 1H, 
NH);
13
C NMR (75 MHz, DMSO-d6): δ 112.7 (C-4’), 113.2 (C-3’), 141.7 (C-5’), 
145.1 (C-2’), 146.1 (C-2), 151.8 (C-9), 155.5 (C-7), 175.9 (C-5). 
2-(Thiophen-2-yl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-
one (H5d) 
Yield 64%; mp 273ºC (EtOH-water); ESI-MS m/z 250.0 (M-1)
+; purity ˃ 95%; tR 
2.13 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 7.22 (dd, 1H, H-4’, J = 4.1, 4.1 Hz), 
7.74 (d, 1H, H-3’ J = 3.4), 7.78 (d, 1H, H-5’ J = 4.9 Hz), 13.11 (s, 1H, NH), 14.22 (br. 
s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 128.3 (C-4’), 128.4 (C-5’), 129.5 (C-
3’), 131.7 (C-2’), 141.0 (C-2), 151.2 (C-9), 158.1 (C-7), 175.2 (C-5). 
2-(Pyridin-2-yl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-
one (H5e) 
Yield 63%; mp 280-282 ºC (EtOH-water); ESI-MS m/z 245.4 (M-1)
+; purity ˃ 95%; 
tR 2.16 min (B);   
1
H NMR (300 MHz, DMSO-d6): δ 7.54-7.57 (m, 1H, H-5’), 7.98-
8.02 (m, 1H, H-3’), 8.11-8.13 (m, 1H, H-4’), 8.74- 8.75 (m, 1H, H-6’), 13.17 (s, 1H, 
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NH), 14.93 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6), δ, 123.2 (C-4’) 125.8 
(C-6’), 138.0 (C-5’), 141.8 (C-3’), 148.4 (C-1’), 150.4 (C-2), 152.0 (C-9), 162.1 (C-
7), 176.0 (C-5). 
5-Thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one (H5f) 
Yield 54%; mp > 300ºC (EtOH); ESI-MS m/z 168.1 (M-1)
+; purity ˃ 95%; tR 2.11 
min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 8.17 (s, 1H, CH), 13.05 (s, 1H, NH), 
14.05 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 141.9 (C-2), 151.5 (C-9), 
153.6 (C-7), 176.0 (C-5). 
2-([1,1’-Diphenyl]-4-ylmethyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7(4H)-one (H5f) 
Yield 63 %; mp 210-212 °C (EtOH-water); ESI-MS m/z 334.1 (M-1)
+; purity ˃ 95%; 
tR 1.69 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 5.62 (s, 2H, PhCH2), 7.21-7.41 
(m, 9H, Ar-H), 12.96 (s, 1H, NH), 13.78 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-
d6): δ 50.5 (CH2), 127.2 (C-3’ and C-5’), 128.8 (C-2’’, C-4’’and C-6’’), 128.9 (C-3’’ 
and C-5’’), 129.3 (C-1’, C-4’ and C-1’’), 141.5 (C-2’ and C-6’) 141.7 (C-2), 151.6 
(C-9), 166.8 (C-7), 175.8 (C-5). 




To a stirred solution of 2-substituted-5-thioxo-5,6-dihydro-4H-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7-one (5 mmol) in  4 ml of 2.5 M NaOH, iodomethane ( 933 µl, 7.5 
mmol) was added, the stirring was continued for 30 minutes. A solid precipitate was 
observed which upon acidification (pH 1-3) with 2.5 M HCl afforded another solid. 
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The precipitated solid was filtered, washed with ice cold water and recrystallized from 
water-ethanol system.  
2,5-Bis(methylthio)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(6H)-one (H6a) 
Yield 54%; mp 241-243ºC (Ethanol-water); ESI-MS m/z 228.0 (M-1)
+; purity ˃ 95%; 
tR 4.28 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 2.57 (s, 3H, SMe), 2.58 (s, 3H, 
SMe), 13.41 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 13.2 (SMe), 13.2 
(SMe), 142.4 (C-2), 157.3 (C-9), 165.0 (C-5), 165.1 (C-7). 
5-(Methylthio)-2-phenyl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(6H)-one (H6b) 
Yield 58%; mp 292-294ºC (Ethanol-water); ESI-MS m/z 258.0 (M-1)
+; purity ˃ 95%; 
tR 4.67 min (D); 
1
H NMR (300 MHz, DMSO-d6): δ 2.62 (s, 3H, SMe), 7.54-7.55 (m, 
3H, H-3’, H-4’ and H-5’), 13.15 (br. s, 1H, NH); 13C NMR (75 MHz, DMSO-d6): δ 
13.9 (SMe), 127.1 (C-2’ and C-6’), 129.4 (C-3’and C-5’), 130.4 (C-4’), 131.0 (C-1’), 
143.8 (C-2), 157.9 (C-9), 163.1 (C-5), 165.3 (C-7). 
 General procedure for the synthesis of 2-substituted-7-thioxo-6,7-dihydro-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one (H3a-H3b) 
In a suspension of 3(5)-amino-5(3)-(het)aryl-1,2,4-triazoles (3 mmol) in dry acetone 
(15 ml), ethoxycarbonyl isothiocyanate (3.3 mmol) was then added. The reaction 
mixture was allowed to stir at room temperature for 20 minutes and after that, the 
precipitated product was filtered off, washed with acetone and dried under vacuum. 
The obtained 3-substituted-5-amino-1-carbethoxylthiocarbamoyl-1,2,4-triazole was 
heated on water bath for 20 minutes after dissolving it in alkaline solution of ethanol 
(80%). After cooling, the solvent was evaporated under vacuum, and the residue was 
dissolved in water (25 ml). The resulting suspension was acidified up to pH 1-3 using 
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2.5 M HCl. The precipitated product was filtered off, recrystallized with suitable 
solvent and dried under vacuum.  
2-(Methylthio)-7-thioxo-6,7-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one 
(H3a) 
Yield 72%; mp 254-256 ºC (EtOH-water); ESI-MS m/z 214.1 (M-1)
+; purity ˃ 95%; 
tR 2.14 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 2.57 (s, 3H, SMe), 13.03 (s, 1H, 
NH); 
13
C NMR (75 MHz, DMSO-d6): δ 13.9 (SMe), 146.6 (C-2), 149.9 (C-9), 
165.9(C-5), 169.6 (C-7). 
2-Phenyl-7-thioxo-6,7-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one 
(H3b) 
Yield 59 %, mp 285-287 ºC (EtOH-water), ESI-MS m/z 244.4 (M-1)
+; purity ˃ 95%; 
tR 12.11 min (C); 
1
H NMR (300 MHz, DMSO-d6): δ 7.53-7.55 (m, 3H, H-3’, H-4’ 
and H-5’), 8.04-8.06 (m, 2H, H-2’ and H-6’), 13.12 (s, 1H, NH); 13C NMR (75 MHz, 
DMSO-d6): δ 127.2 (C-2’ and C-6’), 129.5 (C-3’and C-5’), 129.7 (C-4’), 131.3 (C-
1’), 146.7 (C-2), 150.1 (C-9), 162.9 (C-5), 170.8 (C-7). 
 General procedure for the synthesis of 7-(methylthio)-2-substituted-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one (H4a-H4b) 
To a stirred solution of 2-substituted-5-thioxo-5,6-dihydro-4H- [1,2,4]triazole[1,5-
a][1,3,5]triazin-7-one (5 mmol) in  4 ml of 2.5 M NaOH, iodomethane ( 933 µl, 7.5 
mmol) was added, the stirring was continued for 30 min. A solid precipitate was 
observed which upon acidification (pH 1-3) with 2.5 M HCl afforded another solid. 
The precipitated solid was filtered, washed with ice cold water and recrystallized from 




Yield 67 %; mp 274-276 ºC (EtOH-water); ESI-MS m/z 228.3 (M-1)
+; purity ˃ 95%; 
tR 2.38 min; 
1
H NMR (300 MHz, DMSO-d6): δ 2.57 (two s, 6H, 2SMe), 12.98 (s, 1H, 
NH); 
13
C NMR (75 MHz, DMSO-d6): δ 12.7 (SMe), 13.3 (SMe), 151.1 (C-2), 152.1 
(C-9), 161.6(C-5), 165.5 (C-7).  
7-(Methylthio)-2-phenyl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5(4H)-one (H4b) 
Yield 61 %; mp 300-301 ºC (EtOH-water); ESI-MS m/z 258.3(M-1)
+; purity ˃ 95%; 
tR 14.40 min (C); 
1
H NMR (300 MHz, DMSO-d6): δ 2.61 (s, 3H, SMe), 7.53-7.55 (m, 
3H, H-3’, H-4’ and H-5’), 8.04-8.06 (m, 2H, H-2’ and H-6’), 13.06 (s, 1H, NH); 13C 
NMR (75 MHz, DMSO-d6): δ 11.8 (SMe), 125.6 (C-2’ and C-6’), 127.9 (C-3’and C-
5’), 127.9 (C-4’), 129.82 (C-1’), 150.2 (C-2), 151.1 (C-9), 161.2 (C-5), 161.6 (C-7). 
 General procedure for the synthesis of 2-substituted-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-5,7(4H,6H)-dione (H2a-H2b) 
7-Methylsulfanyl- 2-substituted-4H-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-one (5 
mmol) was suspended in aqueous NaOH (15 mmol) solution. To it, hydrogen 
peroxide (10 mmol) was added and allowed the reaction mixture to stir at 60-70 
º
C for 
4 hours. The reaction mixture was acidified (pH 1-3) using 2.5 M HCl. The solid 
afforded was collected by filtration, washed well with cold water, and recrystallized 
by aqueous ethanol. 
2-(Methylthio)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5,7(4H,6H)-dione (H2a) 
Yield 68 %; mp 284-286 ºC (EtOH-water); ESI-MS m/z 198.1 (M-1)
+; purity ˃ 95%; 
tR 2.20 min; 
1
H NMR (300 MHz, DMSO-d6): δ 2.54 (s, 3H, SMe), 11.82 (s, 1H, NH), 
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12.82 (s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 13.3 (SMe), 142.6 (C-2), 148.6 
(C-9), 151.9 (C-5), 163.9 (C-7). 
 2-Phenyl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5,7(4H,6H)-dione (H2b) 
Yield 54%; mp 318-319 ºC (EtOH-water), ESI-MS m/z 228.2 (M-1)
+; purity ˃ 95%; 
tR 2.31 min; 
1
H NMR (300 MHz, DMSO-d6): δ 7.52-7.54 (m, 3H, H-3’, H-4’ and H-
5’), 8.03-8.05 (m, 2H, H-2’ and H-6’), 11.94 (s, 1H, NH), 12.90 (s, 1H, NH); 13C 
NMR (75 MHz, DMSO-d6): δ 127.0 (C-2’ and C-6’), 129.4 (C-3’and C-5’), 130.0 (C-
4’), 131.0 (C-1’), 143.9 (C-2), 149.3 (C-9), 152.5 (C-5), 162.2 (C-7). 
9.1.4 General procedure for the synthesis 2-benzyl-5-thioxo-5,6-
dihydro[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one and its derivatives (H7, H8 
and H9) 
 General procedure for synthesis of benzyl-1H-1,2,4-triazol-5-amine and its 
derivatives (91) 
A mixture of aryl acetic acid or aryl acetyl chloride (10 mmol) and aminoguanidine 
HCl (20 mmol) were heated in an oil bath for 20 minutes at 180-185 ºC. After 
cooling, water (25 ml) was added with continuous stirring to make a homogeneous 
suspension.  To it, 2 ml 5M NaOH was added to basify the suspension. The 
precipitated products ((het)arylamidoguanidines) was filtered, washed with water and 
dried. The (het)arylamidoguanidines (5 mmol) were treated with microwave 
irradiation power (100W) for 5 to 8 minutes in water. After cooling, the precipitated 




 Synthesis of benzyl triazole and their 
1
H NMR spectral data (* signals of the 
minor tautomeric form 3-amino-1,2,4-triazoles). 
 
3-Benzyl-1H-1,2,4-triazole-5-amine (91a) 
Yield 65 %; mp 155-156 ºC (water); 
1
H NMR (300 MHz, DMSO-d6): δ 3.72 (s, 2H, 
CH2), 5.08* and 5.85 (two s, 2H, NH2), 7.17-7.26 (m, 5H, Ph), 11.68 and 12.52* (two 
s, 1H, NH). 
3-(4-(Trifluoromethyl)benzyl-1H-1,2,4-triazole-5-amine (91b) 
Yield 72 %; mp 168-170 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): δ 3.86 
(s, 2H, CH2), 5.16* and 5.88 (two s, 2H, NH2), 7.48 (d, 2H, H-3’ and H-5’, J = 8.0 
Hz), 7.63 (d, 2H, H-2’ and H-6’, J =8.0 Hz),, 11.74 and 12.55* (two s, 1H, NH). 
3-(4-Chlorobenzyl)-1H-1,2,4-triazole-5-amine (91c) 
Yield 78 %; mp 170 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): δ 3.73 (s, 
2H, CH2), 5.09* and 5.84 (two s, 2H, NH2), 7.27 (d, 2H, H-3’ and H-5’, J = 8.4 Hz), 
7.32 (d, 2H, H-2’ and H-6’, J =8.1 Hz), 11.68 and 12.48* (two s, 1H, NH). 
3-(4-Bromobenzyl)-1H-1,2,4-triazole-5-amine (91d) 
Yield 72 %; mp 176-177 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): δ 3.72 
(s, 2H, CH2), 5.11* and 5.83 (two s, 2H, NH2), 7.21 (d, 2H, H-3’ and H-5’, J = 8.0 





Yield 68 %; mp 157-159 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): δ 3.72 
(s, 2H, CH2), 5.10* and 5.87 (two s, 2H, NH2), 7.03-7.16 (m, 2H, H-3’ and H-5’), 
7.23-7.33 (m, 2H, H-2’ and H-6’), 11.70 and 12.51* (two s, 1H, NH). 
3-(4-Methylbenzyl)-1H-1,2,4-triazole-5-amine (91f) 
Yield 81 %; mp 181-183 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): δ 2.24 
(s, 3H, Me), 3.66 (s, 2H, CH2), 5.05* and 5.82 (two s, 2H, NH2), 7.06 (d, 2H, H-3’ 
and H-5’, J = 7.2 Hz), 7.13 (d, 2H, H-2’ and H-6’, J = 8.0 Hz), 11.64 and 12.46* (two 
s, 1H, NH). 
3-(4-Methoxybenzyl)-1H-1,2,4-triazole-5-amine (91g) 
Yield 83 %; mp 170-172 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): δ 3.68 
(s, 2H, CH2), 3.70 (s, 3H, MeO), 5.11* and 5.81 (two s, 2H, NH2), 6.83 (d, 2H, H-3’ 
and H-5’, J = 8.5 Hz), 7.15 (d, 2H, H-2’ and H-6’, J = 8.8 Hz), 11.64 and 12.43* (two 
s, 1H, NH). 
3-(4-Hydroxybenzyl)-1H-1,2,4-triazole-5-amine (91h) 
Yield 68 %; mp 205-207 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): δ 3.57 
(s, 2H, CH2), 5.10* and 5.76 (two s, 2H, NH2), 6.64 (d, 2H, H-3’ and H-5’, J = 7.8 
Hz), 7.02 (d, 2H, H-2’ and H-6’, J =8.4 Hz), 9.13 (s, 1H, OH) 11.57 and 12.53* (two 






Yield 66 %; mp 212-213 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): δ 3.86 
(s, 2H, CH2), 5.25* and 5.89 (two s, 2H, NH2), 7.46 (d, 2H, H-3’ and H-5’, J = 8.5 
Hz), 7.74 (d, 2H, H-2’ and H-6’, J = 8.3 Hz),, 11.76 and 12.54* (two s, 1H, NH). 
3-(3,4-Dichlorobenzyl)-1H-1,2,4-triazole-5-amine (91j) 
Yield 67 %; mp 212-214 ºC (water-ethanol); 
1
H NMR (300 MHz, DMSO-d6): δ 3.77 
(s, 2H, CH2), 5.14* and 5.90 (two s, 2H, NH2), 7.24-7.27 (m, 1H, H-6’), 7.52-7.54 (m, 
2H, H-2’ and H-5’), 11.74 and 12.51* (two s, 1H, NH). 
 General procedure for synthesis of N-(3(5)-substituted-benzyl-1,2,4-triazol-
5(3)-yl)-N’-carbethoxythioureas/carbethoxyurea (93, 92)  
In a well stirred suspension of 3-benzyl-1H-1,2,4-triazole-5-amine and its derivatives 
(3 mmole) in anhydrous dimethylformamide (DMF, 4 ml), ethoxycarbonyl 
isothiocyanete (3.3 mmole) or ethoxycarbonyl isocyanate (3.3 mmole) was added and 
stirred the reaction mixture for 4.5-5 hours at room temperature. Following this step, 
50-60 ml water was added to get more precipitated product. The product was filtered 
and washed with cold water. The products obtained were recrystallized from ethanol 





Table 22. Synthesis of N-(3(5)-substituted-benzyl-1,2,4-triazol-5(3)-yl)-N’-
carbethoxythioureas/carbethoxyurea and their 
1










H NMR (400 MHz, DMSO-d6) 
CO2Et CH2 Ar 
tautomer A tautomer B 





1.24, t, 3H, J 
= 7.0 Hz; 
4.20, q, 2H, 










1.25, t, 3H, J 
= 7.0 Hz; 
4.21, q, 2H, 












1.25, t, 3H, J 
= 6.9 Hz; 
4.20, q, 2H, 
J = 6.9 Hz
 
4.08 7.31, d, J = 
8.4 Hz,  2H; 
7.39,  d, J = 
7.7 Hz, 2H 






1.25, t, 3H, J 
= 7.0 Hz; 
4.20, q, 2H, 
J = 7.0 Hz
 
4.06 7.25, d, J = 
8.3 Hz,  2H; 
7.51,  d, J = 
7.9 Hz, 2H 






1.25, t, 3H, J 
= 7.0 Hz; 
4.20, q, 2H, 
J = 6.8 Hz
 
4.08 7.06-7.39, 
m, 4H  






1.24, t, 3H, J 
= 7.0 Hz; 
4.19, q, 2H, 
J = 6.8 Hz
 
4.01 2.26, s, 3H, 
Me; 7.11-
7.17, m, 4H 
11.78 12.04 13.49 11.42 13.75 
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Table 22. Synthesis of N-(3(5)-substituted-benzyl-1,2,4-triazol-5(3)-yl)-N’-
carbethoxythioureas/carbethoxyurea and their  
1










1H NMR (400 MHz, DMSO-d6) 
CO2Et CH2 Ar 
tautomer A tautomer B 







3H, J = 
7.0 Hz; 
4.20, q, 
2H, J = 
6.9 Hz
 
4.01 3.72, s, 3H, 
MeO; 6.88, 
d, 2H, J = 
8.4 Hz; 
7.20, d, 2H, 
J = 8.6 Hz 







3H, J = 
7.0 Hz; 
4.20, q, 
2H, J = 
6.9 Hz
 
3.93 9.30, s, 1H, 
OH; 6.70, d, 
2H, J = 8.3 
Hz; 7.06, d, 
2H, J = 8.4 
Hz 







3H, J = 
7.0 Hz; 
4.20, q, 
2H, J = 
7.0 Hz
 
4.15 7.50, d, 2H, 
J = 8.3 Hz; 
7.80, d, 2H, 
J = 7.9 Hz 
11.76 12.04 13.62 11.46 13.85 






3H, J = 
7.0 Hz; 
4.20, q, 
















3H, J = 
7.0 Hz; 
4.17, q, 









13.13 9.95 13.55 
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 General procedure for synthesis of 2-benzyl-7-thioxo-6,7-dihydro-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one and its derivatives (H8-H8i) and 
2-benzyl-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5,7(4H,6H)-dione (H7) 
To a stirred solution of NaOH (9 mmol) in ethanol (80%, 20 ml), corresponding 
carbethoxyurea or carbethoxythiourea (3 mmol) was added and heated on water bath 
for 20 minutes with continuous stirring. After cooling, the solvent was evaporated 
under vacuum, and the residue was suspended in water (25 ml). The resulting 
suspension was acidified up to pH 1-3 using 2.5 M HCl. The precipitated product was 
filtered off, recrystallized with suitable solvent and dried under vacuum. 
2-Benzyl-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(4H)-one (H8) 
Yield 55 %; mp 246 °C (EtOH-water); ESI-MS m/z 242.3(M-1)
+; purity ˃ 95%; tR 
1.68 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.01(s, 2H, PhCH2), 7.23-7.29 (m, 
5H, Ph), 12.99 (s, 1H, NH), 14.10 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 
34.7 (CH2), 127.1 (C-4’), 128.9 (C-2’and C-6’), 129.5 (C-3’ and C-5’), 137.4 (C-1’), 
141.6 (C-2), 151.5 (C-9), 165.0 (C-7), 175.8 (C-5). 
5-Thioxo-2-(4-(trifluoromethyl)benzyl)-5,6-dihydro-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7(4H)-one (H8a) 
Yield 67 %; mp 280-281 °C (EtOH-water); ESI-MS m/z 326.1 (M-1)
+; purity ˃ 95%; 
tR 4.53 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.15 (s, 2H, PhCH2), 7.54 (d, 2H, 
H-3’ and H-5’, J = 7.9 Hz), 7.69 (d, 2H, H-2’ and H-6’, J = 7.9 Hz) 13.03 (s, 1H, 
NH), 14.12 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 33.8 (CH2), 124.3 (q, 
CF3, J = 271.9 Hz), 125.1 (q, C-3’ and C-5’, J = 3.7 Hz), 127.4 (q, C-4’, J = 31.8 Hz), 
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Yield 64 %; mp 241-243 °C (EtOH-water); ESI-MS m/z 292.2 (M-1)
+; purity ˃ 95%; 
tR 5.44 min (D); 
1
H NMR (300 MHz, DMSO-d6): δ 4.02 (s, 2H, PhCH2), 7.32 (d, 2H, 
H-3’ and H-5’, J = 8.6 Hz), 7.38 (d, 2H, H-2’ and H-6’, J = 8.5 Hz), 13.00 (s, 1H, 
NH), 14.14 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 33.9 (CH2), 128.7 (C-
2’and C-6’), 131.3 (C-3’ and C-5’), 131.8 (C-4’), 136.4 (C-1’), 141.6 (C-2), 151.6 (C-
9), 164.6 (C-7), 175.8 (C-5). 
2-(4-Bromobenzyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H8c) 
Yield 65 %; mp 238-240 °C (EtOH-water); ESI-MS m/z 338.0 (M-1)
+; purity ˃ 95%; 
tR 1.69 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.00 (s, 2H, PhCH2), 7.26 (d, 2H, 
H-3’ and H-5’, J = 8.0 Hz), 7.51 (d, 2H, H-2’ and H-6’, J = 8.1 Hz) 12.98 (s, 1H, 
NH), 13.88 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 33.40 (CH2), 119.7 
(C-4’), 131.1 (C-2’and C-6’), 131.2 (C-3’ and C-5’), 136.2 (C-1’), 141.0 (C-2), 151.1 
(C-9), 164.0 (C-7), 175.2 (C-5). 
2-(4-Fluorobenzyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H8d) 
Yield 72 %; mp 260-262 °C (EtOH-water); ESI-MS m/z 276.1 (M-1)
+; purity ˃ 95%; 
tR 1.68 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.01 (s, 2H, PhCH2), 7.11-7.16 
(m, 2H, H-3’ and H-5’), 7.32-7.35 (m, 2H, H-2’ and H-6’), 13.00 (s, 1H, NH), 14.09 
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(br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 33.8 (CH2), 115.6 (d, C-3’ and C-
5’, J = 21.3 Hz), 131.3 (d, C-2’ and C-6’, J = 8.1 Hz), 133.5 (d, C-1’, J = 3.7 Hz), 
141.6 (C-2), 151.5 (C-9), 161.6 (d, C-4’, J = 242.1 Hz), 164.9 (C-7), 175.8 (C-5). 
2-(4-Methylbenzyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H8e) 
Yield 72 %; mp 244-246 °C (EtOH-water); ESI-MS m/z 272.1 (M-1)
+; purity ˃ 95%; 
tR 1.68 min (A);
1
H NMR (300 MHz, DMSO-d6): δ 2.26 (s, 3H, Me), 3.96 (s, 2H, 
PhCH2), 7.10 (d, 2H, H-3’ and H-5’, J = 7.8 Hz), 7.17 (d, 2H, H-2’ and H-6’, J = 8.0 
Hz) 13.00 (s, 1H, NH), 14.03 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 21.1 
(Me), 34.3 (CH2), 129.3 (C-2’and C-6’), 129.4 (C-3’ and C-5’), 134.2 (C-4’), 136.1 
(C-1’), 141.6 (C-2), 151.5 (C-9), 165.2 (C-7), 175.8 (C-5). 
2-(4-Methoxybenzyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H8f) 
Yield 78 %; mp 243-244 °C (EtOH-water); ESI-MS m/z 288.1 (M-1)
+; purity ˃ 95%; 
tR 1.68 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 3.72 (s, 3H, MeO), 3.93(s, 2H, 
PhCH2), 6.86 (d, 2H, H-3’ and H-5’, J = 8.7 Hz), 7.21 (d, 2H, H-2’ and H-6’, J = 8.7 
Hz) 12.98 (s, 1H, NH), 14.09 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 33.8 
(CH2), 55.5 (MeO), 114.2 (C-2’and C-6’), 129.2 (C-4’), 130.5 (C-3’ and C-5’), 141.6 
(C-1’), 151.4 (C-2), 158.5 (C-9), 165.3 (C-7), 175.8 (C-5). 
2-(4-Hydroxybenzyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H8g) 
Yield 65 %; mp 268-270 °C (EtOH-water); ESI-MS m/z 274.0 (M-1)
+; purity ˃ 95%; 
tR 1.75 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 3.87 (s, 2H, PhCH2), 6.69 (d, 2H, 
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H-3’ and H-5’, J = 8.2 Hz), 7.08 (d, 2H, H-2’ and H-6’, J = 8.2 Hz), 9.26 (s, 1H, OH), 
12.98 (s, 1H, NH), 14.05 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 33.9 
(CH2), 115.6 (C-2’and C-6’), 127.4 (C-4’), 130.4 (C-3’ and C-5’), 141.6 (C-1’), 151.4 
(C-2), 156.5 (C-9), 165.5 (C-7), 175.8 (C-5). 
4-((7-Oxo-5-thioxo-4,5,6,7-tetrahydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-
yl)methyl)benzonitrile (H8h) 
Yield 60 %; mp ˃ 300 °C (EtOH-water); ESI-MS m/z 302.1 (M-1)+; purity ˃ 95%; tR 
1.64 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.10 (s, 2H, PhCH2), 7.42 (d, 2H, 
H-3’ and H-5’, J = 8.2 Hz), 7.69 (d, 2H, H-2’ and H-6’, J = 8.2 Hz) 12.95 (s, 1H, 
NH), 13.71 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 34.0 (CH2), 127.5 (C-
4’), 129.1 (C-2’and C-6’), 129.3 (C-3’ and C-5’), 141.1 (C-1’), 142.0 (C-2), 163.9 (C-
9), 167.0 (C-7), 175.4 (C-5). 
2-(3,4-Dichlorobenzyl)-5-thioxo-5,6-dihydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-
7(4H)-one (H8i) 
Yield 57 %; mp 265-267 °C (EtOH-water); ESI-MS m/z 326.1 (M-1)
+; purity ˃ 95%; 
tR 1.75 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.07 (s, 2H, PhCH2), 7.30-7.33 
(m, 1H, H-2’), 7.56-7.59 (m, 3H, H-5’ and H-6’), 13.04 (s, 1H, NH), 14.15 (br. s, 1H, 
NH); 
13
C NMR (75 MHz, DMSO-d6): δ 33.5 (CH2), 129.8 (C-6’), 130.0 (C-2’), 130.9 
(5’), 131.3 (C-4’), 138.5 (C-1’), 141.6 (C-2), 151.6 (C-9), 164.1 (C-7), 175.8 (C-5). 
2-Benzyl-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7(4H,6H)-dione (H7) 
Yield 47 %; mp ˃ 300 °C (EtOH-water); ESI-MS m/z 242.3 (M-1)+; purity ˃ 95%; tR 
4.41 min (D); 
1
H NMR (300 MHz, DMSO-d6): δ 4.00 (s, 2H, PhCH2), 7.04-7.61 (m, 
5H, Ar-H), 11.81 (s, 1H, NH), 12.69 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): 
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δ 34.8 (CH2), 127.04 (C-4’), 128.8 (C-2’and C-6’), 129.5 (C-3’ and C-5’), 137.5 (C-
1’), 143.9 (C-2), 149.4 (C-9), 152.1 (C-7), 164.8 (C-5). 
 General procedure for synthesis of 2-benzyl-5-(methylthio)-[1,2,4]triazolo[1,5-
a][1,3,5]triazin-7(6H)-thione (H9) 
To a stirred solution of 7-Phenyl-2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-
a][1,3,5]triazin-4-one in 4 ml of 2.5 M NaOH, iodomethane ( 933 µl, 7.5mmol) was 
added, the stirring was continued for 30 min. A solid precipitate was observed which 
upon acidification (pH 1-3) with 2.5 M HCl afforded another solid. The precipitated 
solid was filtered, washed with ice cold water and recrystallized from water-ethanol 
system.  
2-Benzyl-5-(methylthio)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7(6H)-thione (H9) 
Yield 54 %; mp 96-98°C (EtOH-water); ESI-MS m/z 272.3 (M-1)
+; purity ˃ 95%; tR 
2.08 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 2.54 (s, 3H, SMe), 4.04 (s, 2H, 
PhCH2), 7.20-7.37 (m, 5H, Ar-H), 13.11 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-
d6): δ 13.2 (SMe), 34.4 (CH2), 126.4 (C-4’), 128.2 (C-2’and C-6’), 128.8 (C-3’ and 
C-5’), 137.1 (C-1’), 143.6 (C-2), 157.1 (C-9), 164.6 (C-7), 165.3 (C-5). 
9.1.5 General procedure for the synthesis pyrazolo[1,5-a][1,3,5]triazin (H10, 
H11, H12 and H14) 
 General procedure for synthesis of  cyanoacetophenone (95)209, 210 
The bromoacetophenone (10 mmol) was dissolved in 20 ml ethanol and stirred 
together with a solution of 20 mmol NaCN in 10 ml water at room temperature for 1 
hour. The brownish solution was filtered and the solvent evaporated to dryness in 
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vacuum. The residue was suspended in 50 ml water and stirred for additional 3 hours 
at room temperature. The mixture was filtered and the filtrate was acidified with 
concentrated hydrocholoric acid to afford cyanoacetophenone. 
 Synthesis of cyanoacetophenone and their 1H NMR spectral data 
 
3-Oxo-3-phenylpropanenitrile (95a)  
Yield 79 %; mp 68-69 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 4.76 (s, 2H, CH2), 7.54-
7.99 (m, 5H, Ar-H).  
3-Oxo-3-(4-chlorophenyl)-propanenitrile (95b)  
Yield 82 %; mp 115-117 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 4.75 (s, 2H, CH2), 
7.65 (d, 2H, H-3’ and -5’, J = 8.5 Hz), 7.94 (d, 2H, H-2’ and -6’, J = 8.6 Hz). 
3-Oxo-3-(4-bromophenyl)-propanenitrile (95c)  
Yield 84 %; mp 146-148 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 4.74 (s, 2H, CH2), 
7.79 (d, 2H, H-3’ and -5’, J = 8.6 Hz), 7.86 (d, 2H, H-2’ and -6’, J = 8.7 Hz). 
3-Oxo-3-(4-fluorophenyl)-propanenitrile (95d)  
Yield 73 %; mp 50-52 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 4.76 (s, 2H, CH2), 7.38-
7.45 (m, 2H, H-3’ and -5’), 8.00-8.05 (m, 2H, H-2’ and -6’) 
3-Oxo-3-(4-methylphenyl)-propanenitrile (95e)  
Yield 64 %; mp 90-92 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 2.39 (s, 3H, Me), 4.71 







3-Oxo-3-(4-methoxyphenyl)-propanenitrile (95f)  
Yield 71 %; mp 100-102 ºC; 
1
HNMR (300 MHz, DMSO-d6): δ 3.86 (s, 3H, MeO), 
4.67 (s, 2H, CH2), 7.08 (d, 2H, H-3’ and -5’, J = 8.9 Hz), 7.91 (d, 2H, H-2’ and -6’, J 
= 8.8 Hz). 
3-Oxo-3-(4-cyanophenyl)-propanenitrile (95g)  
Yield 57 %; mp 102-104 ºC; 
1
HNMR (300 MHz, DMSO-d6): δ 4.80 (s, 2H, CH2), 
7.78-8.19 (m, 4H, Ar-H). 
3-Oxo-3-(3,4-dichlorophenyl)-propanenitrile (95h)  
Yield 72 %; mp 94-95 ºC; 
1
HNMR (300 MHz, DMSO-d6): δ 4.77 (s, 2H, CH2 ), 7.38-
8.31 (m, 3H, Ar-H). 
 General procedure for synthesis of  pyrazol-3-ylamine derivatives (96)211 
Cyanoacetophenone (5 mmol) prepared by above mentioned procedure were subjected 
to microwave irradiation at 150 ºC for one hour in ethanol in presence of hydrazine 
hydrate (10 mmol). After cooling, the ethanol was evaporated and the residue was 
triturated with diethyl ether (DEE) and precipitated products were filtered off, washed 
with DEE and recrystallized by DEE and methanol. 
 Synthesis of pyrazol-3-ylamine derivatives and their 1H NMR spectral data 
 
3-Phenyl-1H-pyrazol-5-amine (96a) 
Yield 75 %; mp 115-117 ºC (DEE-methanol); 
1
H NMR (300 MHz, DMSO-d6): δ 
4.75 (br.s, 2H, NH2), 5.75 (s, 1H, CH), 7.24-7.27 (m, 1H, H-4’), 7.35-7.39 (m, 2H, H-





Yield 88 %; mp 165-166 ºC (DEE-methanol); 
1
H NMR (300 MHz, DMSO-d6): δ 
5.28(br.s, 2H, NH2), 5.76 (s, 1H, CH), 7.42 (d, 2H, H-3’ and -5’, J = 8.7 Hz), 7.67 (d, 
2H, H-2’ and -6’, J = 8.7 Hz), 10.73 (br.s, 1H, NH). 
3-(4-Bromophenyl)-1H-pyrazol-5-amine (96c) 
Yield 81 %; mp 164-166 ºC (DEE-methanol); 
1
H NMR (300 MHz, DMSO-d6): δ 
4.91 (br.s, 2H, NH2), 5.75 (s, 1H, CH), 7.55 (d, 2H, H-3’ and -5’, J = 8.5 Hz), 7.61 (d, 
2H, H-2’ and -6’, J = 8.6 Hz), 11.80 (br.s, 1H, NH). 
3-(4-Fluorophenyl)-1H-pyrazol-5-amine (96d) 
Yield 61 %; mp 84-86 ºC (DEE-methanol); 
1
H NMR (300 MHz, DMSO-d6): δ 4.83 
(br.s, 2H, NH2), 5.73 (s, 1H, CH), 7.20 (dd, 2H, H-3’ and -5’, J = 8.7, 8.7  Hz), 7.68 
(dd, 2H, H-2’ and -6’, J = 8.8, 5.6 Hz), 11.69 (br.s, 1H, NH). 
3-(4-Methylphenyl)-1H-pyrazol-5-amine (96e) 
Yield 72 %; mp 148-150 ºC (DEE-methanol); 
1
H NMR (300 MHz, DMSO-d6): δ 
2.30 (s, 3H, Me), 4.75 (br.s, 2H, NH2), 5.72 (s, 1H, CH), 7.17 (d, 2H, H-3’ and -5’, J 
= 7.9 Hz), 7.53 (d, 2H, H-2’ and -6’, J = 7.9 Hz), 11.80 (br.s, 1H, NH) 
3-(4-Methoxyphenyl)-1H-pyrazol-5-amine (96f) 
Yield 68 %; mp 129-131 ºC (DEE-methanol); 
1
H NMR (300 MHz, DMSO-d6): δ 
3.33 (s, 3H, MeO), 4.75 (br.s, 2H, NH2), 5.68 (s, 1H, CH), 6.94 (d, 2H, H-3’ and -5’, 





Yield 69 %; mp 176-178 ºC (DEE-methanol); 
1
H NMR (300 MHz, DMSO-d6): δ 
5.02 (br.s, 2H, NH2), 5.85 (s, 1H, CH), 7.79-7.86 (m, 4H, Ar-H), 11.94 (br.s, 1H, 
NH). 
3-(3,4-Dichlorophenyl)-1H-pyrazol-5-amine (96h) 
Yield 79 %; mp 138-140 ºC (DEE-methanol); 
1
H NMR (300 MHz, DMSO-d6): δ 
4.99 (br.s, 2H, NH2), 5.73 (s, 1H, CH), 7.59-7.66 (m, 2H, H-5’ and 6’), 7.89-7.90 (m, 
1H, H-2’), 11.82 (br.s, 1H, NH). 
3-(t-Butyl)-1H-pyrazol-5-amine (96i) 
Yield 76 %; oil; 
1
H NMR (300 MHz, DMSO-d6): δ 1.18 (s, 9H, C(CH3)3), 4.38  (br.s, 
2H, NH2), 5.18 (s, 1H, CH ), 10.80 (br.s, 1H, NH) 
 General procedure for synthesis of N-carbethoxy-N’-(3-aryl-
pyrazolyl)thiourea/urea derivatives (97, 98 and 110)  
In a well stirred suspension of aminopyrazol (3 mmol) in anhydrous 
dimethylformamide (DMF, 4 ml), ethoxycarbonyl isothiocyanate (3.3 mmol) or 
ethoxycarbonyl isocyanate (3.3 mmol) was added and stirred the reaction mixture for 
4.5-5 hours at room temperature. Following this step, 50-60 ml water was added to 
this reaction mixture and the precipitate thus formed was filtered and washed with 






Table 23. Synthesis of N-carbethoxy-N’-(3-aryl-pyrazolyl)thiourea/urea  derivatives 
and their  
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H NMR (300 MHz, DMSO-d6) 
CO2Et CH Ar NH NH N(1)H 
98a Ph 
% yield: 89, mp: 
275 ºC , (Ethanol-
water) 
1.27, t, 3H, J = 
7.1 Hz; 4.23, q, 
2H, J = 7.1 Hz
 
7.39 7.37, t, 1H, J = 7.4 Hz; 
7.47, t, 2H, J = 7.7 Hz; 
7. 74, d, 2H, J = 7.3 Hz 
11.37 12.04 13.23 
98b 4-ClC6H4 
% yield: 92, mp: 
275-277 ºC ,  
(Ethanol-water) 
1.27, t, 3H, J = 
7.1 Hz; 4.23, q, 
2H, J = 7.1 Hz
 
7.43 7.53, d, 2H, J = 8.2 Hz; 
7.76, d, 2H, J = 8.5 Hz 
11.38 12.04 13.29 
98c 4-BrC6H4 
% yield: 89, mp: 
279-281 ºC , 
(Ethanol-water) 
1.27, t, 3H, J = 
7.0 Hz; 4.23, q, 
2H, J = 7.0 Hz
 
7.44 7.66, d, 2H, J = 8.7 Hz; 
7.70, d, 2H, J = 8.7 Hz 
11.38 12.04 13.30 
98d 4-FC6H4 
% yield: 80, mp: 
255-257 ºC , 
(Ethanol-water) 
1.27, t, 3H, J = 
7.0 Hz; 4.23, q, 
2H, J = 7.0 Hz
 
7.38 7.31, t, 2H, J = 8.7 Hz; 
7.78, dd, 2H, J = 8.7, 
5.3  Hz 
11.37 12.03 13.21 
98e 4-MeC6H4 
% yield: 84, mp: 
263-264 ºC , 
(Ethanol-water) 
1.27, t, 3H, J = 
7.1 Hz; 4.23, q, 
2H, J = 7.1 Hz
 
7.35 2.33, s, 3H, Ar-
Me;7.27, d, 2H, J = 8.0 
Hz; 7.62, d, 2H, J = 8.2 
Hz 
11.35 12.03 13.13 
98f 4-MeOC6H4 
% yield: 89, mp: 
250 ºC , (Ethanol-
water) 
1.27, t, 3H, J = 
7.1 Hz; 4.23, q, 
2H, J = 7.1 Hz
 
7.30 3.80, s, 3H, Ar-
MeO;7.03, d, 2H, J = 
8.8 Hz; 7.66, d, 2H, J = 
8.8 Hz 
11.34 12.02 13.05 
98g 4-CNC6H4 
% yield: 78, mp: 
290-292 ºC , 
(Ethanol-water) 
1.26, t, 3H, J = 
7.0 Hz; 4.22, q, 
2H, J = 7.0 Hz
 
7.55 3.41, m, 4H 11.40 12.04 13.50 
98h (3,4) DiClC6H3 
% yield: 82, mp: 
185 ºC , (Ethanol-
water) 
1.27, t, 3H, J = 
7.0 Hz; 4.22, q, 
2H, J = 7.0 Hz 
7.50 7.74, m, 2H; 8.05, m, 
1H. 








Table 23. Synthesis of N-carbethoxy-N’-(3-aryl-pyrazolyl)thiourea/urea derivatives 
and their  
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H NMR (300 MHz, DMSO-d6) 
CO2Et CH Ar NH NH N(1)H 
98i t-butyl 
% yield: 81, mp: 
270 ºC , (Ethanol-
water) 
1.24, t, 3H, J = 
7.2 Hz; 4.21, q, 
2H, J = 7.0 Hz
 
6.83 1.22-1.27, m, 12 H 11.25 11.97 12.43 
97 Ph urea 
% yield:  89, mp: 
250 ºC , (Ethanol-
water) 
1.25, t, 3H, J = 
7.0 Hz; 4.19, q, 
2H, J = 7.0 Hz
 
6.79 7.31-7.39, m, 1H, 7.41-
7.50, m, 2H, 7.69-7.79, 
m, 2H 
10.06 1.43 12.90 
110 8 ph thiourea 
% yield:  84, mp: 
191-192 ºC , 
(Ethanol-water) 
1.26, t, 3H, J = 
7.0 Hz; 4.21, q, 
2H, J = 7.1 Hz 
- 7.20 , t, 1H , J = 7.5 Hz; 
7.33, t,  2H, J =7.6 Hz; 
7.48, d, 2H,  J = 7.8Hz; 
8.12, s, 1H 
11.08 11.35 12.94 
 
 
 General procedure for synthesis of  7-phenyl-2-thioxo-2,3-dihydro-1H-
pyrazolo[1,5-a][1,3,5]triazin-4-one (H11-H11h), 8-phenyl-2-thioxo-2,3-




To a stirred solution of NaOH (9 mmol) in ethanol (80%, 20 ml), corresponding 
carbethoxyurea or carbethoxythiourea (3 mmol) was added and heated on water bath 
for 20 minutes with continuous stirring. After cooling, the solvent was evaporated 
under vacuum, and the residue was suspended in water (25 ml). The resulting 
suspension was acidified up to pH 1-3 using 2.5 M HCl. The precipitated product was 







Yield 71%; mp 286-288 ºC (Ethanol-water); ESI-MS m/z 243.0 (M-1)
+; purity ˃ 
95%; tR 5.32 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 6.39 (s, 1H, CH), 7.38-7.54 
(m, 3H, H-3’,H-4’ and H-5’), 7.88-8.00 (m, 2H, H-2’ and H-6’), 12.75 (s, 1H, NH), 
13.56 (s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 87.3 (C-8), 126.8 (C-3’ and C-
5’), 129.4 (C-2’ and C-6’), 130.1 (C-4’), 131.7 (C-1’), 142.0 (C-7), 142.1 (C-9), 155.9 
(C-4), 173.6 (C-2). 
7-(4-Chloro-Phenyl)-2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-a][1,3,5]triazin-4-one 
(H11a) 
Yield 69%; mp 290-292 ºC (Ethanol-water); ESI-MS m/z 277.2 (M-1)
+
; purity ˃ 
95%; tR 6.37 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 6.43 (s, 1H, CH), 7.54 (d, 
2H, H-3’ and H-5’, J = 8.3), 7.98 (d, 2H, H-2’ and H-6’, J = 8.3), 12.79 (s, 1H, NH), 
13.58 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 87.3 (C-8), 128.5 (C-2’ and C-
6’), 129.4 (C-3’ and C-5’), 130.6 (C-4’), 134.7 (C-1’), 141.9 (C-7), 142.3 (C-9), 154.7 
(C-4), 173.6 (C-2). 
7-(4-Bromo-Phenyl)-2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-a][1,3,5]triazin-4-one 
(H11b) 
Yield 66%; mp ˃ 300 ºC (Ethanol-water); ESI-MS m/z 322.9 (M-1)+; purity ˃ 95%;  
tR 6.62 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 6.42 (s, 1H, CH), 7.66 (d, 2H, H-
3’ and H-5’, J = 8.3), 7.90 (d, 2H, H-2’ and H-6’, J = 8.3), 12.77 (s, 1H, NH), 13.58 
(s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 87.3 (C-8), 123.4 (C-4’), 128.8 (C-2’ 
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Yield 74%; mp 270-272 ºC (Ethanol-water); ESI-MS m/z 261.3 (M-1)
+
; purity ˃ 
95%; tR 5.56 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 6.40 (s, 1H, CH), 7.30 (dd, 
2H, H-3’ and H-5’ J = 8.9, 8.9 Hz), 8.00 (dd, 2H, H-2’ and H-6’ J = 8.7, 5.7 Hz), 
12.75 (s, 1H, NH), 13.56 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): 86.6 (C-8), 
115.7 (d, C-3’ and C-5’, J = 21.8 Hz), 127.7 (d, C-1’, J = 2.9 Hz), 128.4 (d, C-2’ and 
C-6’, J = 8.7 Hz), 141.4 (C-7), 141.6 (C-9), 154.4 (C-4), 162.8 (d, C-4’, J = 246.3 
Hz), 173.0 (C-2). 
7-(4-Methyl-Phenyl)-2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-a][1,3,5]triazin-4-one 
(H11d) 
Yield 65%; mp 286-288 ºC (Ethanol-water); ESI-MS m/z 257.3 (M-1)
+; purity ˃ 
95%; tR 5.93 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 3.58 (s, 3H, ArMe), 6.49 (s, 
1H, CH), 7.42 (d, 2H, H-3’ and H-5’ J = 7.9), 7.96 (d, 2H, H-2’ and H-6’ J = 8.3), 
12.89 (s, 1H, NH), 13.69 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 21.5 
(ArMe), 87.1 (C-8), 126.7 (C-2’ and C-6’), 129.0 (C-1’), 129.9 (C-3’ and C-5’), 







Yield 68%; mp 292-294ºC (Ethanol-water); ESI-MS m/z 273.0 (M-1)
+; purity ˃ 95%; 
tR 5.27 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 3.82 (s, 3H, ArMeO), 6.33 (s, 1H, 
CH), 7.03 (d, 2H, H-3’ and H-5’ J = 9.0), 7.88 (d, 2H, H-2’ and H-6’ J = 8.7), 12.72 
(s, 1H, NH), 13.53 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 55.8 (ArMeO), 
86.9 (C-8), 114.8 (C-2’ and C-6’), 124.2 (C-1’), 128.3 (C-3’ and C-5’), 142.0 (C-7), 
155.8 (C-9), 160.9 (C-4), 173.5 (C-2). 
7-(4-Cyano-Phenyl)-2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-a][1,3,5]triazin-4-one 
(H11f) 
Yield 61%; mp ˃ 300 ºC (Ethanol-water); ESI-MS m/z 287.2 (M-1)+; purity ˃ 95%; 
tR 4.41 min (B); 
1
H NMR (300 MHz, DMSO-d6): δ 6.50 (s, 1H, CH), 7.97-8.16 (m, 
4H, Ar-H), 12.82 (s, 1H, NH), 13.64 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 
87.6-87.7 (C-8), 126.6-126.8 (C-2’ and C-6’), 128.6-130.4 (C-3’ and C-5’), 131.9 (C-
4’), 134.3 (CN), 135.5-135.8 (C-1’), 142.0-142.3 (C-7), 154.9-155.1 (C-9), 167.4-
167.9 (C-4), 173.6 (C-2). 
7-(3,4-Dichloro-Phenyl)-2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-a][1,3,5]triazin-4-
one (H11g) 
Yield 63%; mp 287-289 ºC (Ethanol-water); ESI-MS m/z 312.9 (M-1)
+; purity ˃ 
95%; tR 7.68 min (B);
1
H NMR (300 MHz, DMSO-d6): δ 6.52 (s, 1H, CH), 7.71 (d, 
1H, H-6’, J = 8.3 Hz), 7.94 (dd, 1H, H-5’, J = 8.5 Hz, J = 2.1 Hz,), 8.18 (d, 1H, H-2’, 
J = 1.9 Hz), 12.80 (s, 1H, NH), 13.63 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 
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87.7 (C-8), 126.7 (C-6’), 128.4 (C-2’), 131.6 (C-5’), 132.3 (C-4’), 132.4 (C-3’), 132.5 
(C-1’), 141.9 (C-7), 142.3 (C-9), 153.6 (C-4), 173.6 (C-2). 
7-t-Butyl-2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-a][1,3,5]triazin-4-one (H11h) 
Yield 55%; mp 268-270 ºC (Ethanol-water); ESI-MS m/z 223.1 (M-1)
+; purity ˃ 
95%; tR 4.71 min (D);
1
H NMR (300 MHz, DMSO-d6): δ 1.23 (s, 9H, t-but), 5.83 (s, 
1H, CH), 12.59 (s, 1H, NH), 13.37 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 
30.1 (3CH3), 33.0 (t-but), 87.1 (C-8), 141.1 (C-7), 142.0 (C-9), 167.5 (C-4), 173.4 (C-
2). 
8-Phenyl-2-thioxo-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one (H14) 
Yield 60%; mp 222-224˚C (Ethanol-water); ESI-MS m/z 245.0 (M-1)+; purity ˃ 95%; 
tR 6.17 min (B); 
1
HNMR (300 MHz, DMSO-d6): δ7.02 (m, 5H, Ar-H), 8.17 (s, 1H, 
CH), 12.80 (s, NH, 1H). 
13
CNMR (75 MHz, DMSO-d6): δ106.5 (C-8), 128.1 (C-4’), 
129.2 (C-2’ and C-6’), 129.5 (C-3’ and C-5’), 130.2 (C-1’), 137.2 (C-7), 142.6 (C-9), 
146.2 (C-4), 174.9 (C-2). 
7-Phenyl-1H-pyrazolo[1,5-a][1,3,5]triazin-2,4-dione (H10) 
Yield 55 %; mp 312-314 ºC(Ethanol-water); ESI-MS m/z 227.1 (M-1)
+; purity ˃ 
95%; tR 4.42 min (D);
1
H NMR (300 MHz, DMSO-d6): δ 6.30 (s, 1H, CH), 7.40-7.49 
(m, 3H, H-3’,H-4’ and H-5’), 7.92 (d, 2H, H-2’ and H-6’, J = 8.7 Hz), 11.61 (s, 1H, 
NH), 12.00 (s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 85.9 (C-8), 126.0 (C-3’ 
and C-5’), 128.7 (C-2’ and C-6’), 129.2 (C-4’), 131.5 (C-1’), 141.7 (C-7), 144.2 (C-
9), 148.3 (C-4), 155.0 (C-2). 
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 General procedure for synthesis of 2-methylsulfanyl-7-phenyl-3H-pyrazolo[1,5-
a][1,3,5]triazin-4-one (H12) 
To a stirred solution of 7-phenyl-2-thioxo-2,3-dihydro-1H-pyrazolo[1,5-
a][1,3,5]triazin-4-one (H11) in 4 ml of 2.5 M NaOH, iodomethane ( 933 µl, 7.5mmol) 
was added, the stirring was continued for 30 minutes. A solid precipitate was 
observed which upon acidification (pH 1-3) with 2.5 M HCl afforded another solid. 
The precipitated solid was filtered, washed with ice cold water and recrystallized from 
water-ethanol system.  
2-Methylsulfanyl-7-phenyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one (H12) 
Yield 46 %; mp 240-242ºC (Ethanol-water); ESI-MS m/z 257.3(M-1)
+; purity ˃ 95%; 
tR 6.27 min (B);
1
H NMR (300 MHz, DMSO-d6): δ 6.90 (s, 1H, CH), 7.41-7.54 (m, 
3H, H-3’,H-4’ and H-5’), 7.96-8.01 (m, 2H, H-2’ and H-6’), 12.92 (s, 1H, NH). 13C 
NMR (75 MHz, DMSO-d6): δ 13.6 (SMe), 94.9 (C-8), 126.6 (C-3’ and C-5’), 129.3 
(C-2’ and C-6’), 129.8 (C-4’), 132.4 (C-1’), 143.8 (C-7), 150.0 (C-9), 156.0 (C-4), 
157.7 (C-2). 
9.1.6 General procedure of synthesis of (8-benzyl-4-oxo-2-thioxo-1,2,3,4-
tetrahedro pyrazolo[1,5-a][1,3,5]triazin-7-yl)-thiourea and their derivatives (13-
13n) 




In a 95% ethanolic (10 ml) solution of malononitrile (10 mmol) appropriate aromatic 
aldehyde (10 mmol) was added. The solution was stirred at room temperature until 
precipitation was complete or overnight. Following this step, additional ethanol (20 
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ml) was added and the mixture was cooled to 0 °C in an ice bath. NaBH4 (5 mmol) 
was added to the vigorously stirred mixture and the reduction was completed in about 
10 minutes. The reaction mixture was poured into a beaker containing cold water (40 
ml) and 1.0 M HCl was added to quench all hydride. Additional cold water was 
introduced to afford more precipitation. The cold precipitate was collected by vacuum 
filtration and washed with cold water (Method A). If crystallization/precipitation did 
not occur, then the mixture was extracted using water and dichloromethane solvent 
system (Method B). 




Yield 81 % (method A); mp 79 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 3.33 (d, 2H, 
CH2, J = 6.9 Hz), 5.11 (t, 1H, CH(CN)2, J = 6.9 Hz), 7.33-7.41 (m, 5H, Ar-H). 
2-(4-(Trifluoromethyl)benzyl)-malononitrile (100b) 
Yield 76 % (method A); mp 68 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 3.47 (d, 2H, 
CH2, J = 6.6 Hz), 5.17 (t, 1H, CH(CN)2, J = 6.9 Hz), 7.61 (d, 2H, H-3’ and H-5’, J = 
8.1 Hz ), 7.78 (d, 2H, H-2’ and H-6’, J = 8.1 Hz ). 
2-(4-Chlorobenzyl)-malononitrile (100c) 
Yield 82 % (method A); mp 82 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 3.34 (d, 2H, 
CH2, J = 6.8 Hz), 5.10 (t, 1H, CH(CN)2, J = 6.8 Hz), 7.40 (d, 2H, H-3’ and H-5’, J = 





Yield 76 % (method A); mp 83-85 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 3.33 (d, 
2H, CH2, J = 6.8 Hz), 5.10 (t, 1H, CH(CN)2, J = 6.8 Hz), 7.34 (d, 2H, H-3’ and H-5’, 
J = 8.4 Hz ), 7.60 (d, 2H, H-2’ and H-6’, J = 8.3 Hz ). 
2-(4-Fluorobenzyl)-malononitrile (100e) 
Yield 69 % (method A); mp 113-115 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 3.34 (d, 
2H, CH2, J = 6.9 Hz), 5.08 (t, 1H, CH(CN)2, J = 6.9 Hz), 7.22 (dd, 2H, H-3’ and H-5’, 
J = 8.8,  8.8 Hz ), 7.42 (d, 2H, H-2’ and H-6’, J = 8.6, 5.5 Hz ). 
2-(4-Phenylbenzyl)-malononitrile (100f) 
Yield 78 % (method A); mp 114-116 ºC; 
1
HNMR (300 MHz, DMSO-d6): δ 3.39 (m, 
2H, CH2), 5.15 (m, 1H, CH(CN)2), 7.34-7.72 (m, 9H, Ar-H). 
2-(4-Phenoxybenzyl)-malononitrile (100g) 
Yield 74 % (method A); mp 98-100 ºC; 
1
HNMR (300 MHz, DMSO-d6): δ 3.32 (d, 
2H, CH2, J = 6.8 Hz), 5.08 (t, 1H, CH(CN)2, J = 6.9 Hz), 6.99-7.43 (m, 9H, Ar-H). 
2-(4-Methylbenzyl)-malononitrile (100h) 
Yield 73 % (method A); mp 72 ºC; 
1
HNMR (300 MHz, DMSO-d6): δ 2.30 (s, 3H, 
Me), 3.29 (d, 2H, CH2, J = 7.4 Hz),  5.06 (t, 1H, CH(CN)2, J = 6.8 Hz), 7.19 (d, 2H, 
H-3’ and H-5’, J = 7.9 Hz ), 7.25 (d, 2H, H-2’ and H-6’, J = 7.9 Hz ). 
2-(4-Ethylbenzyl)-malononitrile (100i) 
Yield 82 % (method A); mp 52-54 ºC; 
1
HNMR (300 MHz, DMSO-d6): δ 1.17 (t, 3H, 
CH3, J = 7.6 Hz ), 2.60 (d, 2H, CH2, J = 7.6 Hz ), 3.28 (d, 2H, CH2, J = 5.5 Hz), 5.06 
(t, 1H, CH(CN)2, J = 6.5 Hz), 7.22 (d, 2H, H-3’ and H-5’, J = 7.6 Hz ), 7.28 (d, 2H, 




Yield 73 % (method A); mp 76-78 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 3.26 (d, 
2H, CH2, J = 6.9 Hz), 3.75 (s, 3H, MeO), 5.03 (t, 1H, CH(CN)2, J = 6.9 Hz), 6.94 (d, 
2H, H-3’ and H-5’, J = 8.6 Hz ), 7.29 (d, 2H, H-2’ and H-6’, J = 8.6 Hz ). 
2-(4-Hydroxybenzyl)-malononitrile (100k) 
Yield 73 % (method A);  mp 168-171 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 3.19 (d, 
2H, CH2, J = 6.8 Hz), 4.98 (t, 1H, CH(CN)2, J = 6.8 Hz), 6.75 (d, 2H, H-3’ and H-5’, 
J = 8.4 Hz ), 7.16 (d, 2H, H-2’ and H-6’, J = 8.5 Hz ), 9.49 (s, 1H, OH). 
2-(4-Cyanobenzyl)-malononitrile (100l) 
Yield 82 % (method A); mp 118-120 ºC; 
1
H NMR (300 MHz, DMSO-d6): δ 3.47 (d, 
2H, CH2, J = 6.0 Hz), 5.17 (t, 1H, CH(CN)2, J = 6.9 Hz), 7.59 (d, 2H, H-3’ and H-5’, 
J = 8.4 Hz ), 7.89 (d, 2H, H-2’ and H-6’, J = 8.3 Hz ). 
2-(Furan-2-ylmethyl)malononitrile (100m) 
Yield 85 % (method B); oil; 
1
H NMR (300 MHz, DMSO-d6): δ 3.45 (d, 2H, CH2, J = 
6.3 Hz), 5.13 (t, 1H, CH(CN)2, J = 6.3 Hz), 6.39-6.42 (m, 1H, H- 4’), 6.45-6.47 (m, 
1H, H-3’), 7.67 (s, 1H, H-5’). 
2-(Thiophen-2-ylmethyl)malononitrile (100n) 
Yield 56 % (method B); oil; 
1
H NMR (300 MHz, DMSO-d6): δ 3.60 (d, 2H, CH2, J = 
6.0 Hz), 5.11 (t, 1H, CH(CN)2, J = 6.0 Hz), 7.05 (dd, 1H, H- 4’, J = 3.5 and 5.1 Hz ), 
7.12 (dd, 1H, H-3’, J = 1.2 and 3.5 Hz,), 7.50 (d, 1H, H-5’, J = 1.3 and 5.1 Hz). 
2-(Naphthalen-1-ylmethyl)malononitrile (100o) 
Yield 55 % (method B); oil; 
1
H NMR (300 MHz, DMSO-d6): δ 3.89 (d, 2H, CH2, J = 
7.6 Hz), 5.89 (t, 1H, CH(CN)2, J = 7.6 Hz), 7.48-8.30 (m, 8H, Ar-H). 
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 General procedure of synthesis of 4-benzyl-1H-pyrazol-3,5-diamine (101) 
In a ethanolic suspension of 2-benzyl-malononitrile and its derivatives (3 mmol),  
hydrazine hydrate (6 mmol) was added and the resulting reaction mixture was 
refluxed for 3-10 hours. After refluxing, the ethanol was evaporated to dryness and 
the residue was recrystallized using suitable solvents or purified using column 
chromatography. 
 Synthesis of 4-benzyl-1H-pyrazol-3,5-diamine and its derivatives and their  1H 






Yield 79 %; mp 144-146 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.49 (s, 
2H, CH2), 4.25 (br.s, 4H, (NH2)2), 7.07-7.24 (m, 5H, Ar-H), 9.69 (br.s, 1H, NH)  
4-(4-(Trifluoromethyl)benzyl-1H-pyrazol-3,5-diamine (101b) 
Yield 67 %; mp 66-68 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.60 (s, 
2H, CH2), 4.37 (br.s, 4H, (NH2)2), 7.43 (d, 2H, H-3’ and H-5’, J = 8.0 Hz ), 7.58 (d, 
2H, H-2’ and H-6’, J = 8.0 Hz ), 10.01 (br.s, 1H, NH). 
4-(4-Chlorobenzyl)-1H-pyrazol-3,5-diamine (101c) 
Yield 75 %; mp 152-154 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.48 (s, 





Yield 84 %; mp 166-168 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.47 (s, 
2H, CH2), 4.31 (br.s, 4H, (NH2)2), 7.17 (d, 2H, H-3’ and H-5’, J = 8.3 Hz ), 7.40 (d, 
2H, H-2’ and H-6’, J = 8.3 Hz ), 9.97 (br.s, 1H, NH). 
4-(4-Fluorobenzyl)-1H-pyrazol-3,5-diamine (101e) 
Yield 59 %; mp 180-182 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.48 (s, 
2H, CH2), 4.30 (br.s, 4H, (NH2)2), 7.03 (dd, 2H, H-3’ and H-5’, J = 8.8, 8.8 Hz ), 7.23 
(dd, 2H, H-2’ and H-6’, J = 8.3, 5.8 Hz ), 9.95 (br.s, 1H, NH). 
4-(4-Phenylbenzyl)-1H-pyrazol-3,5-diamine (101f) 
Yield 59 %; mp 180-182 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.55 (s, 
2H, CH2), 4.31 (br.s, 4H, (NH2)2), 7.25-7.72 (m, 9H, Ar-H), 10.01 (br.s, 1H, NH). 
4-(4-Phenoxybenzyl)-1H-pyrazol-3,5-diamine (101g) 
Yield 79 %; mp 128-130 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.49 (s, 
2H, CH2), 4.33 (br.s, 4H, (NH2)2), 6.81-7.47 (m, 9H, Ar-H), 10.63 (br.s, 1H, NH). 
4-(4-Methylbenzyl)-1H-pyrazol-3,5-diamine (101h) 
Yield 72 %; mp 168-170 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 2.23 (s, 
3H, Me), 3.44 (s, 2H, CH2), 4.21 (br.s, 4H, (NH2)2), 7.02 (d, 2H, H-3’ and H-5’, J = 
7.9 Hz ), 7.09 (d, 2H, H-2’ and H-6’, J = 7.9 Hz ), 9.94 (br.s, 1H, NH). 
4-(4-Ethylbenzyl)-1H-pyrazol-3,5-diamine (101i) 
Yield 66 %; mp 138-140 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 1.13 (t, 
3H, CH3, J = 7.6 Hz ), 2.53 (d, 2H, CH2, J = 7.5 Hz ), 3.40 (s, 2H, CH2), 4.25 (br.s, 
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4H, (NH2)2), 7.04 (d, 2H, H-3’ and H-5’, J = 7.9 Hz ), 7.12 (d, 2H, H-2’ and H-6’, J = 
8.0 Hz ), 9.63 (br.s, 1H, NH). 
4-(4-Methoxybenzyl)-1H-pyrazol-3,5-diamine (101j) 
Yield 65 %; mp 146-148 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.42 (s, 
2H, CH2), 3.69 (s, 3H, MeO),  4.22 (br.s, 4H, (NH2)2), 6.78 (d, 2H, H-3’ and H-5’, J = 
8.5 Hz ), 7.12 (d, 2H, H-2’ and H-6’, J = 8.4 Hz ), 9.94 (br.s, 1H, NH). 
4-(4-Hydroxybenzyl)-1H-pyrazol-3,5-diamine (101k) 
Yield 76 %; mp 184-186 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.37 (s, 
2H, CH2), 4.20 (br.s, 4H, (NH2)2), 6.61 (d, 2H, H-3’ and H-5’, J = 8.4 Hz ), 7.00 (d, 
2H, H-2’ and H-6’, J = 8.4 Hz ), 9.35 (br.s, 1H, NH and OH). 
4-(4-Cyanobenzyl)-1H-pyrazol-3,5-diamine (101l) 
Yield 74 %; mp 101-102 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.59 (s, 
2H, CH2), 4.39 (br.s, 4H, (NH2)2), 7.41 (d, 2H, H-3’ and H-5’, J = 8.4 Hz ), 7.69 (d, 
2H, H-2’ and H-6’, J = 8.3 Hz ), 9.94 (br.s, 1H, NH). 
4-(Furan-2-ylmethyl)-1H-pyrazol-3,5-diamine (101m) 
Yield 59 %; mp 147-149 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.50 (s, 
2H, CH2), 4.27 (br.s, 4H, (NH2)2), 5.94-5.95 (m, 1H, H-4’), 6.28-6.30 (m, 1H, H-3’), 
7.44-7.45 (m, 1H, H-5’), 9.85 (br.s, 1H, NH). 
4-(Thiophen-2-ylmethyl)-1H-pyrazol-3,5-diamine (101n) 
Yield 73 %; mp 118-120 ºC (EA-hexane); 
1
H NMR (300 MHz, DMSO-d6): δ 3.69 (s, 
2H, CH2), 4.28 (br.s, 4H, (NH2)2), 6.80-6.83 (m, 1H, H-4’), 6.86-6.89 (m, 1H, H-3’), 
7.19-7.23 (m, 1H, H-5’), 10.04 (br.s, 1H, NH). 
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4-( Naphthalen-2-ylmethyl)-1H-pyrazol-3,5-diamine (101o) 
Yield 55 %; oil; 
1
H NMR (300 MHz, DMSO-d6): δ 3.51 (s, 2H, CH2), 4.01-4.08 (br.s, 
4H, (NH2)2), 7.20-8.39 (m, 8H, Ar-H), 10.09 (br.s, 1H, NH). 
 General procedure of synthesis of corresponding thiourea derivatives of 
pyrazol-3,5-diamine (102) 
In a well stirred suspension of 4-benzyl-1H-pyrazol-3,5-diamine and its derivatives (3 
mmol) in anhydrous dimethylformamide (DMF, 4 ml), ethoxycarbonyl isothiocyanete 
(6 mmol) was added and stirred the reaction mixture for 4.5-5 hours at room 
temperature. Following this step, 50-60 ml water was added to get more precipitated 
product. The product was filtered and washed with cold water. The products obtained 














Table 24. Synthesis of corresponding thiourea derivatives of pyrazol-3,5-diamine and 
their  
1





Cpd R % Yield & mp 
1
H NMR (300 MHz, DMSO-d6) 
 
2CO2Et CH2 Ar 2NH 2NH N(1)H 




1.23, t, 6H, 
J = 7.0 Hz; 
4.16, q, 4H, 
J = 7.0 Hz 
3.65 7.07-7.23, 
m, 5H 
10.87 11.39 12.88 




1.21, t, 6H, 
J = 7.1 Hz; 
4.14, q, 4H, 
J = 7.1 Hz 
3.74 7.40, d, 2H, 
J = 7.9 Hz; 
7.51, d, 2H,   










1.24, t, 6H, 
J = 7.0 Hz; 
4.17, q, 4H, 












1.24, t, 6H, 
J = 7.0 Hz; 
4.17, q, 4H, 
J = 6.7 Hz 
3.61 7.13, d, 2H, 
J = 8.4 Hz; 
7.34, d, 2H,   










1.23, t, 6H, 
J = 6.9 Hz; 
4.16, q, 4H, 
J = 6.8 Hz 
3.62 6.95-6.99, 
m, 2H; 7.18-




102f 4-PhC6H4 % yield: 90, 
mp: 189-190 
ºC, (Ethanol) 
1.14, t, 6H, 
J = 7.0 Hz; 
4.07, q, 4H, 
J = 6.8 Hz 
3.69 7.20-7.73, 
m, 9H 
10.87 11.38 12.90 
102g 4-
PhOC6H4 




1.22, t, 6H, 
J = 7.0 Hz; 
4.16, q, 4H, 












1.23, t, 6H, 
J = 7.0 Hz; 
4.16, q, 4H, 
J = 7.0 Hz 
3.59 2.21, s, 3H, 
Me; 6.96, d, 
2H,  J = 7.9 
Hz; 7.04, d, 
2H,   J = 7.9 
Hz 
10.86 11.39 12.86 




1.23, t, 6H, 
J = 7.0 Hz; 
4.16, q, 4H, 
J = 6.4 Hz 
3.60 1.12, t, 3H, 
CH3,  J = 
7.6 Hz; 4.16, 











Table 24. Synthesis of corresponding thiourea derivatives of pyrazol-3,5-diamine and 
their  
1




 General procedure of synthesis of (8-benzyl-4-oxo-2-thioxo-1,2,3,4-tetrahydro-
pyrazolo[1,5-a][1,3,5]triazin-7-yl)-thiourea and its derivatives (H13-H13n) 
To a stirred solution of NaOH (9 mmol) in ethanol (80%, 20 ml), corresponding 
carbethoxythiourea (3 mmol) was added and heated on water bath for 20 minutes with 
continuous stirring. After cooling, the solvent was evaporated under vacuum, and the 
residue was suspended in water (25 ml). The resulting suspension was acidified up to 
pH 1-3 using 2.5 M HCl. The precipitated product was filtered off, recrystallized with 
suitable solvent and dried under vacuum. 
Cpd R 
% Yield & 
mp 
1
H NMR (300 MHz, DMSO-d6) 
 
2CO2Et CH2 Ar 2NH 2NH N(1)H 
102j 4-
MeOC6H4 




1.23, t, 6H, 
J = 7.0 Hz; 
4.16, q, 4H, 
J = 7.0 Hz 
3.67 3.34, s, 3H, 
OMe; 6.72, 
d, 2H, J = 
8.4 Hz; 
7.07, d, 2H, 










1.24, t, 6H, 
J = 7.0 Hz; 
4.17, q, 4H, 
J = 7.0 Hz 
3.51 6.54, d, 2H,  
J = 8.4 Hz; 
6.94, d, 2H, 
J = 8.4 Hz 
10.87 11.38 12.82 




1.24, t, 6H, 
J = 7.0 Hz; 
4.16, q, 4H, 
J = 7.0 Hz 
3.73 7.38, d, 2H,  
J = 8.0 Hz; 
7.63, d, 2H, 
J = 7.9 Hz 
10.81 11.38 12.94 




1.25, t, 6H, 
J = 7.0 Hz; 
4.20, q, 4H, 
J = 7.0 Hz 
3.68 5.97-6.00, 
m, 1H; 6.24-
6.29, m, 1H; 
7.38-7.43, 
m, 1H 
11.04 11.43 12.92 
102n 2-
thiophenyl- 




1.24, t, 6H, 
J = 7.0 Hz; 
4.18, q, 4H, 
J = 7.0 Hz 
3.87 6.76-6.86, 
m, 2H; 7.22-
7.26, m, 1H 
10.99 11.45 12.91 
102o 2-
Napthalinyl 




1.22, t, 6H, 
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Yield 73 %; mp 239-241 °C (EtOH-water); ESI-MS m/z 331.1 (M-1)
+; purity ˃ 95%; 
tR 1.70 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.11(s, 2H, CH2), 7.12-7.33 (m, 
5H, Ph), 8.94 and 9.07 (two s, 2H, (C=S) NH2), 10.06 (s, 1H, (C=S) NH), 12.70 (s, 
1H, NH), 13.57 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 24.2 (CH2), 92.0 
(C-8), 125.8 (C-4’), 127.8 (C-3’ and C-5’), 128.2 (C-2’and C-6’), 138.5 (C-1’), 139.6 
(C-7), 140.7 (C-9), 151.9 (C-4), 173.5 (C-2), 179.8 (NH(C=S)NH2). 
[8-(4-Trifluoromethyl-benzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydro-pyrazolo[1,5-
a][1,3,5]triazin-7-yl]-thiourea (H13a) 
Yield 71 %; mp 189-191 °C (EtOH-water); ESI-MS m/z 399. (M-1)
+; purity ˃ 95%; 
tR 1.68 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.21 (s, 2H, CH2), 7.39 (d, 2H, H-
3’ and H-5’, J = 7.9 Hz), 7.65 (d, 2H, H-2’ and H-6’, J = 8.1 Hz), 8.95 and 9.10 (two 
s, 2H, (C=S) NH2), 10.21 (s, 1H, (C=S) NH), 12.65 (s, 1H, NH), 13.53 (br. s, 1H, 
NH);  
13
C NMR (75 MHz, DMSO-d6): δ 24.4 (CH2), 91.0 (C-8), 124.4 (q, CF3, J = 
271.9 Hz), 124.9 (q, C-3’ and C-5’, J = 3.7 Hz), 126.7 (q, C-4’, J = 31.5 Hz), 128.6 




Yield 78 %; mp 243-245 °C (EtOH-water); ESI-MS m/z 365.1 (M-1)
+; purity ˃ 95%; 
tR 1.70 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.09 (s, 2H, CH2), 7.18 (d, 2H, H-
3’ and H-5’, J = 8.4 Hz), 7.33 (d, 2H, H-2’ and H-6’, J = 8.5 Hz), 8.94 and 9.05 (two 
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s, 2H, (C=S) NH2), 10.11 (s, 1H, (C=S) NH), 12.69 (s, 1H, NH), 13.53 (br. s, 1H, 
NH);  
13
C NMR (75 MHz, DMSO-d6): δ 23.7 (CH2), 91.6 (C-8), 128.0 (C-3’ and C-
5’), 129.7 (C-2’and C-6’), 130.4 (C-4’), 138.7 (C-1’), 138.7 (C-7), 140.7 (C-9), 151.8 
(C-4), 173.5 (C-2), 179.8 (NH(C=S)NH2). 
[8-(4-Bromo-benzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydro-pyrazolo[1,5-
a][1,3,5]triazin-7-yl]-thiourea (H13c) 
Yield 82 %; mp 222-224 °C (EtOH-water); ESI-MS m/z 411.1 (M-1)
+; purity ˃ 95%; 
tR 1.73 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.07 (s, 2H, CH2), 7.13 (d, 2H, H-
3’ and H-5’, J = 8.4 Hz), 7.46 (d, 2H, H-2’ and H-6’, J = 8.4 Hz), 8.93 and 9.05 (two 
s, 2H, (C=S) NH2), 10.09 (s, 1H, (C=S) NH), 12.67 (s, 1H, NH), 13.52 (br. s, 1H, 
NH);  
13
C NMR (75 MHz, DMSO-d6): δ 23.8 (CH2), 91.6 (C-8), 118.9 (C-4’), 130.2 
(C-3’ and C-5’), 131.0 (C-2’and C-6’), 138.8 (C-1’), 139.2 (C-7), 140.8 (C-9), 151.9 
(C-4), 173.6 (C-2), 179.9 (NH(C=S)NH2). 
[8-(4-Fluoro-benzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydro-pyrazolo[1,5-
a][1,3,5]triazin-7-yl]-thiourea (H13d) 
Yield 65 %; mp 221-223 °C (EtOH-water); ESI-MS m/z 349.0 (M-1)
+; purity ˃ 95%; 
tR 1.69 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.09 (s, 2H, CH2), 7.10 (dd, 2H, 
H-3’ and H-5’, J = 8.9, 8.9 Hz), 7.20 (dd, 2H, H-2’ and H-6’, J = 8.7, 5.6 Hz), 8.94 
and 9.05 (two s, 2H, (C=S) NH2), 10.09 (s, 1H, (C=S) NH), 12.69 (s, 1H, NH), 13.55 
(br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 23.4 (CH2), 92.7 (C-8), 114.8 (d, 
C-3’ and C-5’, J = 21.3 Hz),  129.6 (d, C-2’ and C-6’, J = 7.3 Hz), 135.7 (d, C-1’, J = 
2.9 Hz),  138.6 (C-7), 140.8(C-9), 151.8(C-4), 160.6 (d, C-4’, J = 241.4 Hz), 173.5(C-





Yield 70 %; mp 239-241 °C (EtOH-water); ESI-MS m/z 407.1 (M-1)
+; purity ˃ 95%; 
tR 1.68 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.16 (s, 2H, CH2), 7.27 (d, 2H, H-
3’’ and H-5’’, J = 8.2 Hz), 7.33 (t, 1H, H-4’’, J = 7.3 Hz), 7.44 (t, 2H, H-2’’ and H-
6’’, J = 7.7 Hz ), 7.58 (d, 2H, H-3’ and H-5’, J = 8.2 Hz), 7.63 (d, 2H, H-2’ and H-6’, 
J = 7.5 Hz),  8.98 and 9.12 (two s, 2H, (C=S) NH2), 10.15  (s, 1H, (C=S) NH), 12.67 
(s, 1H, NH), 13.52 (br. s, 1H, NH). 
13
C NMR (75 MHz, DMSO-d6): δ 23.9 (CH2), 
92.0 (C-8), 126.4 (C-3’ and C-5’), 126.5 (C-2’and C-6’), 127.1 (C-4’), 128.4 (C-3’’ 
and C-5’’), 128.8 (C-2’’and C-6’’), 137.8 (C-1’), 138.8 (C-4’’), 139.0 (C-1’’), 139.9 
(C-7), 140.8 (C-9), 151.9 (C-4), 173.6 (C-2), 179.8 (NH(C=S)NH2). 
[4-Oxo-8-(4-phenoxy-benzyl)-2-thioxo-1,2,3,4-tetrahydro-pyrazolo[1,5-
a][1,3,5]triazin-7-yl]-thiourea (H13f) 
Yield 81 %; mp 210-212 °C (EtOH-water); ESI-MS m/z 423.2 (M-1)
+; purity ˃ 95%; 
tR 1.84 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.09 (s, 2H, CH2), 6.81-7.45 (m, 
9H, Ar-H), 8.96 and 9.07 (two s, 2H, (C=S) NH2), 10.07 (s, 1H, (C=S) NH), 12.68 (s, 
1H, NH), 13.53 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 23.6 (CH2), 92.1 
(C-8), 118.1 (C-3’ and C-5’), 118.6 (C-2’and C-6’), 123.0 (C-4’), 129.4 (C-3’’ and C-
5’’), 129.9 (C-2’’and C-6’’), 134.8 (C-1’), 138.6 (C-4’’), 140.8 (C-1’’), 151.9 (C-7), 







Yield 76 %; mp 254-256 °C (EtOH-water); ESI-MS m/z 345.1 (M-1)
+; purity ˃ 95%; 
tR 5.14 min (D); 
1
H NMR (300 MHz, DMSO-d6): δ 2.25 (s, 3H, Me), 4.05 (s, 2H, 
CH2), 7.04-7.09 (m, 5H, Ar-H), 8.93 and 9.03 (two s, 2H, (C=S) NH2), 9.98 (s, 1H, 
(C=S) NH), 12.69 (s, 1H, NH), 13.55 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-
d6): δ 20.5 (Me), 23.7 (CH2), 92.4 (C-8), 112.7 (C-3’ and C-5’), 128.7 (C-2’and C-




Yield 73 %; mp 228-230 °C (EtOH-water); ESI-MS m/z 359.1 (M-1)
+; purity ˃ 95%; 
tR 1.71 min (A);
1
H NMR (300 MHz, DMSO-d6): δ 1.14 (t, 3H, CH3, J = 7.6 Hz ), 
2.55 (q, 2H, CH2, J = 7.6 Hz ), 4.05 (s, 2H, CH2), 7.07 (d, 2H, H-3’ and H-5’, J = 8.3 
Hz), 7.11 (d, 2H, H-2’ and H-6’, J = 8.5 Hz), 8.94 and 9.07 (two s, 2H, (C=S) NH2), 
10.03 (s, 1H, (C=S) NH), 12.63 (s, 1H, NH), 13.54 (br. s, 1H, NH); 
13
C NMR (75 
MHz, DMSO-d6): δ 15.7 (Me),  23.8 (CH2), 27.7 (CH2), 92.4 (C-8), 127.5 (C-3’ and 
C-5’), 127.8 (C-2’and C-6’), 136.8 (C-4’), 138.6 (C-1’), 140.8 (C-7), 141.2 (C-9), 
151.9 (C-4), 173.5 (C-2), 179.8 (NH(C=S)NH2). 
 [8-(4-Methoxy-benzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydro-pyrazolo[1,5-
a][1,3,5]triazin-7-yl]-thiourea (H13i) 
Yield 69 %; mp 252-254 °C (EtOH-water); ESI-MS m/z 361.1 (M-1)
+; purity ˃ 95%; 
tR 1.67 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 3.71 (s, 3H, OMe), 4.03 (s, 2H, 
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CH2), 6.84 (d, 2H, H-3’ and H-5’, J = 8.8 Hz), 7.10 (d, 2H, H-2’ and H-6’, J = 8.7 
Hz), 8.95 and 9.04 (two s, 2H, (C=S) NH2), 9.99 (s, 1H, (C=S) NH), 12.70 (s, 1H, 
NH), 13.56 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 23.3 (CH2), 54.9 
(MeO), 92.7 (C-8), 113.6 (C-3’ and C-5’), 128.8 (C-2’and C-6’), 131.4 (C-4’), 138.2 
(C-1’), 140.7 (C-7), 151.9 (C-9), 157.5 (C-4), 173.5 (C-2), 179.7 (NH(C=S)NH2). 
[8-(4-Hydroxy-benzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydro-pyrazolo[1,5-
a][1,3,5]triazin-7-yl]-thiourea (H13j) 
Yield 80 %; mp 219-221 °C (EtOH-water); ESI-MS m/z 347.1 (M-1)
+; purity ˃ 95%; 
tR 1.65 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 3.97 (s, 2H, CH2), 6.66 (d, 2H, H-
3’ and H-5’, J = 8.5 Hz), 6.96 (d, 2H, H-2’ and H-6’, J = 8.5 Hz), 8.94 and 9.03 (two 
s, 2H, (C=S) NH2), 9.17 (s, 1H, OH), 9.90  (s, 1H, (C=S) NH), 12.68 (s, 1H, NH), 
13.54 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 23.3 (CH2), 92.7 (C-8), 
114.9 (C-3’ and C-5’), 128.7 (C-2’and C-6’), 129.5 (C-4’), 138.2 (C-1’), 140.7 (C-7), 
151.9 (C-9), 155.4 (C-4), 173.5 (C-2), 179.7 (NH(C=S)NH2). 
[8-(4-Cyano-benzyl)-4-oxo-2-thioxo-1,2,3,4-tetrahydro-pyrazolo[1,5-
a][1,3,5]triazin-7-yl]-thiourea (H13k) 
Yield 62 %; mp 259-262°C (EtOH-water); ESI-MS m/z 356.1 (M-1)
+
; purity ˃ 95%; 
tR 1.65 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.20 (s, 2H, CH2), 7.34 (d, 2H, H-
3’ and H-5’, J = 8.3 Hz), 7.46 (d, 2H, H-2’ and H-6’, J = 8.3 Hz), 8.96 and 9.06 (two 
s, 2H, (C=S) NH2), 10.22 (s, 1H, (C=S) NH), 12.74 (s, 1H, NH), 13.55 (br. s, 1H, 
NH);  
13
C NMR (75 MHz, DMSO-d6): δ 24.7 (CH2), 90.6 (C-8), 108.7 (CN), 118.9 
(C-4’), 128.9 (C-3’ and C-5’), 132.0 (C-2’and C-6’), 138.9 (C-1’), 140.8 (C-7), 145.8 





Yield 74 %; mp 227-229 °C (EtOH-water); ESI-MS m/z 321.0 (M-1)
+; purity ˃ 95%; 
tR 1.67 min (A);
1
H NMR (300 MHz, DMSO-d6): δ 4.13 (s, 2H, CH2), 6.00 (d, 1H, H-
3’, J = 3.1 Hz), 6.34 (dd, 1H, H-4’, J = 3.1, 1.9  Hz), 7.55 (d, 1H, H-5’, J = 1.0 Hz),  
8.98 and 9.09 (two s, 2H, (C=S) NH2), 10.12 (s, 1H, (C=S) NH), 12.72 (s, 1H, NH), 
13.54 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 18.5 (CH2), 89.2 (C-8), 
105.5 (C-4’), 110.4 (C-3’), 138.5 (C-5’), 140.7 (C-2’), 141.6 (C-7), 151.8 (C-9), 152.9 
(C-4), 173.5 (C-2), 179.8 (NH(C=S) NH2). 
 (4-Oxo-8-thiophen-2-ylmethyl-2-thioxo-1,2,3,4-tetrahydro-pyrazolo[1,5-
a][1,3,5]triazin-7-yl]-thiourea (H13m) 
Yield 72 %; mp 242-244 °C (EtOH-water); ESI-MS m/z 337.0 (M-1)
+; purity ˃ 95%; 
tR 1.68 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.30 (s, 2H, CH2), 6.81 (d, 1H, H-
3’, J = 2.8 Hz), 6.92 (dd, 1H, H-4’, J = 5.0, 3.5  Hz), 7.32 (d, 1H, H-5’, J = 5.0 Hz),  
8.97 and 9.06 (two s, 2H, (C=S) NH2), 10.19 (s, 1H, (C=S) NH), 12.72 (s, 1H, NH), 
13.61 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 19.4 (CH2), 92.1 (C-8), 
124.0 (C-4’), 124.5 (C-5’), 126.7 (C-3’), 138.2 (C-2’), 140.7 (C-7), 142.6 (C-9), 151.6 
(C-4), 173.5 (C-2), 179.8 (NH(C=S) NH2). 
(8-Naphthalen-2-ylmethyl-4-oxo-2-thioxo-1,2,3,4-tetrahydro-pyrazolo[1,5-
a][1,3,5]triazin-7-yl]-thiourea (H13n) 
 Yield 63 %; mp 230-233 °C (EtOH-water); ESI-MS m/z 381.2 (M-1)
+; purity ˃ 95%; 
tR 2.36 min (A); 
1
H NMR (300 MHz, DMSO-d6): δ 4.56 (s, 2H, CH2), 6.85-6.26 (m, 
11H, Ar-H), 9.00 and 9.26 (two s, 2H, (C=S) NH2), 10.22 (s, 1H, (C=S) NH), 12.72 
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(s, 1H, NH), 13.48 (br. s, 1H, NH); 
13
C NMR (75 MHz, DMSO-d6): δ 22.2 (CH2), 
90.0 (C-8), 123.1 (Ar-C), 123.8 (Ar-C),  125.5 (Ar-C), 125.6 (Ar-C), 125.7 (Ar-C),, 
126.2 (Ar-C), 128.2 (Ar-C), 131.5 (Ar-C), 133.1 (Ar-C), 135.4 (Ar-C),  139.1 (C-7), 
140.8 (C-9), 152.6 (C-4), 173.5 (C-2), 179.9 (NH(C=S) NH2). 
9.2 Molecular modeling study 
The CoMFA analysis was performed with the SYBYL-X 1.3  molecular modeling 
software.  A total of 43 compounds (training set) and 13 compounds of series H8 and 
its related structure (test set) comprised of 1,2,4-triazolo[1,5-a][1,3,5]triazine and 
pyrazolo[1,5-a][1,3,5]triazine scaffold was energy minimized using the SYBYL-X 
1.3  standard Tripos force field  with a distance dependent dielectric function until a 
root mean square (rms) deviation of 0.001 kcal/mol Å was achieved. The partial 
atomic charges required for the electrostatic interaction were computed using the 
Gasteiger-Huckel method. The most active compound (H13) was chosen as the 
template molecule and shared backbone or core structure was identified on which 
other molecules were aligned by database alignment method implemented in SYBYL-
X 1.3. CoMFA steric and electrostatic interaction fields were calculated with the 
standard Tripos force field at each lattice intersection point of a regularly spaced grid 
of 2.0 Å.  The values of the steric and electrostatic fields were truncated at 30 
kcal/mol. To generate statistically significant 3D QSAR models, partial least squares 
(PLS) regression analysis was used. To aid vizualization, the CoMFA results were 





9.3 Biological characterisation  
9.3.1 In vitro thymidine phosphorylase enzyme assay 
To evaluate in-vitro TP inhibitory activity of synthesized compounds, a 
spectrophotometric assay method was adopted, originally developed by Krenitsky 
(Krenitsky et al, 1979)
214
. Briefly, recombinant thymidine phosphorylase, expressed 
in E. coli (T2807- Sigma Aldrich) and thymidine (substrate) were used in this assay. 
The absorbance at 290 nm was recorded on a Shimadzu UV Mini 1240 UV-Vis 
Spectrophotometer. 200mM and 10mM potassium phosphate buffers were prepared 
from anhydrous monobasic potassium phosphate and deionised water, and adjusted to 
pH 7.4 (A) and 7.0 (B) respectively using 1M NaOH solution. The enzyme was 
diluted just before use to a concentration of 1.5 units/ml with buffer B.  For enzyme 
inhibition, 100µM stock solutions of test compounds in DMSO were serially diluted. 
5 mM thymidine solution was prepared using buffer A.  
Enzymatic reaction was initiated by addition of substrate (200 µl, 5mM) into a cuvette 
containing 780 µl of potassium phosphate buffer (pH 7.4), 10 µl of enzyme at 
concentration of 1.5 U, and 10 µl of test compounds dissolved in DMSO, which was 
mixed by rapid inversion, and decrease in absorbance due to conversion of thymidine 
to thymine was followed after 4, 8, 12, 16 and 20 min and from the slope of change in 
absorbance, the initial reaction rate was determined. Same experiments were 
performed using 10 µl of DMSO to calculate slope of uninhibited enzyme. For 
calculation of enzyme inhibition, the initial rates of change in absorbance at different 
concentrations of inhibitor were converted to % inhibition of enzyme, and plotted 
against inhibitor concentration using Graphpad Prism vs 4.0 to give the IC50 at 50% 
inhibition.   
254 
 
The percentage activity of each inhibitor was calculated by the following formulae: 
 (i)  Activity =    
(ii) Inhibition = 100% - Activity 
All the experiments were carried out at least in duplicate. 
9.3.2 Enzyme Inhibition kinetics Study 
The inhibitory effect of enzyme was evaluated with varying concentration of 
thymidine (1000, 500, 300, 200, 100 µM) in the presence of different concentration of 
inhibitor. The saturating concentration of inorganic phosphate was fixed at 25 mM. 
This experiment was also carried out with varying concentration of inorganic 
phosphate (20, 10, 5, 2 mM) in the presence of different concentration of inhibitor. 
The saturating concentration of thymidine was fixed at 1000 µM. The conversion of 
dThd to thymine was monitored for both substrates. All the experiments were 
conducted in triplicate. 
9.3.3 MTT assay 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) colorimetric 
assay 
239
 was adopted  to determine cytotoxicity of synthesized compounds on breast 
cancer cell line MDA-MB-231.  In brief, cells grown to 80% confluence were diluted 
with suitable media and seeded at a density of 5000 cells/well in  96-well plates and 
were incubated for 24 hours.  After that, the old media was aspirated out and 200 μl of 
the fresh media was added having inhibitor compounds that were dissolved in DMSO, 
and plates are incubated at 37 
º
C in a humidified atmosphere of 5% CO2 for 72 hours. 
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DMSO (0.5 %) was used as vehicle control to ensure that solvent did not interfere 
with cell growth. After 72 hours, 50 μl of MTT was added to cells, and after 4 hours 
of incubation, the purple formazan precipitated formed was solubilized in DMSO. 
The absorbance was determined in a microtiter plate reader (Tecan Genios 
Spectrophotometer) at 570 nm. The % cell viability was determined by the following 
formula- 
% Cell viability =  
9.3.4 Gelatine zymography 
Gelatine zymography was preformed according to reported method with slight 
modifications (Liotta and Stetler-Stevenson 1990)
240
. MDA-MB-231 cells were 
seeded onto a six-well plates in RPMI with 10% FBS, and allowed to propagate to 
80% confluence. The cells were then maintained in serum-free medium for at least 24 
hours prior to designated treatments with compounds and PMA (80 nM). Following 
24 hours incubation of cells with PMA, the conditioned medium was collected and 
centrifuged at 8000g for 8 minutes at 4 ºC to remove cells and debris. Quantify the 
protein content of the conditioned medium using protein assay kit. The volume of 
each samples having equal amount of protein was adjusted by adding PBS to samples. 
The resulting sample was mixed with 3X loading buffer and subjected to 
electrophoresis on a 7.5% SDS-PAGE gel containing 0.1% (w/v) gelatine using 1X 
Tris-Glycin SDS running buffer at 100 V for 90-120 minutes. Following 
electrophoresis, the gels were washed in renaturing buffer (2.5% Triton X-100) for 30 
minutes twice to remove SDS and then equilibrated for 30 minutes in 1X zymogram 
developing buffer (50mM tris, 10mM CaCl2, 0.15M NaCl, pH-7.5). The gels were 
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subsequently incubated in fresh developing buffer at 37 °C for 24 hours to allow 
gelatine digestion. The gelatinolytic activity of MMPs was visualized by staining the 
gels with 1% coomassie blue R-250 in 50% methanol, 10% acetic acid, 40% water 
(v/v) and destained with 50% methanol, 10% acetic acid, 40% water (v/v) until clear 
bands suggestive of gelatine digestion were visualized.  
9.3.5 Cell invasion assay 
The cell invasion assay was conducted using BD BioCoat™ Matrigel™ Invasion 
Chambers according to the manufacturer’s instructions. After treatment with different 
concentrations of compounds or DMSO, the MDA-MB-231 cells were harvested and 
200 μl of cell suspension containing 1 × 106 cells/ml cells suspended in serum-free 
medium was seeded into the upper chamber of Matrigel-coated filter inserts.  The 
culture media (600 μl) containing 10% FBS and/or chemoattractant was added to each 
well of the 24 well plate (lower compartment). The plate was incubated for 24 hours 
in a tissue culture incubator. After incubation, the non-invading cells as well as 
matrigel from the interior of the inserts were removed using cotton swabs. Cells that 
had invaded to the lower surface of the membrane were fixed with ethanol (70%) for 
10 minutes, and stained with 0.2% crystal in 2% (v/v) ethanol/water for 15 minutes. 
The inserts were washed with water, allowed to be air-dried, and the invaded cells 
were detected and enumerated under a light microscope. 
9.3.6 VEGF Assay 
To quantify the VEGF expression in samples, a colorimetric enzyme-linked 
immunosorbent assay was performed according to the manufacturer’s instructions. 
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After treatment of MDA-MB-231 cells with different concentrations of compounds or 
DMSO, the cell supernatant was collected and it was subjected to centrifugation 
(5000g for 5 minutes) to remove cells and debris. The samples were diluted with 
dilution buffer in desired proportion. Following this step, 0.1 ml of different VEGF 
standard solutions as well as properly diluted sample were placed into the precoated 
96-well plate and incubate the plate at 37 °C for 90 minutes. Subsequently, the 
content of the plate were discarded and 0.1ml of biotinylated anti-human VEGF 
antibody working solution was added into each well and incubated for another 60 
minutes. The plate was washed using 0.01 M TBS and 0.1ml of Avidin-Biotin-
Peroxidase Complex working solution was added and incubated the plate for 30 
minutes. After washing, 90 ul of prepared TMB colour developing agent was added 
into each well and incubated for 20-25 minutes. Thereafter, 0.1ml of prepared TMB 
stop solution was added into each well resulting in change of colour of content into 
yellow and the absorbance at 450 nm was measured. 
9.3.7 IL-8 assay   
The quantification of IL-8 in cell culture supernatant samples was performed 
according to manufacturer’s instructions via a colorimetric enzyme-linked 
immunosorbent assay. 
In this assay, 50 μl of reconstituted standard or sample were added to each well of 
human IL-8 coated 96-well plate and incubated for one hour  at room temperature 
(20-25°C). The plates were washed using wash buffer and 50 μl of biotinylated anti-
human IL-8 antibody was added into each well and incubated for another one hour at 
room temperature. After washing away the unbound biotinylated antibody, 100 μl of 
prepared Streptavidin-HRP Solution was pipetted to each well and incubated for 30 
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minutes. Thereafter, the wells were again washed, and 100 ul of TMB substrate 
solution was  added to the wells and placed the plates in the dark at room temperature 
for 30 minutes. The colour developed in each well was proportionate to the amount of 
IL-8 bound. The stop solution (100 μl) was added that changed the colour from blue 
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